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Summary 
 
Selective estrogen receptor modulators (SERMs) are used clinically to treat breast 
cancer as they inhibit estrogen both in promoting cell proliferation and expressing 
ER-mediated gene expression. SERMs are compound that block the effect of estrogen 
on estrogen receptor (ER). However, the complexity of estrogen receptor biology 
hinders an effective drug design. Our lab is interested in examining the global ER 
binding sites and the corresponding gene expression profiles upon treatment of ER by 
different SERMs.  
Chromatin Immunoprecipitation assay (ChIP) was performed on MCF-7 breast 
tumor cells in the presence or absence of E2/SERMs or a combination of E2+SERMs 
and immunoprecipitated with ERα antibodies. We tested a panel of 24 validated 
binding and 27 non-binding control sites by real-time PCR analysis. Overall, our 
studies indicated that binding site variations were associated with differences in ER 
binding dynamics and intensity as a function of the ligand used. Subsequently, global 
studies investigating genome-wide binding sites through customized tiling array 
containing more than 40,000 mapped and putative ER binding sites from Nimblegen 
were initiated. The design issues and considerations for a customised array including 
the selection of probes were discussed. Various validations to assess the performance 
of the customised array were carried out. 
Genome-wide binding sites profiles with the customised array were obtained for 
different drug treatments (E2 and SERMs), different antibodies (ERα, H3K4Me1, 
FOXA1 and GATA3), different experiments (ChIP and Formaldehyde-Assisted 
Isolation of Regulatory Elements (FAIRE)) and different cell lines (MCF-7 and 
Ishikawa cell lines). In order to mine out all the biological information, numerous 
  VII 
computational approaches are attempted and developed for data exploration and 
analysis. Various parameters and algorithms are being fine-tuned for extracting the 
best representative biological information. Variable Factor Linear Model (VFLM) 
was developed and implemented, which detected 6482 ER binding sites for ChIP-chip 
experiment immunoprecipitated with ERα antibody in E2 treatment. The VFLM peak-
finding method was also implemented in the entire customised array data.  
We also obtained genome-wide gene expression profiles with the Affymetrix 
array (HG-U133 Plus) for different drugs treatments (E2, T, R and I) at different time 
points (0, 3, 6, 9, 12, 24 and 48 hours). For Affymetrix experiments, the Pooled 
Variance Meta-analysis methods was used, followed by applying a Data-driven 
Smoothness Enhanced Variance Ratio Test (dSEVRAT) method for assessing the 
smoothness of the expression of gene across time point. We selected regulated genes 
based on 3 criterias: P-value≤0.05, smoothness score≥200 and fold change≥1.5. 
In literature, correlations between binding and expression profiles to decipher the 
complex process of gene regulation have been made. Affymetrix experiments have 
been performed with different E2/SERMs treatments across varying time points in 
both MCF-7 and Ishikawa cells. The 2 cell lines allow comparison on the tissue-
specific sensitivity, which is of therapeutical value. The comprehensive expression 
data were correlated with the binding profiles to infer direct target genes and 
functional binding sites. 
Binding and transcription regulation are also substantially influenced by the 
chromatin structure. The presence of nucleosomes will limit the accessibility of 
transcription factors and their partners. Through joint effort, studies on the positioning 
of nucleosomes were carried out whereby all the nucleosome experiments were 
performed by other while the author was assigned the computational analysis. Two 
  VIII 
Nimblegen high-density arrays with 2.1 millons probes have been designed, tiling the 
entire chromosome 21 & 22 arrays with additional selected regions throughout human 
genome. 
Lastly, emerging evidences show that regulatory genetic variations have an 
influence on gene regulation like changing binding site recognition. For the functional 
studies, we have concentrated on Single Nucleotide Polymorphisms (SNPs) present 
within transcriptional binding sites and its biological functions. Since breast cancer 
cell lines for different binding sites polymorphism are not readily available, the 
polymorphism studies were performed in lymphoblastoid cell lines. ChIP analysis 
was performed on 8 different cell lines with different genotypes to assess the binding 
affinity. Furthermore, the binding characteristics associated with homogygous 
genotype were also carried out in an allele-specific Taqman assay. Interestingly, the 
SNPs have different regulation of the target gene PRKAG2 through expression 
studies and AMPK proteins through western blots. These studies above discovered 
and confirmed a functional SNP within binding site that exhibits an allele-specific 
transcription factor binding.  
 Together, the information from binding sites, gene expression profiles upon 
drug treatments, nucleosome profiles and the information from studying regulatory 
genetic variations will help to decipher the mechanism of Estrogen Receptor gene 
regulation over time and over several pharmacologic interventions: E2 and SERMS.   
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Chapter 1 Introduction 
1.1     Background 
The important role of estrogen receptor in breast cancer 
The most common form of malignant cancer faced by women worldwide is breast 
cancer. According to the Singapore Cancer Society, about 1000 women of all ethic 
groups are diagnosed with breast cancer annually and the rate of the number of 
affected women is increasing at 3%. Breast cancer has a high incidence rate of about 
12% for American and 4~5 % for Singaporean women 
(http://www.singaporecancersociety.org.sg). Breast cancer usually originates from the 
uncontrolled, excessive cell divisions occurring at the milk ducts and glands, thus 
forming a lump or tumour. If untreated, the cancer will invade the nearby stroma 
which consists of blood and lymphatic vessels and metastases to lung, bones and liver 
(Sledge and Miller 2003). The end result is death. Beside death, there is also great 
emotional impact on the well-being of the women as the treatments may involve 
lumpectomy or mastectomy which may represent a loss of feminity and beauty to the 
woman involved. There are undesirable side-effects of drugs that add to the 
discomfort and stresses on the patient.  In both premalignant and malignant breast 
cancers, estrogen receptor α (ERα) is often found with higher protein levels than in 
normal tissue presence. Estrogen receptor can be used as one of the factors for 
predicting and diagnosing breast cancer (Ali and Coombes 2000) .  
Estrogen receptor belongs to the family of steroid receptor and is activated by the 
hormone estrogen. Estrogen exerts its effects through growth and proliferation of 
breast tissue. When estrogen binds to an estrogen receptor, the receptor dissociates 
from its cytoplasmic chaperones, the receptor-associated proteins. The hormone–
Lee Yew Kok  PhD Thesis 
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receptor complex then moves to the nucleus, binds to the estrogen-response element 
(EREs) (5’-GGTCAnnnTGAXX-3’) (Klinge 1999) through the DNA-binding domain 
(DBD) of the receptor and stimulates transcription. Alternatively, ER binds to DNA 
indirectly by tethering to other TFs like AP-1 (Kushner, Agard et al. 2000) and Sp1 
(Porter, Saville et al. 1997). Preinitiation complex is formed by the assembly of RNA 
polymerase II (POL II), TATA-box–binding protein (TBP), associated factors and 
transcription factors. The ER-E2 complex also interacts with co-factors such as 160-
kD steroid-receptor coactivator protein (P160) and p300–cyclic AMP response-
element–binding protein (CBP). Some of the recruited factors have histone modifying 
activities that decondense the chromatin for accessibility of transcription factor to 
chromatin. The above description portrays a classical pathway of estrogen signal 
transduction. A modified pathway of estrogen signaling requires the pioneer factor of 
forkhead protein FoxA1 that opens the chromatin to allow ER accessibility (Carroll, 
Liu et al. 2005).  
Two estrogen receptor subtypes - ERα and ERβ  
ERα was discovered and cloned in 1986 (Greene, Gilna et al. 1986) and only 
after about 10 years later, ERβ was also discovered (Kuiper, Enmark et al. 1996). 
Both ERα and ERβ have the following modular structure in Figure 1. The domain 
A/B located at the NH2- terminal contains the ligand-independent activation function 
(AF-1) which has very low sequence homology (~18%) between ERα and ERβ. AF-1 
serves the purpose of cell- and promoter-specific transactivation. On the other hand, 
the DNA binding domain (DBD) has very high sequence homology (~97%) between 
ERα and ERβ. The DBD located in C domain comprises of two zinc-fingers (Green, 
Kumar et al. 1988) that recognises specific hormone response elements and contains 
both the dimerisation and nuclear localisation signal (NLS). A hinge region (domain 
Lee Yew Kok  PhD Thesis 
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D) serves to connect the domain C to domain E. In domain E, the ligand binding 
domain (LBD) and the ligand-dependent activation function (AF-2) are located. The 
sequence homology between ERα and ERβ in domain E is around 60%. Domain E 
also contains the dimerisation and NLS.  
 
 
Figure 1 Domain of Estrogen Receptor 
ERα and ERβ also have vastly different expressions in different tissues. 
Comparing the relative level of ERα and ERβ when both ER subtypes are detected in 
the tissues, the relative level of ERα is found to be much higher than ERβ in 
mammary gland, kidney, pituitary and uterus tissues. On the contrary, ERβ is much 
higher than ERα in lung, bladder and prostate tissues. Both ERα and ERβ are present 
in roughly equal distribution in bone, ovary, testes and thymus tissues. In liver tissue, 
only ERα is present. Since estrogen receptors are distributed in different levels in 
many tissues and estrogen enhances the activity of estrogen receptor, estrogen also 
exhibits differential effects in different tissues and examples include osteoporosis, 
prostate and colon cancer. It is found that the effects from estrogen are not only 
governed by the levels and the sub-types of the estrogen receptor found, but the 
estrogenic effects are also both promoter and cell-specific to the particular 
environments found in different tissues.  
Selective Estrogen Receptor Modulator and ER 
One of the major strategies to treat and prevent breast cancer is to inhibit the 
agonistic property of ER.  Selective Estrogen Receptor Modulators (SERMs) have 
been developed as compounds with a mixed agonist/ antagonist activity on estrogen 
receptors. Ideally, SERMs should have an antagonist effect on breast and uterus tissue 
N
A/B                    C               D               E               F 
LBD      AF- COAF-1                     DBD
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but agonist effect on bone. SERMs are used clinically as drugs to treat and prevent 
breast cancer or osteoporosis despite we understand very little on their mechanism of 
actions and there are numerous side effects of drug administration. Side effects may 
include diarrhoea, pain at back and abdominal, vomiting, headache and constipation. 
Hormone therapy using Tamoxifen increases the risk of endometrial cancer, 
premature menopause in woman and even stroke. There are also cases that the drugs 
were ineffective and patients developed resistance to the drugs. If we understand more 
about the molecular basis of SERM action, better SERMs can be designed with 
negligible side effects and to be more effective with higher specificity. Tamoxifen 
was developed and used for treating early breast cancer since 1980s. Now Tamoxifen 
is used in advanced breast cancer, as an adjuvant for early breast cancer or post-
operation in late breast cancer. However, Tamoxifen has good efficacy mostly in ER-
positive breast cancer patients and most recurring breast cancer develops resistance to 
Tamoxifen. Based on the results provided from in-vitro assays which showed that 
both p300 and histone acetyl transferases (HATs) were recruited to the promoter of 
TFF1 E2-induced gene in Tamoxifen-resistant MCF-7 cell line, Shou, J. et al. 
suggests that HATs is involved in the mechanism of Tamoxifen resistance (Shou, 
Massarweh et al. 2004). Another SERM is ICI 182,780 (FaslodexTM), which was the 
first steroidal estrogen antagonist. It worked by degrading estrogen receptor, and thus 
removed the effects of estrogen. It maintained its efficacy even in breast carcinoma 
resistant to Tamoxifen therapy. The drug was shown to exhibit anti-proliferative 
effects on both breast and endometrium in both pre-clinical and clinical trial (Howell, 
Osborne et al. 2000). There are many SERMs that exhibit different degrees of 
agonist/antagonist effects in different tissues. Tamoxifen displays partial agonistic 
/antagonistic effects while ICI is a pure antagonist in breast tissues. Raloxifene is one 
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of the SERMs that exhibits both estrogenic and anti-estrogenic effects depending on 
the tissues. Raloxifene acts as an agonist in bone and lipid levels, but behaves as an 
antagonist in breast and uterine tissues (Fitzpatrick, Berrodin et al. 1999). Raloxifene 
has been shown to be effective in treating osteoporesis. Raloxifene also reduces the 
growth of breast cancer cell in vitro (Wolczynski, Surazynski et al. 2001). The 
knowledge on the mechanism of SERMs in terms of the interactions with ER and the 
affinity of the resulting ER-SERM complexes with DNA are as follows: ICI binds to 
ER with similar affinity as E2 whereas Tamoxifen has lesser affinity than E2 to ER. 
In both cases, chaperones proteins are also released. Unlike binding to E2 where both 
AF1 and AF2 are active, only AF1 is active in Tamoxifen binding that gives it partial 
agonist activity while both AF1 and AF2 are not active in ICI binding and ER is also 
rapidly degraded (Howell, Osborne et al. 2000). Tamoxifen competes with E2 through 
displacing the carboxy-terminal helix (H12) from co-activator docking site in the 
LBD domain. ICI eliminates completely any interaction between H12 and the LBD 
domain that H12 becomes very flexible and are not placed in any particular position 
like ER-E2 or ER_SERMs (Pike, Brzozowski et al. 2001). Different conformation 
changes will be induced by different ligands complexes with ER and these in turn 
cause differential ER stability. Wu, Yang et al. reported that GW5668 ligand similarly 
dislocates H12 like Tamoxifen but also decreases the ER stability, which may explain 
that GW5668 works in Tamoxifen resistance breast cancer (Wu, Yang et al. 2005).  
Besides opposing the action of ER in breast cancer treatment, depletion of the natural 
hormone E2 is an alternative treatment. This is implemented by the use of aromatase 
inhibitor which prevents the conversion of androgen to estrogen especially in post-
menopausal woman. The inhibitor can also hinder the production of estrogen during 
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the productive years of premenopausal woman. As with most cancer, chemotherapy 
treatment also applies to breast cancer.  
As can be seen above, ER exerts its diverse effects in many cell types through the 
ligand structures, the concentration of ERα and ERβ, promoter context and the 
proportion of co-activators and co-repressors. For the subsequent sections, estrogen 
receptor will refer to ERα unless specified otherwise. 
ERα has a half-life of 4-5 hour in both breast cancer and uterine tissue when 
ligand is not present (Eckert, Mullick et al. 1984; Monsma, Katzenellenbogen et al. 
1984; Nardulli and Katzenellenbogen 1986). The protein stability of transcriptional 
factor is inversely proportional to its rate of transcriptional activities (Philips, Chalbos 
et al. 1993; Imhof and McDonnell 1996). 
Transcriptional controls from histones  
Another significant transcriptional control is the discovery of histones and their 
functions to control the accessibility of chromatin to transcription factors. Histones 
are lysine (K) and arginine (R) rich proteins, which are also highly conserved and 
basic. Table 1 shows the characteristic of histones of their molecular weight, number 
of amino acids and amino acid composition.  
Table 1 Characteristic of Histones 
Lysine(%) Arginine(%)
H1 17.0~28.0 200-265 27 2
H2A 13.9 129-155 11 9
H2B 13.8 121-148 16 6
H3 15.3 135 10 15
H4 11.3 102 11 4
Histones Molecular Weight (kDa)




Histones and other nuclear proteins tightly bound DNA and they form the simple 
‘beads on a string’ structure, which is then packed into very compact chromatin. The 
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chromatin is also organised into two domains- euchromatin and heterochromatin. 
Euchromatin represents loosely-packed chromatin which also contains high 
concentration of active genes. Heterochromatin is tightly-packed chromatin which is 
usually saturated with highly repetitive DNA. There are also various proteins present 
for the assembly and packaging of chromatin, DNA repair, DNA transcription and 
replication, DNA and histone modifications and DNA recombinant. Nucleosome is 
the most basic structural component of chromatin, 180-200 based-pair DNA of which 
146bps wraps to histone octamer consists of a pair of H2A, H2B, H3 and H4. The 
linker histone that ties the nucleosomes together is called H1. The nucleosome is a 
stable structure that controls the access of transcription factor to DNA through the 
interaction of positively-charged histone tails with negatively-charge DNA. 
Nucleosome is known for its function in DNA packaging and in carrying epigenetic 
information. The presence of nucleosomes strongly decreases the rate of transcription 
by preventing the access to promoters. Histone acetylations have a main role in 
remodeling chromatin structure, changing many nuclear processes. Acetylation has 
the effect of neutralizing the positive charge of histones, causing it to release the 
negatively-charged DNA-now accessible to transcription factor. Hypoacetylated 
histones cause genes to be transcriptionally inactive. Two groups of proteins involved 
in chromatin remodeling. The first group is histone acetyl transferases (HATs) which 
acetylates the N-terminal tails of histones and the second group is ATP-dependent 
proteins such as SWI/SNF complex [Mating type SWItching; Sucrose 
NonFermenting]. SWI/SNF complex consists of 11 proteins and they can reposition 
the nucleosome by sliding it down the DNA. RNA polymerase can move along the 
stretch of DNA by translocating the histones sequentially by 75 to 80 base pairs 
within the nucleosome thereby nucleosomes’ positioning remains undisturbed. At 
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transcriptionally active genes, histone variants H2A.Z and H3.3 are found instead of 
H2A and H3. H2A.Z is incorporated into nucleosomes by the catalytic exchanger of 
SWR1 protein (Mizuguchi, Shen et al. 2004) while the replacement of histone H3 
with histone variant H3.3 requires CHD1 motor protein (Konev, Tribus et al. 2007). 
Histone modification is more conserved than DNA methylation and is universal 
among the eukaryotic organism from yeast to human. On the other hand, DNA 
methylation is more common only in complex genomes of higher eukaryotic 
organisms.   
Epigenetics is the study of processes that establish metastable (i.e. somatically 
heritable) states of gene expression without altering the DNA sequence. DNA 
methylation has been proven to play important role in epigenetics of the genome by 
regulating the higher-order chromatin structures.  There are at least two development 
periods, in which genome-wide methylation occurs, resulting in proliferation and 
differentiation of many types of cells. The periods are during the development of 
germ cells and preimplantation embryo. Imprinting of genes and stem cell 
differentiation are also affected by the epigenetics reprogramming. Epigenetics is also 
likely to regulate the regeneracy of a whole organism from a small part in normal 
development and in cloned animals. Histones modifications also play similar roles as 
DNA methylation.  
Distribution of ER binding sites  
Many recent studies seem to suggest that promoter-proximal regions do not 
account for the majority of the estrogen-response genes. As such, it seems that there is 
a long distance regulation from ERE sites acting as enhancers such as looping effects, 
but the transcriptional regulation is carried out by the basic transcription machinery. 
Based on the above findings on genome distribution of transcription factors, the use of 
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promoter array targeting upstream region of 5’ end of genes or CpG islands array 
targeting CG rich regions would miss a large percentage of loci. This is even more 
relevant in mammalian cells in which genes constitute only a small portion of the 
whole genome and transcriptional factors can function at variable distance and up to 
25kb as proven in ß-globin gene regulation experiment (Horak, Mahajan et al. 2002). 
Given the close proximity of tandem loci spacing on average of as little as a few bps, 
the use of PCR or BAC arrays are not appropriate as the probes are too long and do 
not provide resolution though they have greater genomic nucleotides coverage. 
Moreover, strand specificity cannot be determined and it is also labour intensive. 
Oligonucleotides-based array that have 25-60 bps probes and high-density features is 
the best type of array for surveying the binding sites. A good example is the studies 
on the unbiased mapping of transcription factor binding sites along human 
chromosomes 21 and 22 using all the non-repetitive sequences (Cawley, Bekiranov et 
al. 2004). 
Single Nucleotide Polymorphisms (SNPs) and its roles in diseases and gene 
regulation 
One of the main motivations in deciphering the detailed mechanism of 
transcription regulation is to provide cures to diseases and cancers. There is evidence 
that numerous diseases are highly associated with a particular allele while complex 
diseases are also affected by variants through subtle mechanisms. As such, there is 
emerging interest on regulatory genetic variations within expression promoter and 
transcription factor binding region. Genome wide studies were carried out to identify 
functional SNPs in the promoter regions of human gene (Mottagui-Tabar, Faghihi et 
al. 2005). There are also attempts to characterise the promoter polymorphism 
(Buckland, Hoogendoorn et al. 2005).Examples of association studies on promoter 
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polymorphism and diseases are BCL2 gene for chronic lymphocytic leukemia 
(Nuckel, Frey et al. 2006), Interferon regulatory factor-1 for hepatitis C virus 
infection (Cheong, Cho et al. 2006) and insulin VNTR polymorphism with type 1 
diabetes (Durinovic-Bello, Jelinek et al. 2005). Evidence has shown that SNPs occur 
in higher frequency in gene promoter regions than those further upstream. 
Additionally, SNPs are also highly associated with transcription factor binding sites as 
compared with non-binding site sequences (Guo and Jamison 2005). Useful 
information from SNPs found in the binding sites can be extracted and used to tailor 
patient specific therapy. Numerous papers have shown that binding sites occur in 
many different places and different binding sites serve different functions. For 
example, after genome-wide analysis of CREB transcription factor on rat genome, 
only 40% of the total unique genomic loci were within 2kb of the transcriptional start 
site of an annotated gene and 49% were within 1kb of CpG islands (Impey, McCorkle 
et al. 2004).  
Analysis of ChIP-on-chip data 
The invention of ChIP technique enables the in-vivo capturing of the actual 
physical interaction between transcription factors and actual genome location through 
cross-linking the proteins and DNA together. Microarray technology has also been 
matured to an advanced level of chip manufacture with smaller features, accurate 
printing of probes and higher probe density per array. Nimblegen has synthesized 2.1 
billons probes on a single chip. The use of microarray following ChIP experiment, 
which is also known as ChIP-on-chip allows the snapshots of genome-wide physical 
interactions of protein-DNA to be interrogated at the same time. Much of the initial 
focus has been to identify transcription factor binding sites across the whole genome. 
However, there is an increasing trend for quantifying the binding site affinity using 
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the microarray probe intensities. Comparison has been made to correlate the fold 
change obtained from real-time PCR with the microarray probe intensity. Much of the 
interests are on comparing the changes in the binding site affinity upon drug 
treatments as the level of binding site affinity is generally proportional to transcription 
activity, which in turn affects the gene regulation network. It is preferred to have a 
new algorithm that can directly quantify the change in the binding site intensity from 
drug A to drug B.  
Moreover, the new algorithm should also be able to make full use of biological 
and technical replicates since the array technology is much cheaper and commonly 
available. Many replicates are made feasible as the arrays are now reused. Many 
protocols are invented and tested to strip the array and have successfully reused the 
stripped arrays. The most commonly ChIP-on-chip methods are MAT, ChIPOTle and 
MACS. These are single array methods that do not take into account of many factors. 
Hence there is a need for a new algorithm that considers many treatments, many 
technical or biological replicates, batches. As such, a new algorithm called Variable 
Factor Linear Modeling (VFLM) is developed in this report. VFLM works on the 
basis of a moving sliding window with linear modelling and it can be used for 
quantifying absolute affinity as well as differential affinity.  
 
1.2 Scope and Strategy 
My research focus is to understand the mechanisms of regulation by estrogen 
receptor and how it is modulated by SERMS. This is mainly achieved by eliciting and 
examining the modulation of the global ER binding sites and the gene expression 
profiles upon treatment of ER by different SERMs – Tamoxifen, Raloxifene and ICI. 
My strategy involves both the wet lab and the computational approaches, covering 
Lee Yew Kok  PhD Thesis 
  12 
several aspects of transcriptional regulation from chromatin structure to binding site 
profiling to gene expression profiling. Gene expression profiling experiments using 
Affymetrix chips and data analysis were performed in MCF-7 and Ishikawa cell lines 
for 8 different treatments: DMSO (control), E2, Tamoxifen+E2, Tamoxifen, 
Raloxifene +E2, Raloxifene, ICI+E2 and ICI with a time course.  I designed and 
validated a customised Nimblegen array to profile ER binding. The customised 
nimblegen array put together all true and putative ER binding sites from various 
sources. The arrays were utilised to profile the ER binding sites and their modulation 
by SERMS by doing ChIP with different treatments and antibodies. Subsequently, 
different types of correlations between the binding profiles and gene expressions 
profiles were carried out to explore new interesting information on Transcriptional 
Regulation by ER.  
As the binding and transcription regulation are substantially influenced by the 
chromatin structure which may be greatly defined by variations in the 
positioning/occupancies of neucleosomes, the presence of nucleosomes will limit the 
accessibility of transcription factors and their partners. To study the influence of 
neucleosomes, we have designed and validated a Nimblegen tiling array of 2.1M 
probes spanning the entire chromoses 21 & 22 along with additional selected regions 
throughout human genome. Using this array, we profiled the nucleosome occupancies 
and their component modifications under E2 treatment. Cross-comparisons among 
binding site, gene expression and nucleosome positioning profiles have been made.   
A novel method was developed to analyse the Nimblegen array data both from 
binding site profiling experiments as well as the neucleosome profiling experiments 
based on linear model.  
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Lastly, functional studies in binding site were carried out. For polymorphism 
studies in binding sites, different breast cancer cell lines that have vast variations in 
the polymorphism pattern in binding sites are not readily available. As such, we chose 
lymphoblastoid cell lines as the model system to study and characterise functional 
binding sites with polymorphism. This confirmed a functional SNP within binding 
site that exhibits an allele-specific transcription factor binding.  
 
1.3 Report Layout  
The first chapter of the report starts with the introduction and research 
significance. The background related the research project is explained and relevant 
literatures are reviewed. The scope and strategy in querying the hypotheses are also 
outlined. Chapter 2 describes all the design considerations and validations in 
constructing a customised ER binding sites array. Chapter 3 describes the biological 
experiments performed to examine and compare the binding sites’ profiles with 
different treatments and different antibodies. Chapter 4 describes the results and the 
comparison of the gene expression landscape obtained after SERMs treatments. 
Chapter 5 is an exciting chapter where the linkage and correlation between binding 
sites and gene expressions are scrutinised in detail to unravel further new mechanism 
of gene regulation. Chapter 6 describes the functional studies on SNP found within a 
functional binding site. Chapter 7 is the concluding chapter, drawing summaries and 
linking the findings across the previous chapters. Lastly, detailed tables and graphs 
are provided in the appendices. 
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Chapter 2 Construction of Customized Estrogen Receptor 
Binding Sites Array 
We have designed a specially customized Nimblegen tiling array which contains 
all-inclusive mapped & putative ER binding sites to investigate the modulation of ER 
binding at a genome scale under different treatments in a cost- and time-effective 
manner. We have collated more than 40,000 binding sites from the literature and ERE 
prediction algorithm (Vega, Lin et al. 2006).  
 The inception of high-throughput technologies such as ChIP-on-chip and ChIP-
Sequencing enable many thousands of binding sites or the whole human genome to be 
interrogated. Earlier the detection of ER binding sites were limited to a few genomic 
locations at a time through experiments such as gel mobility shift assay, luciferase 
assay system and lastly ChIP experiments coupled with quantitative PCR. DNA 
microarray is a multiplex innovation that contains as large as millions of microscopic 
spots of DNA oligonucleotides, which target short section of a gene or DNA region of 
interests such as binding sites. The first high-throughput detection of ER binding sites 
were focused on chromosome 21 and 22 with Affymetrix Genechip Chromosome 
21/22 1.0F Array Set (P/N 900545), which consists of 3 arrays set using 25-mer 
oligos at 35bps spacing tiling on all the unmasked regions specified by RepeatMasker . 
Altogether there were 57 ER binding sites detected across chromosome 21 and 22, in 
which majority of them were not found proximal to promoter regions of genes 
(Carroll, Liu et al. 2005). The first unbiased genome-wide survey on all ER binding 
sites were carried out in Affymetrix Human tiling 1.0 microarrays, which consists of 
14 chips set using 25-mer oligos at 35bps spacing that span the entire non-repetitive 
regions defined by RepeatMasker . The study detected 3665 ER binding sites at 
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higher threshold of which only 4% of the binding sites were within 1kb promoter 
regions (Carroll, Meyer et al. 2006). Another unbiased method for genome-wide 
analysis of ER binding sites was the construction and sequencing of ChIP-PET library 
(Lin, Vega et al. 2007). Signature sequences of 18bps were extracted with MmeI 
restriction enzymes from both the 5’ and 3’ of ChIP DNA and self-ligated together to 
form a single PET (Paired-End diTags). Many different single PETs were 
concatenated and subsequently cloned into a plasmid for sequencing. This 
significantly reduced the amount of DNA to be sequenced yet the enriched ChIP 
DNA can be mapped to genome as the boundary of the sonicated fragments is 
demarcated by the Paired-End diTags. The binding sites are determined through 
comparing the tag counts generated from ChIP DNA relative to input DNA as the 
background. The ChIP-PET approach mapped 1234 high confidence ER binding sites 
of which only 4% of the binding sites were within 5kb from TSS of all genes. Taken 
together, the studies from Carroll, Meyer et al. and Lin, Vega et al. have unanimously 
shown that the majority of binding sites were far away. 
Building on the vast information gained on the location charateristics of ER 
binding sites, a suitable customized ChIP-on-chip platform needs to be chosen. The 
above studies in interrogating the ER binding sites clearly prove that promoter-
proximal regions do not account for the majority of the estrogen receptor binding sites. 
As such, the use of promoter array targeting upstream region of 5’ end of genes or 
CpG islands array targeting CG rich regions would miss a large percentage of ER 
binding sites. Given that a sizeable number of ER binding sites are in close proximity 
to one another, the use of PCR or bacterial artificial chromosome (BAC) arrays are 
not appropriate as the probes are too long and do not provide resolution though they 
have greater genomic nucleotides coverage. Moreover, strand specificity cannot be 
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determined for PCR arrays as both the target and its complementary sequences are 
present at each feature. It is also labour intensive to create the individual ~1kb PCR 
fragment. Oligonucleotides-based array that have 25-75 bps probes and high-density 
features is the best type of array for surveying the binding sites. Nimblegen array 
system was chosen because it can accommodate about 385,000 isothermal probes 
with variable probe lengths 45-75 bps.  
The customized Nimblegen array incorporates all the mapped and highly-putative 
ER binding sites identified from all the aforementioned studies. Another source of the 
probed regions came from ERE motif-finding program (Vega, Lin et al. 2006). There 
are also additional binding sites from the literature and in-house studies validated 
through quantitative PCR. The selection of all putative ER binding sites effectively 
shrinks the DNA regions to be tiled with probes yet still comprehensively surveys the 
whole genome. This also brings about a significant reduction in the number of chips 
required as well as saving in cost and time. Instead of 3 chips across chromosome 21 
and 22 which detected 57 ER binding sites or 14 chips across whole genome which 
detected 3665 highly probable ER binding sites, a single chip is designed which can 
survey more than 40,000 highly-putative ER binding sites at once. One of the major 
limitations in ChIP-on-chip studies is that a few µg of DNA is required for array 
hybridization yet ChIP assay typically yield less than 50ng from a single 150mm 
round plate of cultured cells. In summary, a single customized array requires less 
sample, lower reagents cost and labor hour, but yet comprehensively examined many 
thousands of experimentally validated ER binding sites genome-wide. 
Besides, the customized array also offers several improvements and advantages 
than the platforms used in previous studies. Nimblegen platform offers greater 
specificity as the 45-75mers probes are longer than the 25-mer probes in Affymetrix 
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system. Nimblegen platform utilized isothermal probes which ensure similar 
specificity in hybridization. A large number of important regions may be missing out 
from the non-repetitive regions. The customized Nimblegen array makes use of 
frequency of occurrence of probes in the whole genome that will increase the regions 
covered. The average probe spacings in customized array are also comparable to the 
average spacings in the Affymetrix chip. Nimblegen platform uses maskless synthesis 
process so there is flexibility in modifying the probes in the array. Lastly, the 
comparison using single chip compared to a set of multiple chips would not be 
subjected much to batch effects or human variation errors such as the use of master 
mix in reagents. Therefore, the chosen Nimblegen platform provides greater 
specificity, design flexibility, improved analysis, more uniform hybridization, and 
coverage of repetitive regions. 
2.1 Selection of input regions 
Our approach used to interrogate the binding sites profiles of a transcription 
factor affected by different drugs across the genome, was achieved through careful 
selection of probed regions. Since the regions are derived from previously validated 
binding sites, there is greater experimental confidence inherently that the binding sites 
detected on the customized chip would have been experimentally determined twice. 
Table 2 shows the summary of the regions selected for the customized ER binding 
sites array. The paragraphs that follow will describe the selected regions and explain 
the selection of regions in details.  
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Table 2 Regions selected for customized binding sites array include binding 
sites reported in literatures, ChIP-PET(Lin, 2007), ERE Prediction(Vega, 2006), 
ChIP-chip (Carroll, 2006) and negative controls  
moPET1-2 moPET3-5 moPET6+
No. of 













7574 Exons Probes- 4997
Prokaryotes Probes- 100
PET1 Probes- 10036






Maximum overlap PET (moPET) is defined as the maximum number of PETs of all sub-
regions in a cluster.  
Selection of input regions from  ChIP-PET Data (Lin, Vega et al. 2007) 
ChIP-PET data will be referred to as Lin for the remaining sections of thesis. 
Criteria in choosing the probed regions from Lin include: (1) Ditags that specifically 
bind to 1 genomic location; (2) Clusters that contain more than 2 ditags. In total, an 
approximate 10 million bps long regions were selected. The ChIP-PET technology 
and the term moPET are described in the appendix. High confidenced Lin data are 
from moPET 3+ while low confidence Lin data are from moPET2 category.  
Since the selected ChIP-PET clusters were of variable lengths, we examined the 
distribution of clusters sizes (Figure 2). There were not many clusters longer than 
4000bps. The bulk of the cluster sizes centre around 600 to 1200, which is closed to 
the optimal shearing size of about 500~1000bps for ChIP experiment. 
 
Figure 2 Distribution of ChIP-PET cluster sizes 
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Selected ChIP-PET clusters from specified criterias have variable lengths that the 
majority of the cluster sizes are closed to the optimal shearing size for ChIP experiment. 
Selection of input regions from ChIP-chip (Carroll, Meyer et al. 2006) 
10599 unique ER binding sites at the lower FDR threshold of 5%, including the 
higher confidence 3665 binding sites at FDR of 1% were included in the array. The 
binding sites were obtained with three biological replicates through the intersection of 
a nonparametric generalized Mann-Whitney U-test (P-value < 10-5) and MAT 
algorithm. BLAT was performed to remove identical binding sites. The clusters were 
also of variable length. Greater than 80% of the clusters have sizes between 800 to 










































Figure 3 Distribution of ChIP-chip (Carroll, Meyer et al. 2006) cluster sizes 
Selection of predicted binding sites  
The predicted binding sites were obtained using the h-ERE algorithm which 
utilizes machine learning with training sets from both the validated binding and non-
binding motifs collected from various experimental sources (Vega, Lin et al. 2006) . 
A decision tree was used for classifying the potential binders and non-binders based 
on the binding and non-binding scores. The 'stringent' criteria of the algorithm were 
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used to define 38,024 putative ERE sites in the human genome. Each ERE has 19bps 
long sequence and was extended 250bps on both sides. Upon expanding each ERE 
site to 519 bps long, the number of input predicted regions has reduced to 37499 due 
to some ERE sites are in close proximity. A total of 220458 probes were tiled for the 
37499 predicted binding (ERE) sites. When this number of probes added to the probes 
obtained in other categories, the total number of probes far exceeded what an array 
can accommodate. So the number of probes in the predicted regions was reduced to 
182970 since other categories of input region are of higher importance. The predicted 
regions were further reduced by removing all the probes in the regions that have ≥ 1 
non-unique probe (1529 regions removed); keeping only the “central” 6 probes for 
regions that have > 6 probes and lastly randomly removed 4546 regions. 
Selection of ER binding sites from literature references and in-house studies 
Validated ER binding sites and non binding sites were collected and probes had 
been designed and incorporated into the array. Validated ER binding sites and non 
binding sites are tabulated in Table 3 and Table 4 respectively.  
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Table 3 ER binding sites validated in literatures or in-house 
Acc Num/Promoter ID* Name Genomic Location Pattern Reference
PROM0307S00001656 PDZK1 chr1:143,215,756-143,215,768 GGTCAcccAGTCC Internal
NM_000674 ADORA1 chr1:199,790,269-199,790,281 GGTTAgggTGACC Bourdeau et al. 2004, Internal
 PROM0307S00002573 ADORA1 chr1:199,790,414-199,790,426 GGTGTcttTGACC Internal
NM_001227 CASP7 chr10:115,428,398-115,428,410 GGTCAgggTGAAC Bourdeau et al. 2004
NM_001227 CASP7 chr10:115,428,492-115,428,504 GGTCGgggTGAAC Bourdeau et al. 2004
NM_001227 CASP7 chr10:115,428,572-115,428,584 GGTCAgggTGAAC Bourdeau et al. 2004
NM_001227 CASP7 chr10:115,428,612-115,428,624 GGTCAgggTGAAC Bourdeau et al. 2004
NM_001227 CASP7 chr10:115,428,652-115,428,664 GGTCAgggTGAAC Bourdeau et al. 2004
NM_001227 CASP7 chr10:115,428,689-115,428,701 GGTCAgggTGAAC Bourdeau et al. 2004
NM_001227 CASP7 chr10:115,428,743-115,428,755 GGTCAgggTGAAC Bourdeau et al. 2004
 PROM0307S00020873 FLJ30973 chr15:55,670,850-55,670,862 GGGCAgtgTGGCC Internal
 PROM0307S00020873 FLJ30973 chr15:55,671,545-55,671,557 GGTCAcccTGCTC Internal
NM_001089 ABCA3 chr16:2,319,793-2,319,805 GGTCAcggTGTTC Lin et al. 2004
NM_005082 EFP chr17:52,323,321-52,323,333 GGTCAtggTGACC Klinge Review 2001, Bourdeau et al. 2004
 PROM0307S00025715 MGC26694 chr19:19,035,118-19,035,130 GTTCAgagTGACC Internal
 PROM0307S00025862 KIAA1533 chr19:40,182,519-40,182,531 GGCCTggcTGACC Internal
 PROM0307S00026011 ACTN4 chr19:43,897,093-43,897,105 GGTCActgTGACT Internal
 PROM0307S00026372 GPR77 chr19:52,532,131-52,532,143 GGTCActcTGACA Internal
NM_000064 C3 chr19:6,671,884-6,671,902 GGTGGcccTGACC Klinge Review 2001
NM_148903 GREB1 chr2:11,603,634-11,603,646 GGTCAaaaTGACC Bourdeau et al. 2004
NM_148903 GREB1 chr2:11,615,324-11,615,336 GGTCAtcaTGACC Bourdeau et al. 2004
NM_148903 GREB1 chr2:11,621,861-11,621,873 AGTCAgtgTCACC Internal
NM_148903 GREB1 chr2:11,623,258-11,623,270 GGTCAttcTGACC Bourdeau et al. 2004, Lin et al. 2004 
 PROM0307S00003333 CYP1B1 chr2:38,214,993-38,215,005 GGTCGcgcTGCCC Internal
 PROM0307S00003333 CYP1B1 chr2:38,215,049-38,215,061 GGTCAaagCGGCC Internal
NM_003489 NRIP1 chr21:15,359,833-15,359,845 GGTCAaagTGACC Lin et al. 2004
 PROM0307S00027970 TFF1 chr21:42,659,626-42,659,638 GGTCCtggTGTCC Internal
 PROM0307S00027970 TFF1 chr21:42,659,906-42,659,918 AGCCAagaTGACC Internal
NM_003225 TFF1 chr21:42,660,106-42,660,118 GGTCAcggTGGCC Klinge Review 2001
 PROM0307S00028194 CRKL chr22:19,595,695-19,595,707 AGTCAatcTAACC Internal
NM_002343 LTF chr3:46,481,739-46,481,751 GGTCAaggCGATC Bourdeau et al. 2004
NM_001657 AREG chr4:75,676,340-75,676,352 GGACAaggTGTCC Internal
NM_017770 ELOVL2 chr6:11,154,748-11,154,760 GGTCAtctTGATG Internal
NM_003376 VEGF chr6:43,844,381-43,844,393 AATCAgacTGACT Klinge Review 2001
NM_002346 LY6E chr8:144,170,802-144,170,814 GGACAagaTGACC Bourdeau et al. 2004
NM_004878 PTGES chr9:129,597,654-129,597,666 GGACAgccTGGCC Internal
882 FLJ32833 chr1:108,492,542-108,492,560 ttaGGTCAgctTGTCCcag Internal
137 C1orf21 chr1:181,327,606-181,327,624 ctgGGTCAgcaTGACCttc Internal
1221 1221 chr11:64,942,548-64,942,566 ctgGGGCAtgcTCACCtca Internal
23b SLC38A1 chr12:44,881,783-44,881,801 cagAGTGAactTGACCtga Internal
23a SLC38A1 chr12:44,881,800-44,881,818 gagGGTCAtccCAACCcca Internal
1616 1616 chr16:2,781,142-2,781,160 ccaGGTCGgctTGCCCtta Internal
323 323 chr16:743,678-743,696 atgGGTCActgTGACCcag Internal
1305 1305 chr17:46,382,536-46,382,554 cccGGACAcgaTGTCCccc Internal
239 TEX14 chr17:54,072,183-54,072,201 cacGGTCAtggTGACCtga Internal
401 SEC15L2 chr2:72,713,948-72,713,966 ggaGGTCTaggTGACCtcg Internal
17 17 chr20:54,945,262-54,945,280 gggAGACAcccTGACCtaa Internal
1607 1607 chr3:132,571,914-132,571,932 aggGGTCAtggTGACAtta Internal
1259 SLC6A6 chr3:14,429,604-14,429,622 ctgGGTCActgTGTCCgga Internal
1361 SIAH2 chr3:151,957,126-151,957,144 acaGGTCAccaTGACCtgg Internal
484 SNX24 chr5:122,216,372-122,216,390 cagGGTTAtctTAACCaac Internal
242 PKIB chr6:122,985,938-122,985,956 tttGGTCAtgtGGGCCtga Internal
1272 1272 chr6:23,720,183-23,720,201 tcgGGTCAtgcTGCCTggg Internal
795 BTBD9 chr6:38,337,561-38,337,579 tggGGTCAtggTGACTcct Internal
95 SHB chr9:37,943,504-37,943,522 gcaGGTGGggcTGCCTcca Internal  
 
Lee Yew Kok  PhD Thesis 
  22 
Table 4 ER non-binding sites validated in literatures or in-house 
Acc Num/Promoter ID* Name Genomic Location Pattern Reference
NM_000549 TSHB chr1:115,283,928-115,283,940 GGTCAgctTGACA Bourdeau et al. 2004
NM_006472 TXNIP chr1:142,927,222-142,927,234 GGTCAgtgGGATC Internal
NM_000427 LOR chr1:150,045,850-150,045,862 GGTCCaaaGGACC Internal
NM_022365 DNAJC1 chr10:22,333,030-22,333,042 GTTCAactTGTCC Internal
NM_000818 GAD2 chr10:26,545,037-26,545,049 GGTCGcagTGACC Bourdeau et al. 2004
NM_000609 CXCL12 chr10:44,202,437-44,202,449 GGTCCagcTGCCC Internal
NM_000609 CXCL12 chr10:44,203,283-44,203,295 TGTCAaaaTGGCC Internal
NM_000926 PGR chr11:100,509,203-100,509,215 AGTCAtgtTGACA Internal
NM_003646 DGKZ chr11:46,321,832-46,321,844 GGCCAtgcTGGCC Internal
 PROM0307S00016490 CTSW chr11:65,403,499-65,403,511 GACCAgccTGACC Internal
 PROM0307S00020376 C14orf131 chr14:101,872,078-101,872,090 GGCCAacaTGACA Internal
 PROM0307S00019823 DLG7 chr14:54,727,987-54,727,999 GGTCGtccAGACC Internal
NM_001437 ESR2 chr14:63,876,354-63,876,366 GACCAgccTGACC Internal
NM_003246 THSB1 chr15:37,657,943-37,657,955 GGTCAatcCCACC Internal
NM_024817 FLJ13710 chr15:69,737,514-69,737,526 AGTCAttgTTACC Internal
NM_024817 FLJ13710 chr15:69,738,257-69,738,269 GGTCAatgTGCGC Internal
NM_024817 FLJ13710 chr15:69,738,459-69,738,471 GCTCActtTGTCC Internal
 PROM0307S00021235 SH3GL3 chr15:82,077,053-82,077,065 GATCTtgcTGACC Internal
 PROM0307S00021337 SMAP-1 chr15:89,278,745-89,278,757 AGTCAatcTGTCC Internal
NM_001089 ABCA3 chr16:2,321,166-2,321,178 GGTCTtttTTACC Internal
 PROM0307S00021613 HCFC1R1 chr16:3,015,149-3,015,161 GACCAgccTGACC Internal
NM_001116 ADCY9 chr16:4,107,737-4,107,749 GGTCAggcTGGTC Internal
NM_001116 ADCY9 chr16:4,108,935-4,108,947 GGTGAaaaTGTCC Internal
 PROM0307S00022205 CAPNS2 chr16:54,100,244-54,100,256 GGTCCgtcCGACC Internal
NM_000430 PAFAH1B1 chr17:2,441,502-2,441,514 CGCCAtgtTGACC Internal
NM_001552 IGFBP4 chr17:35,851,519-35,851,531 GATCActgTAACC Internal
NM_001552 IGFBP4 chr17:35,853,510-35,853,522 GGTCAtgcTGCCC Internal
NM_002894 RBBP8 chr18:18,766,140-18,766,152 GGTCAttcTGCTC Internal
NM_017572 MKNK2 chr19:2,382,491-2,382,503 GGGCAgagTGAGC Internal
 PROM0307S00026367 BBC3 chr19:52,426,840-52,426,852 TGTCAttgTGTCC Internal
 PROM0307S00026367 BBC3 chr19:52,427,249-52,427,261 GGTCAggcTGGTC Internal
NM_148903 GREB1 chr2:11,622,443-11,622,455 TGCCAccaTGACC Internal
NM_148903 GREB1 chr2:11,625,143-11,625,155 TGTCAatcTGTCC Internal
 PROM0307S00003992 EN1 chr2:119,322,563-119,322,575 GGTTAcccTGAAC Internal
NM_020120 UGCGL1 chr2:128,563,200-128,563,212 TGTCAaaaTGTCC Internal
NM_020120 UGCGL1 chr2:128,565,292-128,565,304 TGTCAcatTGAGC Internal
NM_002665 PLGL chr2:87,884,778-87,884,790 GGTCAgtgTGCCA Internal
NM_005067 SIAH2 chr3:151,966,545-151,966,557 GCTCAtagTGCCC Internal
NM_024524 AFURS1 chr3:195,656,453-195,656,465 GGTCAttaATACC Internal
NM_013324 CISH chr3:50,626,609-50,626,621 GGCCAgagGGACC Internal
NM_014583 LMCD1 chr3:8,517,591-8,517,603 GGCCTgcaTGACC Internal
NM_032219 FLJ22269 chr4:673,249-673,261 GGGCAgagTGACT Internal
NM_004354 CCNG2 chr4:78,433,176-78,433,188 GGACAactTGATC Internal
NM_003714 STC2 chr5:172,689,912-172,689,924 GGGCAatgTGAAC Internal
NM_002184 IL6ST chr5:55,327,909-55,327,921 GGTGAgcaTGATC Internal
NM_006622 PLK2 chr5:57,792,972-57,792,984 GGTTAcagCGACC Internal
 PROM0307S00010481 OLIG3 chr6:137,857,308-137,857,320 CGTCAtccTAACC Internal
 PROM0307S00009635 FKBPL chr6:32,206,228-32,206,240 GGCCAgccCGACC Internal
 PROM0307S00009635 FKBPL chr6:32,206,311-32,206,323 CGCCAccaTGACC Internal
NM_000602 SERPINE1 chr7:100,361,980-100,361,992 GACCAgccTGACC Internal
NM_000602 SERPINE1 chr7:100,362,938-100,362,950 GGACAagcTGCCC Internal
NM_000602 SERPINE1 chr7:100,363,852-100,363,864 TGTCAagaAGACC Internal
 PROM0307S00010895 TM4SF13 chr7:16,566,080-16,566,092 GATAAgtcTGACC Internal
NM_000712 BLVRA chr7:43,570,289-43,570,301 GGTCActcTGGCT Internal
NM_000712 BLVRA chr7:43,570,774-43,570,786 AGTCAaccTTACC Internal
NM_001497 B4GALT1 chr9:33,157,593-33,157,605 GCTCAacgCGACC Internal
NM_001497 B4GALT1 chr9:33,158,622-33,158,634 GATCAgaaGGACC Internal
 PROM0307S00029895 PGPL chrY:169,893-169,905 GCTCAcgaTGACG Internal
229 SORCS1 chr10:108,692,194-108,692,212 cacAGTCAtgcTGACCcca Internal
1448 1448 chr14:38,648,346-38,648,364 attGGTCAgagTGACAgaa Internal  
The binding sites were validated in-house using both LightCycler Sytem and Applied 
Biosystems real-time PCR. 
 
Real-time PCR validations on selected binding sites: 24 validated binding and 27 non-
binding sites for estrogen receptor were randomly selected and examined using real-
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time PCR. Enrichment on the above binding sites was obtained using primers flanking 
the specific ERE to detect and quantify the ChIP-ER samples and ChIP-GST control 
DNA obtained from each SERM. Detailed tables for the real-time PCR validations for 
the validated binding and non-binding sites can be found in Appendix A and 
Appendix B respectively. 
 
Figure 4 Profile of ChIP Enrichment after Drug Treatment for Binding Sites 
Figure 4 is the profile of the enrichment for ERE binding sites. For all sites 
except 1, addition of SERM to E2 decreases the fold of enrichment to different 
degrees.  
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Figure 5 Profile of ChIP Enrichment for Non-binding Sites 
Figure 5 is the profile of the enrichment for ERE non-binding sites. The fold of 
enrichments was low in general.  
 
Figure 6 Binding Profiles for SERMs with E2 
Y-axis is the fold of enrichment. X-axis represents the different treatments. Each line 
represents different binding sites. 
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This is a different view for all the ERE-binding sites and E2 + SERM decrease 
the enrichment in general (Figure 6). 
 
Figure 7 Binding Profiles for SERMs only 
Figure 7 visualises the results for treatment with SERMs only. It is seen that RA 
or TA treatments bring up the enrichment in 14 and 15 binding sites respectively. 
Selection of negative controls 
Various negative controls were utilised in the arrays for functioning as 
hybridization controls and assessing the background signals in extraction of positive 
results. There were 4 types of negative controls that serve different functions and are 
likely to have different hybridization signals: 1) Remote regions >100kb from all 
input regions; 2) PET1 regions; 3) Exonic regions and 4) prokaryote sequences. We 
would also expect differential probe signals from closed chromatin, open chromation 
not bounded with transcription factor and open chromatin with occupied transcription 
factor. 
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1) Remote regions >100kb from all input regions: 5001 negative probes 
selected from remote regions at least >100kb from all input regions 
(Figure 8). Sequences 100kb away from all input sequences would mostly 
contain closed chromatin. 
 
Figure 8 Remote regions > 100kb from all input regions 
2) PET1 regions: Another category of negative probes came from unique 
tag with single isolated ditags classified as PET1 excluding all the 
predicted binding sites. An example of an isolated ditag belongs to the 
PET1 classification is depicted in Figure 9. About half of all PET1s 
regions were within 15kb of all our input regions. The filtering was based 
on PET1s >100kb from all our input regions and 3539 regions were 
extracted. Since PET1 is likely to contain more open chromatin with 
unbounded transcription factor, the signals from PET1 probes can be used 
to compare between open chromatin and open chromatin with bound 
transcription factor. 
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Figure 9 An example of an isolated ditag belongs to the PET1 classification 
3) Exonic regions: There were also 4997 negative probes from translated 
exon regions in human genome that were expected to give the background 
signal. In terms of hybridization signals, probes from exons regions 
probably give no or little hybridization signal.  
4) Prokaryote Sequences: There were 100 probes from prokaryotes 
sequences that have no homology and no similarity of up to 5 base pairs 
with the human genome. The prokaryotes probes are expected to give the 
lowest hybridization signals. 
In summary, we have included negative probes that have variable range of 
expected hybridization signals and from different chromatin configurations.  
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2.2 Array design considerations 
Tiling array design must strike a balance between various conflicting criterions 
for optimal design and usage of array. Criteria may include fixed-length or variable-
length probes, probe uniqueness, probe spacings and probe melting points. The 
objectives are to tile the targeted regions with probes unbiasedly at the highest 
resolution and to facilitate optimal data analysis for discovering new biology.  
Probes are designed using a sliding window and scoring on the composition 
within that window. Probes that have long runs (>5) of homopolymers or that are too 
GC rich or AT rich are avoided. The ability of the probes to self-anneal is also taken 
into account. No ambiguous bases must be present and probes should not require 
more than 148 cycles to be synthesized. 
Variable-length probes with 45-75 mers will be easier than 50-mer fixed length 
probes in passing the design criterias that consist of no ambiguous bases and not more 
than 148 cycles in probe synthesis. Variable length probes are adopted so it is easier 
than using fixed-length probes to minimize the variance of the melting points of all 
the probes. 
Besides, designing probes on only the unmasked regions based on Repeatmasker 
(Cawley, Bekiranov et al. 2004), another alternative is to make use of the frequency 
of the occurrence of probes in the whole genome. We may allow up to a certain 
frequency of occurrence such as 80 and mark those probes with high frequency. The 
masked regions are thought not to have biological significance. However, more 
evidence has illustrated the important roles these masked regions signify (Plohl, 
Luchetti et al. 2008). 
It is pertinent to check the distribution and coverage of the probes on the designed 
regions. All the input regions have been tiled with at least 6 probes. Besides ensuring 
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the sufficient number of probes in a region, the probes should be consecutively close 
to one another and distribute evenly throughout the binding region.  
2.3 Quality control of arrays 
Quality of the arrays was firstly assessed by the properties of probes designed: 
melting temperature (Tm), probe lengths and probe spacings. The specificity of the 
hybridization of ChIP DNA samples to the targeted probes is very much dependent on 
the melting temperature of probes, i.e. the higher the melting temperature, the greater 
the specificity. Longer probe length also gives rise to higher melting temperature. The 
actual melting points of all probes are reasonably close to the ideal melting 
temperature of 76 oC. The design is an isothermal array that the about 70% of the 
probes have similar melting temperature between 73 to 77 oC which ensures similar 
specificity in hybridization and avoids any hybridization artifacts or bias (Figure 10).  
 
Figure 10 Histogram of all probes’ melting temperature shows similar melting 
temperature which ensures similar hybridization specificity 
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Such a stringent contol of the melting temperature was achieved by variable 
length probe design as can be seen in Figure 11. The probe lengths are variable and 
range from 45 to 75 nucleotides. There are about 53% of probes between 45 and 47 
nucleotides long, significantly nearly half (47%) of the probes are of 48-65bp long. 
  
Figure 11 Histogram of all probe lengths show about 53% of them are 45~47 
nucleotides 
The relationship between melting temperature, probe length and GC content is 
summarized in Figure 12. In general, higher melting temperature corresponds to 
larger GC and longer probe length. 
We also checked the probe spacings which are defined as from 5’ end of 1 probe 
to the 5’end of the adjacent probe within the input regions. 76% of the probes are 
having probe spacings between 0 to 60 bps. Almost 97% probes have probe spacing 
less than 100bps (Figure 13).   
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Figure 12 Contour map of melting temperature plotted on GC and probe length 
axes illustrates that higher melting temperature corresponds to larger GC and 
longer probe length 
 
               
Figure 13 Histogram of all probe spacings indicate almost 97% of probes have 
probe spacings less than 100bps 
Due to some overlapping input regions, the probes extracted from these regions had 
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Quality control using 3 new arrays hybridized with the same samples 
The objectives are to investigate the reproducibility and consistency of the array 
data generated across 3 different arrays with the same ChIP-E2 sample. Firstly, the 
variance across all the individual probes based on the log2 ratios of E2-ERalpha(Cy5) 
over Input DNA(Cy3) on 3 different new arrays was computed.  
 
Figure 14 Histogram of Variance shows that 77% of all the probes had variances 
less than log2 ratios of E2-ERalpha(Cy5) over Input DNA(Cy3) = 0.3. It 
guarantees that the error of the mean < 30% over 3 replicates 
The result showed that about 77% of all the probes had variances less than 0.3 
(Figure 14). This means the array is capable of producing consistent probe ratios with 
little variations from array to array using the same sample.  
Variance of Signals 
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Besides checking the variances of the arrays, we also investigated the 
reproducibility of the data from the same samples. The scatter plot in Figure 15 
indicates that the 1st and 2nd technical replicates correlates very well that the data from 
the platform or arrays are reproducible. 
 
Figure 15 Scatter Plot of 1st and 2nd Technical Replicates of E2 treatment show 
great reproducibility of the array  
 
2.4 Checking the quality of reused arrays 
We checked the quality of reused arrays by hybridizing the same sample to the 
same arrays for four times that had been stripped 3 times. Figure 16A shows the 
scatter plots between first uses but scanned with different PMTs. Similarly, we plotted 
the scatter plots between 1st and 2nd uses in Figure 16B, between 1st uses and 3rd uses 
in Figure 16C and lastly between 1st uses and 4th uses in Figure 16D. Our study 
showed that the arrays are reusable up to 3rd use, the data from 1st and up to 3rd uses 
correlates very well but not the 1st and 4th uses.   
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Figure 16 Scatter plots between the different reuses on stripped arrays show 
that same array can be reused up to 3 times 
The panel shows the normalized data for Cy5 intensity, Cy3 intensity and the ratio of 
Cy5/Cy3 intensity. Normalization for the probes is based on normalized ratio = 
log.ratio - tukey.biweight(log.ratio) where log.ratio = log2(R)-log2(G). The red line 
corresponds to local regression fitting by lowess method while the purple line 
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2.5 Construction and quality control of HD2.1 Nimblegen chips for 
chromosome 21, 22 and additional regions 
Nucleosomes play an important role in gene regulation by controlling the access 
of transcription factor to DNA. The presence of nucleosomes usually implies physical 
inhibition of transcription factor access. We designed two customised high density 
arrays which contain 2.1 millions probes to tile chromosome 21 & 22 and additional 
selected 206 regions with the aims of studying the dynamic changes of nucleosome 
locations before and after drug treatment. The 178 regions are each 200kbs long and 
selected from greatest confidence ER binding sites from ChIP-PET experiment 
conducted by Lin. In total there are approximately 4.2 millions unique probes. 3 
Biological Replicates on different batches of cells have been performed on 
nucleosome samples with DM, E2 (2 treatments) on MCF-7 using the customized 
nucleosome arrays. In this design, a tightly constant overlapping 50bps probes were 
used for the purpose of defining the nucleosome positions.  
The input regions were examined for the number of probes and coverage. 
Coverage here refers to the regions covered with probes. For example, two 50-mers 
probes overlapping 20bps will have coverage of 80bps. Given that there are large 
regions masked in chr21 and chr22, the percentage of coverage for chr21 and chr22 at 
55.9% and 48.5% coverage are reasonably good. For the additional regions, the 
coverage was 77.3%. 
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 Table 5 Coverage of probes in input regions show good coverage as the 
regions not covered are due to repetitive, low complexity regions 
Input Regions Probes Coverage Length Percent Covered
chr21:1-46944323 1188230 26240149 46944323 55.9%
chr22:1-49554710 1098358 24050411 49554710 48.5%
Additional Regions 2024881 33199242 42963077 77.3%  
Since this is not an isothermal array, Figure 17 shows that only about 39% of 
probes have melting temperature between 73oC to 77oC. This is typical of many 
microarrays. 
 
Figure 17 Histogram of All Probes’ Melting Temperature for Nucleosome Array 
shows that about 39% of probes have melting temperature between 73oC to 77oC 
since this is not an isothermal array 
The probe spacings on the nucleosome arrays are checked. Majority of the probes 
have spacing less than 100bps (Table 6).  
Table 6 Majority of probes are less than 100bps spacings 
chr21:1-46944323 chr22:1-49554710 Additional Regions
Total Probes 1188230 1098358 2024881
Failed probes(Both Sides>100) ~2025 ~2034 1618
Failed probes(Both Sides>150) 985
Failed probes(Both Sides>500) 136  
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The correlations between the 3 biological triplicates were assessed (Table 7). 
Since it is the biological replicates, the correlation between biological replicates in the 
same treatment was about 0.42~0.50. 
Table 7 Correlation between arrays for Normalized Values shows that the 
correlation between biological replicates was about 0.42~0.50 
Correlation E1 E2 E3
E1 1.00
E2 0.50 1.00
E3 0.43 0.42 1.00
Correlation D1 D2 D3
D1 1.00
D2 0.50 1.00
D3 0.47 0.47 1.00  
E1 to E3 denotes the 3 biological triplicates in E2 treatment while D1 to D3 denotes the 
3 biological triplicates in DMSO treatment. 
 
With correlation of 0.49, i.e between E1 and E2 (Table 7), the scatter plot is 
shown in Figure 18. 
 
Figure 18 Scatter plot between ratio for E1 and E2 that has a correlation of 0.49 
E1 to E3 denotes the 3 biological triplicates in E2 treatment 
 
In conclusion, more than 40,000 mapped and putative ER binding sites have been 
incorporated into the customised array. We designed an isothermal array with 
E1 
E2 
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~380,000 probes that each region was tiled with at least 6 probes. The ERα specific 
binding site array followed all the important design considerations covered in this 
chapter. Briefly, variable-length probes were adopted to ensure similar hybridisation 
specificity that 70% of all probes have similar melting temperature between 73 to 77 
oC. Various quality controls of the customised arrays were carried out, which included 
assessments based on probe properties, technical and biological reproducibility and 
reuses of stripped arrays. For examples, 77% of all probes have variances less than 
0.3 within technical replicates; good data correlation up to the 3rd reuses of array and 
97% of all probes have probe spacings less than 100bps. The above validations 
assessed the performance of the array and confirmed that the array is capable for 
querying the biology questions in this thesis.     
With this customised ER chip, genome-wide binding sites profiles can be 
conveniently and comprehensively surveyed for different ChIP assays performed with 
virtually any antibodies, cell lines, drug treatments and concentrations in time course 
experiments. The array has broad applications in comparing the modulating effects of 
SERMs, the co-occupancy and interactions of various factors with ER, the chromatin 
states and histone modifications at those ER binding sites constructed on the array.   
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Chapter 3 Dynamics of Estrogen Receptor Binding in a Genome 
Wide Scale 
 
3.1 ChIP-chip analysis mapped 6482 ER binding sites 
Chromatin Immunoprecipitation (ChIP) assay was performed on MCF-7 breast 
tumor cells subjected to different treatment conditions: Vehicle (DMSO), Estradiol 
(E2), Selective Estrogen Receptor Modulator (SERM) and SERM + E2. MCF-7 
breast tumor cells were estrogen deprived for 3 days, followed by treatment for 45 
minutes. Chromatin Immunoprecipitation (ChIP) assay is an in vivo method to obtain 
enriched DNA fragments bound by a particular transcription factor through cross-
linking with formaldehyde and immunoprecipitated with a specific antibody. 
Formaldehyde cross-linking and sonication were carried out before 
immunoprecipitation was performed for ChIP DNA pull-down with ERα antibody 
(HC-20) or a non-specific GST antibody (Z-5). The cross-linking of proteins such as 
TFs to DNA allows the in-vivo studies on the interactions between TFs and DNA 
(Orlando, Strutt et al. 1997). TFs are recruited to binding sites which consist of both 
promoters and enhancers. Promoters are located within the proximity of TSS of genes 
whereas enhancers are located upstream, downstream or intragenic that is not in 
proximity to TSS. Promoters assemble the essential transcriptional machinery for 
initiation of transcription while enhancers are believed to enhance the assembly 
process by the looping mechanism which stabilises the preinitiation complex (Dion 
and Coulombe 2003). SERMs used in this study included 4-hydroxytamoxifen (T), 
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Raloxifene hydrochloride (R) and ICI 182,780 (I) and their specicific agonist and 
antagonist properties are described in Table 8.  
Table 8 Selection of SERMs 
Index SERMs Properties agonist antagonist Company Remark
1 ICI 182, 780 (I) No Yes TOCRIS No partial agonism
2 4-Hydroxytamoxifen (T) Yes Yes SIGMA More potent 




 ICI is a pure antagonist while Tamoxifen exbihits partial agonist/antagonist properties. 
Raloxifene displays tissue-specific characteristics, i.e. as an agonist in bone but as an 
antagonist in breast and uterine. (Note: 4-hydroxytamoxifen is abbreviated to 
Tamoxifen, Raloxifene hydrochloride to Raloxifene and lastly ICI 182,780 to ICI in this 
report.) 
 
To assess the quality of the experimental data, we plotted the average intensity 
for the biological triplicates along the locus for PTGES, GREB1 and IL6ST. Figure 
19A and B shows that 2 well-known ER binding sites – GREB1 and PTGES have 
high ER occupancy. Lastly, Figure 19C shows IL6ST a non-binding site that has 
negligible occupancy, i.e. low intensity in E2 condition.  
Subsequently, the corresponding changes in the enrichments for various SERMs 
on the above selected binding sites were examined in the heatmap (Figure 20). In 
general, SERMs attenuates ER recruitment, but ICI seems to have the strongest  
inhibition as shown in Figure 20A. For a non-binding site, the intensity for all 
treatments is very low and similar to one another as depicted in Figure 20B. 
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Figure 19 Assessment of experiment data using GREB1, PTGES and IL6ST 
A) Binding site for GREB1 – ER binding site with basal occupancy; B) Binding site for 
PTGES – ER binding site without basal occupancy; C) Binding site for IL6ST – ER non-
binding site. The average values represent the ratio of ChIP-ER/Input DNA and are 
derived from a minimum of two independent experiments. Concentration of E2 is 10nM. 
(E: E2 treated for 45 minutes)  
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Figure 20 Binding site profile for PTGES and IL6ST under SERMs condition 
A) Binding site for PTGES – ER binding site without basal occupancy under SERMs 
condition. Heatmap is also drawn to show the differential binding intensities since the 
plot is too clustered with lines; B) Binding site for IL6ST – ER non-binding site under 
SERMs condition. The average values represent the ratio of ChIP-ER/Input DNA and 
are derived from a minimum of two independent experiments. Concentration of E2 is 
10nM while that of SERMs is 1μM. (E: E2 treated for 45 minutes; D: DMSO used a 
vehicle; T: Tamoxifen treated for 45 minutes; R: Raloxifene treated for 45 minutes; I: 
ICI treated for 45 minutes)  
B 
A 
Along Genomic Location 
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The above binding profiles for the known ER binding sites showed expected 
property of E2 and SERMs. This confirmed that the quality of experimental data may 
be good for surveying the rest of ER binding sites. The following paragraphs 
introduce a new algorithm to determine all the ER binding sites from the ChIP-chip 
data. Various validations were also carried out to assess the statistical significance and 
accuracy of the data. Lastly, comparisons were also made with the previously reported 
putative ER binding sites.  
Results by Variable Factor Linear Model  
To identify the dynamics of ER binding in genome-wide scale, a new peak-
calling algorithm called Variable Factors Linear Modeling (VFLM) has been 
developed. All ChIP-on-chip analysis methods such as MAT, ChIPOTle and MACS 
obtain peaks from single hybridisation experiment. As they cannot handle replicates 
directly, we are forced to analyze the replicates independently and identify final peaks 
using standard non-paramteric meta-analysis procedures. Alternatively, we can 
average the data from different arrays before peaks calling and apply one of the above 
peak calling algorithms. In both cases we are ignoring the multiple factors affecting 
the measurements which will reduce power and sensitivity to detect peaks.  In contrast, 
the VFLM peak calling strategy performs linear modelling using all replicate data in 
one analysis. The advantage is that we can estimate the sources of variations that 
contribute to the errors in peak calling. Moreover, this approach provides estimate of 
variations from factors such as probe effects, batch effects of biological replicates and 
the reuse effect which the previous methods do not take into account. The importance 
of linear modelling can be demonstrated in the illustration 1A. If the experiments are 
carried out in two batches b1 and b2 for two different treatments E2 and DM. The top 
figure shows the distribution of data of a binding site for the two treatments and it can 
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be easily seen that the variations of measurements are large due to batch variations. 
Whereas the bottom figure shows the same measurements, but with the batch effects 
corrected, with much lower variations leading to potential increase in the power of the 
tests.  
 
Illustration 1 Batch effect correction in VFLM  
Another advantage of VFLM is its capability to measure directly the change in 
binding site intensity from one treatment to another by incorporating treatment as a 
factor in the linear model. This feature is not available in the existing peak calling 
methods.  
The fundamental idea in VFLM, similar to the other peak calling algorithms, is to 
use sliding window approach. At each location (x), a linear model shown in Eq1 (for 
single treatment analysis) below is fit for all probes in the window on all replicates. Pi 
is ith the probe in the window of size w at position x, bi is the batch to which the 
replicate was made, Ri is the number of the reuse of the array of the replicate and e is 
the error not accounted by any of these factors. In our analysis the window size (w) 
was chosen to be 500bps and the window was slid with a step-size of 50bps.   
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Upon fitting model at a location x, binding enrichment is computed as the 
average of the co-effecients of all probes in the window [x-w, x+w] i.e. enrichment is 
the average of probe effects. 
 
 
 The p-value of the FCx (px) is obtained by combining the individual p-values of 
the probe effects (pi) from the same [x-w, x+w] using Fisher’s inverse Chi-Square 













Where nx is the number of probes in the window [x-w, x+w] and X22nx is the chi-
square distributios with 2nx degrees of freedom. 
VFLM calls peaks when the p-value falls below PT and the fold changes are 
simultaneously above FCT (Illustration 2). 
 
 
Assumption for error follows 
FCX 
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x 
Illustration 2 Sliding window approach to determine VFLM peaks 
Using VFLM, the number of binding sites for each treatment was obtained for the 
4 categories below: 1) P-value≤0.05, Fold change ≥1.5; 2) P-value≤0.05, Fold change 
≥2; 3) P-value≤0.01, Fold change ≥1.5; 4) P-value≤0.01, Fold change ≥2 as shown in 
Table 9.  
Table 9 Results by Variable Factor Linear Model in MCF-7 
MCF-7 (E2) P<=0.01 P<=0.05 P<=0.01 P<=0.05
1.5 Fold 6482 7165 4729 4926
2 Fold 4748 4966 2682 2706
E2 Peak DM Peak
 
Upon examining Table 9, the parameters of P-value≤0.01, Fold change ≥1.5 were 
chosen to determine the peaks in each treatment. The array platform has lesser 
sensitivity than real-time PCR system so a fold change of 1.5 was chosen instead of 2. 
Comparing the p-value of 0.05 and 0.01 at the fold change of 1.5, there was only a 
little difference in the number of peaks called, so p-value of 0.01 was used as the 
(px) 
(FCx) 
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peaks would have a higher statistical significance (Table 9). Hence, 6482 E2-peaks 
were detected. We proceeded to validate the VFLM results by comparing it to other 
known databases published by Lin and Carroll. 
Validation against known databases  
We evaluated our results by checking the reproducibility of mapped binding sites 
(Table 10). There was high reproducibility of Lin’s and Carroll’s high-confidence 
data at 79.5% and 80% respectively. True positive rate was assessed to be 83.6%. 
False positive rate was low as only 0.9% of the 1819 negative control regions were 
wrongly identified. The reproducibility of Lin’s and Carroll’s low-confidence data 
was reasonably good at 30% and 51.1% respectively. There were only 5.6% of the 
predicted EREs were truly binding. This might show that ERE motif presence alone is 
not sufficient to accurately predict a true binding.  
Table 10 Distribution of Peaks Detected in Current Studies in Different 






























P-values=0.05 46 (83.6%) 953 (77.2%) 2273 (30%) 3114 (85%) 5413 (51.1%) 1716 (5.6%) 5 (7.4%) 17 (0.9%)
Positive Regions Negative Regions
 
 
Since there were overlaps among the 3 major groups of binding sites (Lin, Carroll 
and pERE) besides the additional binding sites from literature references, it would be 
interesting to study their reproducibility. The overlaps among Lin, Carroll and pERE 
are shown in Figure 21A while the overlaps among pERE, high-confidence binding 
sites of Lin and high-confidence binding sites of Carroll are shown in Figure 21B. 
Interestingly, detected 6482 peaks overlap better with Carroll’s. Refering to Figure 
21A, it can be observed that the overlapped binding sites between Lin and Carroll 
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without ERE motif have high reproducibility of 89% but those with ERE motif are 
higher (94%). However, Lin’s and Carroll’s high-confidence data with and without 
ERE motif are similarly highly reproducible at 98% (Figure 21B). Those unique Lin 
or Carroll binding sites with ERE motif are more reproducible than those without 
ERE. In general, those highly reproducible ER binding sites contain ERE motif.  
 
Figure 21 Distribution of Peaks Detected in Overlapped Input Regions. Highest 
percentages of peaks found to be common binding sites with ERE motif  
The 1st Venn diagram shows the peaks found in this thesis as the numerator while the 
reported ER binding sites as the denominator in each category and their overlaps. 
Lastly, the percentage of peaks found over the probed binding sites regions were shown 
in the 2nd Venn diagram. Lin_all and Carroll_all denote the low-confidence binding 
sites for Lin and Carroll respectively while Lin_H and Carroll_H denote the high-
confidence binding sites. 
 
VFLM results were shown to be in good agreement with databases published by 
Lin and Carroll. Here we investigated in greater detail on the overlap between VFLM 















































Overlaps Among pERE, Lin and Carroll 
A: 
B: 
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results and different categories of Lin’s data. It has distinct categories of varying 
confidence binding site sets. Figure 22 shows the percentage of peaks detected in 
different categories of Lin’s data. As could be seen, the percentage of detected peaks 
increased with higher PET number. Higher PET numbers indicated greater confidence 
in the mapped binding sites. This shows that the accuracy of the detected binding sites 






















Figure 22 Percentage of detected peaks increases with higher PET numbers of 
Lin category 
We further examined the distribution of the VFLM peaks for both the detected 
and missed 1234 high-confidence Lin data. For the detected 953 binding sites, the 
percentage of detection increases from 63.9% to 93.7% with increasing moPET 
numbers (Table 11). On the other hand, the distribution of the 281 missed sites 
showed that the percentage of missed sites decreases with increasing moPET numbers 
from 35.9% to 5.9%. 198 out of 281 missed sites (70.5%) belong to the moPET3 
category while 93.7% (284/303) are detected in the moPET category ≥ 6. Detected 
binding sites overlap substantially with higher moPET categories of 1234 binding 
sites (Lin, Vega et al. 2007). This shows that higher moPETs indicates higher 
confidence and associates with higher reproducibility.  
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Table 11 Distribution of detected 953 sites and 281 missed sites in high-
confidence Lin (1234)  
All 1234 Sites
moPET No. Sites No. Sites Percentage(1234) No. Sites
Percentage
(1234)
3 552 353 63.9% 198 35.9%
4 245 198 80.8% 48 19.6%
5 134 118 88.1% 17 12.7%
>=6 303 284 93.7% 18 5.9%
953 Detected Sites 281 Missed Sites
 
 
In summary, VFLM results were validated in databases published by Lin and 
Carroll with greater than 80% reproducibility for the high-confidence data. The next 
validation was carried out to compare the VFLM fold enrichments to the qPCR fold 
change. 
Correlation of Real-time PCR results and E2-ER ChIP-on-chip binding sites 
When correlating qPCR fold change of 77 sites obtained from Lin, C. Y., V. B. 
Vega, et al. (2007) to our ChIP-on-chip peaks, correlation of 0.54 and p-value of 
2.359e-06 (Pearson's product-moment correlation) were obtained. The reason for the 
moderate correlation could be the ChIP-on-chip signals will be lower as there may not 
have probes exactly at the peak location of the targeted binding sites.  
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Figure 23 Scatter plot on ER ChIP-on-chip intensity and qPCR 
We further examined the correlation between qPCR fold change and percentage 
of detection (Figure 24). The detection in the binding sites increased from 43% to 
100% with increasing magnitude of qPCR fold change from 2-24 to 175-551. The 
biggest jump was from 2-24 to 25-49, i.e. 43% to 81%. Fold change of ≥ 25-49 was 







2-24 25-49 50-99 100-174 175-551

















Figure 24 Detected 77 Peaks and Real-time Fold Change 
Correlation = 0.54 
P-value = 2.359e-06 
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In general, VFLM fold enrichments correlate well with qPCR fold change. 
Specifically, there was a very high percentage of detection (80%) in the array when 
the qPCR fold change was greater than 24.  
Good agreement between VFLM peaks and ChIP-Seq results 
Upon assessing VFLM results overlapped greater than 80% with known Lin’s 
and Carroll’s data and correlated well with qPCR fold change, we next compared our 
VFLM peaks with ChIP-Seq results (Unpublished data). ChIP-Seq is a most recent 
unbiased and precise approach to identify TFBS on a genome scale. This approach 
couples chromatin immunoprecipitation (ChIP) with the paired-end ditag (PET) 
sequencing strategy and the Illumina single read sequencing technology. The ChIP 
samples for ChIP-Seq experiments have the same experimental conditions as the 
ChIP-chip experiments. VFLM peaks showed good agreement – 80.0% and 53.6% of 
VFLM peaks overlap with all 17,418 and top 6500 ChIP-Seq peaks respectively 
(Figure 25). The 80% overlap was remarkably good as VFLM peaks were obtained 
from a focused array on ER binding sites and not an unbiased whole genome array.  
Figure 25 Good Overlap between VFLM Peaks and ChIP-Seq Results 
Table 12 compares the reproducibility of various published databases in VFLM 
set and top 6500 ChIPSeq set. VFLM peaks have higher percentage of coverage in 
Lin and Carroll than the ChIP-Seq data, i.e. 12.8% more coverage in high-confidence 
Lin and 16.8% more coverage in high-confidence ChIP-Seq data.  
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Table 12 Table comparing VFLM peaks and ChIP-Seq data. VFLM peaks 






























(6482) 46 (83.6%) 953 (77.2%) 2273 (30%) 3114 (85%) 5413 (51.1%) 1716 (5.6%) 5 (7.4%) 17 (0.9%)
ChIP-Seq
(6500) 46 (83.6%) 823 (66.7%) 1551 (20.5%) 2500 (68.2%) 3934 (37.1%) 1249 (4.1%) 5 (7.4%) 2 (0.1%)
Positive Regions Negative Regions
 
In summary, VFLM peaks overlapped remarkably well with ChIP-Seq data at 
56% and VFLM peaks had higher percentage of coverages in Lin and Carroll than the 
ChIP-Seq data. 
Assessing the biological replicates 
Lastly, we assessed the robustness of the pipeline (ChIP-chip-VFLM) by 
computing the peaks using leave-one-out strategy. As can be seen in Figure 26, TE 
peaks are the results from VFLM using all 3 biological replicates while TE1, TE2 and 
TE3 Peaks are the results from using any 2 biological replicates leaving out 1st, 2nd 
and 3rd replicate respectively. The numbers of peaks found were in general 
comparable to TE across TE1 to TE3. The standard deviation and mean for the TE1, 




TE Peaks TE1 Peaks TE2 Peaks TE3 Peaks
Mean for
TE1 to TE3 
Std. Deviation 
for
TE1 to TE3 
Number of Binding 
Sites 6078 6219 5091 4817 5376 743  
Figure 26 Linear model for MCF-7 (Takes any 2 out of 3) 
Overlap study was performed between TE1, TE2 amd TE3 peaks using the parameters 
Fold change ≥1.5 and p-value ≤0.01. The percentage of overlaps varied from 89% to 
93% with respect to the peaks of smaller size (Table 13).  
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In summary, the standard deviation and mean for the TE1, TE2 and TE3 were 
reasonably good. The leave-one-out strategy showed good rebustness of the pipeline 
(ChIP-chip-VFLM) as the percentage of overlaps were at least 88.7% between two 
leave-one-out computations.  
3.2 Most ER binding sites are pre-occupied by ER and they have a 
greater ER recruitment upon E2 treatment  
For years, researchers have been intrigued by the mechanism by which estrogen 
receptor selects and utilises its binding sites. In the past, most of the analysis on 
estrogen receptor binding concentrated on the ratio of Estradiol (E2) over DMSO 
treatment. Interestingly, the analysis on the individual treatments revealed a number 
of new aspects in the mechanism of estrogen receptor binding. Firstly, we observed 
that most ERα binding sites are occupied by ERα even before estradiol treatment. We 
detected 4729 sites in DMSO treated cells. The binding sites were obtained for each 
drug treatment through VFLM that required at least 1.5 fold enrichment at p-value ≤ 
0.01. In E2 treatment, there were 6482 binding sites. 4205 or 65% of which had a 
preferential binding to locations with basal occupancy, i.e. 90% of DMSO occupied 
remained to be bound by ERα. (Figure 27) 
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Figure 27 Overlap between binding sites found in E2 and DMSO treatment shows 
65% of all E2 binding sites are pre-occupied 
 
 
Figure 28 Histogram of Difference (E2 – DMSO) 
Figure 28 shows the histogram of the difference (E2 – DMSO). 2 cut-offs of 1.2 
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sites with fold change increases upon drug treatment were greater than 1.2 fold 
changes.  
 
Figure 29 Scatter plot between E2 and DMSO treatment 
The black-coloured points denote enrichments greater than 1.5 fold in both E2 and 
DMSO conditions; green-coloured denotes E2 greater than 1.5 fold while blue-coloured 
points denote DMSO greater than 1.5 fold.  
 
Figure 30A showed a well-known ER binding site – GREB1. It was seen that the 
average intensities were quite high even in DMSO condition. This could be an 
example of binding site with high basal occupancy. On the other hand, Figure 30B 
shows a binding site of PTGES that has negligible basal occupancy, i.e. low intensity 
in DMSO condition but the intensity becomes high upon E2 treatment.  
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Figure 30 GREB1 has basal occupancy while PTGES has no basal occupancy 
A) Binding site for GREB1 – ER binding site with basal occupancy; B) Binding site for 
PTGES – ER binding site without basal occupancy. The average values represent the 
ratio of ChIP-ER/Input DNA and are derived from a minimum of two independent 
experiments. Concentration of E2 is 10nM. (E: E2 treated for 45 minutes; D: DMSO 
used a vehicle)  
Pre-occupied estrogen receptor binding sites have a greater ER occupancy 
upon E2 treatment  
We would like to investigate whether pre-occupied estrogen receptor binding 
sites have a greater ER occupancy upon E2 treatment. We plotted the box plots for the 
E2 and DM ratios in the two categories of (1) Pre-occupied (E2_DM) and (2) not pre-
occupied or new binding sites (E2Only). Interestingly, Figure 31 shows that both E2 
B 
A 
GREB1 ~ 9500 
~ 2800 
PTGES 
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and DM fold enrichments (log scale) showed a greater interquartile range of 1.01 and 
0.80 respectively in the ER pre-occupied binding sites compared to the non-occupied 
binding sites of 0.46 and 0.27 for E2 and DM respectively. This implied that pre-
occupied binding sites had higher fold enrichments. Interestingly, E2DM_DM had a 
higher ER enrichment than E2Only_E2, contrary to the notion that binding sites 
enrichments were typically higher in E2 treatment.  
 
Figure 31 Box plots between categories for E2_DM and E2_only 
Both the T-test (Significance for the difference in 2 means) and F test (Significance for 
the difference in 2 variances) between E2DM_E2 and E2Only_E2 shows p-value < 
2.2e-16. Similarly for E2DM_DM and E2Only_E2. 
 
In summary, 65% of all E2 binding sites were pre-occupied and those pre-
occupied sites had higher fold enrichment.  
3.3 SERMs impose small changes to ER binding locations but greatly 
reduce ER binding affinity 
Although SERMs have been successfully used to treat breast cancer patients, the 
exact mechanisms by which SERMs modulate estrogen receptor binding are not well 
understood. Here we examined how SERMs affect the ER binding locations and the 
p < 2.2e-16 
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corresponding binding intensity. Since the customized array is tailored towards all 
literature reported ER binding sites and is not a true whole-genome array, we are 
capturing the changes made by SERMs and counting the peaks of SERMs on the ER 
binding sites available on the array. Figure 32 shows the peaks detected in E2, 
SERMs alone and SERMs + E2. The number of peaks detected among the different 
treatments was fairly similar, ranges from around 5000 to 6000 peaks.  
 
Figure 32 Peaks detected in MCF-7 by Linear Model 
T, R and I indicate Tamoxifene, Raloxifene and ICI respectively while TE, RE and IE 
were combination of E2 and SERMs. 
 
About 80% of the binding sites in SERMs overlapped with those from E2 
treatment as depicted in Figure 33 while between 60~75% of binding sites in E2 
remained intact with those from SERMs as indicated in Figure 34. The results showed 
that E2 or SERMs-liganded estrogen receptors still utilized very similar sites, and 
binding sites induced by SERMs were also very specific and similar to those induced 
by E2.  
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Figure 33 Overlap in peaks between E2 and SERMs (Percentage of SERMs) 
 
Figure 34 Overlap in peaks between E2 and SERMs (Percentage of E2) 
Tamoxifen, Raloxifene and ICI shared a high percentage of binding sites with E2. 
Though ER under these different treatments occupied the same binding sites, the 
intensities were different and mostly attenuated under SERMs condition, compared to 
those of E2. Figure 35 shows that there are unique sites to Tamoxifen and Raloxifene. 
It was interesting that E2, Tamoxifen and Raloxifene shared 4427 common binding 
sites. This indicated the specificity of SERMs since they affected largely ER binding 
sites.  
Overlap in Peaks : 























Overlap in Peaks : 
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Figure 35 Overlap between E2, Tamoxifen and Raloxifene peaks 
After we found that SERMs imposed small changes to ER binding location, we 
next asked whether the changes to ER binding recruitment were affected by SERMs. 
We obtained the peaks that did not just increase upon drug treatments but had a 
difference of greater than 1.5 fold changes and p-value ≤ 0.01 with reference from 
DMSO (control). The differential enrichment (Treatment – DMSO) is given by the 
coefficient of T in the VFLM model as indicated in Eq2. 
Eq2  Differential VFLM equation for finding peaks for the difference 
T denotes the differential fold change due to the different treatments. Peak fold changes 
are computed from average of probe effects. P-values are obtained from fisher inverse 
Chi-Square of p-values of probe effects.  
 
The highest number of binding sites with significant difference from DMSO was 
seen in E2 treatment and number of different binding sites in SERMs from Tamoxifen 
to ICI  far less than that of E2 (Figure 36).  
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Peaks in Difference (Treatment - DMSO) 
















Figure 36 Peaks in Difference (Treatment – DMSO) detected in MCF-7 by Linear 
Model 
The overlap in differential enrichment (Treatment – DMSO) was performed 
between E2 and SERMs. The overlaps were plotted in terms of percentage of E2 
(Figure 37) and percentage of SERM (Figure 38). The overlap of E2 was lower than 
20% while the overlap in SERMs was between 20 to 50%. The 20% overlap in 
percentage of E2 suggested that although the estrogen receptor occupied similar 
binding sites in both E2 and DMSO treatments, those sites were induced with 
different intensity. E2 treatment had the strongest binding sites intensity.   
Overlap in Difference 
(Treatment - DMSO) : 




















Figure 37 Overlap in difference (treatment – DMSO) between E2 and SERMs 
(Percentage of E2) 
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Overlap in Difference 
(Treatment - DMSO) : 




















Figure 38 Overlap in difference (treatment – DMSO) between E2 and SERMs 
(Percentage of SERM) 
To further confirm that the intensities for E2 binding are the strongest, we plotted 
the distribution for E2, T, R and I binding sites in Figure 39 and for E2, TE, RE and 
IE binding sites in Figure 40. In Figure 39, it can be seen that the order of magnitude 
in decreasing manner is E2, T, R and I. Tamoxifen tends to induce ER binding similar 
to E2 whereas ICI tends to inhibit the action of E2 the strongest. We observed the 
same descending order of E2, TE, RE and IE in Figure 40.  
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Figure 39 Distribution of ratio intensities for E2, T, R and I Binding Sites 
 
Figure 40 Distribution of ratio intensities for E2, TE, RE and IE Binding Sites 
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In summary, SERMs and E2 shared about 80% common binding sites but the 
intensities were much lower for SERMs.  
3.4 ER-SERMs utilize tethering mechanism much more than ER-E2 and 
de novo motif predictions indicate shifting of preferential binding 
motif 
Since ER binding sites are expected to predominantly contain full ERE sequence, 
we assessed the distribution of full ERE, half ERE and no ERE in the binding sites 
found in each treatment. As shown in Table 14, all treatments show a high percentage 
(60%) of binding sites carrying the full ERE. This percentage was significantly higher 
than the 4.1% of a randomly generated 100,000 DNA sites. Random sites showed 
42.7% of fragments having half ERE which indicated the abundance of half ERE 
present in genome. The percentages of binding sites with no ERE for all treatments 
range from 5~8 % (see Table 14), which were significantly lower than the background 
of 53.2%.  
Table 14 Distribution of full ERE, half ERE and no ERE 
,
E2 TE T RE R I Random
Total BS 6482 6086 6146 4627 5243 4704 100000
BS with Full ERE 4232 3833 3852 2787 3285 2657 4100
BS with Half ERE 1938 1856 1892 1463 1585 1731 42700
BS with no ERE 312 397 402 377 373 316 53200
BS with Full ERE
(Percentage) 65.3% 63.0% 62.7% 60.2% 62.7% 56.5% 4.1%
BS with Half ERE
(Percentage) 29.9% 30.5% 30.8% 31.6% 30.2% 36.8% 42.7%
BS with no ERE
(Percentage) 4.8% 6.5% 6.5% 8.1% 7.1% 6.7% 53.2%  
The percentages of binding sites with no ERE was significantly lower (p-value = 
0.037) than the percentages of the SERM-unique binding sites contain no ERE (Table 
15) which range from 11~19%. This implies that the unique binding sites to SERMs 
more likely to use alternative binding mechanism such as the tethering mechanisms 
by anchoring to another transcription factor like Sp-1.  
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Table 15 Distribution of full ERE, half ERE and no ERE for unique binding 
sites to SERMs 
TE T RE R I Random
Total BS 1036 1186 580 577 669 100000
BS with Full ERE 530 597 258 253 252 4100
BS with Half ERE 363 421 213 215 344 42700
BS with no ERE 143 168 109 109 73 53200
BS with Full ERE
(Percentage) 51.2% 50.3% 44.5% 43.8% 37.7% 4.1%
BS with Half ERE
(Percentage) 35.0% 35.5% 36.7% 37.3% 51.4% 42.7%
BS with no ERE
(Percentage) 13.8% 14.2% 18.8% 18.9% 10.9% 53.2%
Unique to SERM (Exclusive from E2)
 
When doing de novo motif prediction on the top 500 E2 binding sites, an ERE-
like motif was obtained (Figure 41).  We further tested the motifs underlying unique 
sites. With reference to Figure 42, unique TE and T binding sites also give similar 
ERE-like sequences. For unique RE and R binding site, the obtained 13bps motifs 
were similar to the ERE consensus sequences except a 1 bp shift. Given that unique 
RE and R were different and obtained separately, this 1bp shift was likely not due to 
random. This could be due to a conformation change in ER+R complex (complex 
formed when ER binds with R) that the preferential binding to ERE site was shifted 
by 1 bp. This conformation change was similar for the mixture of ER+E2 / ER+R 
complexes when co-treatments of E2 and R were applied. Lastly, it seemed that ER+I 
complex had the greatest conformation changes that the de novo motif for ER+I 
complex comprised only 1 half-ERE “GGTCA”, i.e. the other half-site “TGACC” 
were not observed from the relative frequency of the nucleotides. The sequences 
flanking the half-ERE were also very different. Furthermore, the typical 3-spacer 
sequences were not present. In summary, ER+I complex had the greatest 
conformation change and the de novo motif was also the least similar to an ERE 
sequence.  
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3.5 Binding sites with basal occupancy are more accessible to TF than 
those without basal occupancy 
Nucleosome positionings and dynamics play important roles in gene regulation 
and malfunctions in nucleosome regulations give rise to cancer and defective growth 
(Bu, Evrard et al. 2007). It has been well-established in yeast that active promoters 
have corresponding nucleosome depletion (Lee, Shibata et al. 2004). We examined 
how the nucleosome occupancy varies on different categories of binding sites that 
were induced in E2 with and without basal occupancy. It is posited that the opening-
up of chromatin was greater in binding sites with basal occupancy than those without 
basal occupancy on average. ERE locations were computationally determined for both 
E2_DM and E2_only categories. Subsequently, the average nucleosome profiles were 
plotted from the center of ERE for each category as shown in Illustration 3.  
 
Illustration 3 How average nucleosome profiles are obtained 
The average nucleosome profiles for about 1507 and 521 binding sites found with 
nucleosome probes for the E2_DM and E2_only categories respectively are shown in 
Figure 43. Using student’s t-test with unequal sample sizes and unequal variances, the 
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p-value was 2.16E-8 for the difference between the nucleosome signals from E2_DM 
and E2_only categories at the center of ERE. The nucleosome profile for E2_DM 
showed a clear depletion of nucleosome, indicative of open chromatin conformation. 
On the other hand, there was no clear nucleosome depletion for the E2_only category. 
The above figure may confirm a typical relationship interplayed between nucleosomes 
and transcription factors binding that nucleosomes were initially well-positioned at 
equal intervals and opened up to facilitate better transcription factor binding. The 
depletion in nucleosomes for E2_DM may also be attributed to constitutive accessible 
promoters that the binding sites are located in DNA regions not associated with any 
histones, i.e. in a linker region. The reasons for the lack of discernable nucleosome 
depletion in E2_Only could be that the accessibility to promoters is transient as 
mediated by the SWI2/SNF2 chromatin remodeling complexes. Hence, the 
nuclesomes may not be positioned permanently in the same place due to transient 
placement or eviction of histones and nucleosome sliding of histone octamer, which 
explains the low average nucleosome occupancy observed for the E2_Only.  
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Figure 43 Nucleosome profiles for E2_DM and E2_only 
We next examined whether the nucleosome profiles had any relation to the ER 
occupancy level. We subdivided E2_DM and E2_only categories by the fold 
enrichment of ER occupancy and plotted the respective nucleosome profiles. There 
were 878, 629, 412 and 109 binding sites found with nucleosome probes for the 
categories E2_DM_gt15 (Fold change≥1.5), E2_DM_lt15 (Fold change≤1.5), 
E2Only_gt15 (Fold change≥1.5) and E2Only_lt15 (Fold change≤1.5) respectively. 
For the category E2_DM, greater fold change corresponded to greater nucleosomes 
depletion. The nuclesome profiles for E2 were found to be significantly different 
between E2_DM_gt15 and E2_DM_lt15 (p-value = 3.649E-136 using student’s t-test). 
For the category E2_only, lesser fold change seemed to have more fluctuations and 
more similar to the DMSO condition.  
p-values = 2.16E10-8 
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Figure 44 Profiles of nucleosome (Categorized w.r.t 1.5 fold change) 
 
3.6 Binding sites with basal occupancy show greatest FAIRE signals and 
highest H3K4Me1 enhancer marks, indicative of more accessible 
DNA regions 
Using ChIP-on-chip experiments covering 30Mb of human genome, it was found 
that active promoters have high signals in H3K4Me3 whereas enhancers have high 
signals in H3K4Me1 but not H3K4Me3 (Heintzman, Stuart et al. 2007). 
Formaldehyde-Assisted Isolation of Regulatory Elements (FAIRE) is an experimental 
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procedure to isolate nucleosome-depleted DNA from chromatin. In FAIRE, DNA 
coincident with the location of DNaseI hypersensitive sites, transcriptional start sites, 
and active promoters in human cell lines is enriched. Both the FAIRE experiment and 
the ChIP experiement with H3K4Me3 antibodies were performed in MCF-7 cell line 
under both E2 and DMSO conditions. 
With reference to Figure 45, the category of E2_DM was seen with the highest 
FAIRE signal, E2_only had the next higher FAIRE signal. Student t-test on the 
FAIRE signal between E2_DM and E2_only showed statistically significant 
difference (p-value =3.392e-12). On the other hand, H3K4Me1 signal stayed the 
highest for the category E2_DM. Student t-test on the H3K4Me1 signal between 
E2_DM and E2_only also showed statistically significant difference (p-value < 2.2e-
12). Only the category E2_DM with basal occupancy has observable high FAIRE and 
H3K4Me1 signals compared to E2_Only category without basal occupancy. High 
H3K4Me1 signals in the category E2_DM might indicate that the majority of the 
basal occupied binding sites were functioning as an enchancer. High FAIRE signals in 
the category E2_DM might indicate that the majority of the basal occupied binding 
sites were located in more opened chromatin configuration. This observation of 
E2_DM involved more in opened chromatin configuration was previously seen in the 
nucleosome profile (Figure 43) and is confirmed again here. On the other hand, the 
binding sites in E2_only category were involved in much lesser role as enhancers and 
situated in much less opened chromatin configuration.  
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Figure 45 Profiles of FAIRE, K4Me1 and Nucleosome Signals 
A) Profiles of FAIRE and K4Me1 Signals for E2_DM; B) Profiles of FAIRE, K4Me1 
and Nucleosome Signals for E2_only; The list of perfect consensus ERE, ERE with 1 or 
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In summary, binding sites with basal occupancy play greater roles as an enhancer 
due to the high H3K4Me1 signals and also situated in more opened chromatin 
configuration as shown by the high FAIRE signals. The above observations were not 
seen so much in binding sites without basal occupancy.   
3.7 FOXA1 does not play majoy role as a pioneering factor but largely 
attrited to constriction while GATA3 functions as co-factor 
Earlier studies on Transfac analysis has detected the presence of enriched 
GATA3 and FOXA1 consensus sequences proximal to ER binding sites (Carroll, 
Meyer et al. 2006; Clark, Burch et al. 2007). ChIP-on-chip studies enable the actual 
mapping of the binding sites of these transcription factors – GATA3 and FOXA1. 
Here we correlated ER binding sites to FOXA1 and GATA3 binding sites to 
investigate in detail their co-occupancy as evidenced by Transfac analysis and how 
FOXA1 may function as pioneer factor, which opens the chromatin to allow ER 
accessibility, as previously reported (Carroll, Liu et al. 2005),. 
 Table 16 shows the VFLM results for FOXA1 and GATA3 based on the same 
criteria used for MCF-7 cell line, i.e. p-value ≤0.01 and fold change ≥1.5, 1725 and 
7706 FOXA1 peaks were found in E2 and DM treatments. Whereas GATA3 has 2074 
and 1371 peaks in E2 and DM treatments. Interestingly, FOXA1 was found to have 
4.5 times more peaks in DMSO condition compared to E2 condition. But GATA3 has 
similar number of peaks in both treatments. 
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Number of Binding Sites 136 2074 1371  
 
Figure 46 shows the overlap between FOXA1 binding sites found in E2 and 
DMSO treatments, 71% of the peaks in E2 have basal occupancy i.e. presnt in DM 
treatment also. On the other hand, very few (~20%) GATA3 peaks in E2 have basal 
occupancy as shown in Figure 47. 
 
Figure 46 Overlap between FOXA1 E2 peaks and FOXA1 DM peaks 
 
 
Figure 47 Overlap between GATA3 E2 peaks and GATA3 DM peaks 
 
We then examined the dynamics of the shifts in TF binding before and after E2 
treatment.  Of particular interest is whether FOXA1 identifies ER binding sites after 
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E2 stimulation which would be the case for a pioneering factor, or GATA3 may be 
found in more ER sites in E2 stimulation as woud be the case for a co-factor.   
We investigated the overlap between ER E2 peaks with both FOXA1 and 
GATA3 peaks under both E2 and DM conditions, see the 3-way venn diagrams 
between ER peaks and FOXA1 peaks in Figure 48.  
 
 
Figure 48 Overlap between FOXA1 peaks and ER peaks 
A: Overlap between FOXA1 DM peaks, ER E2 and DM peaks ; B: Overlap between 
FOXA1 E2 peaks, ER E2 and DM peaks; C: Overlap between ER E2 peaks, FOXA1 E2 
and DM peaks ; D: Overlap between ER DM peaks, FOXA1 E2 and DM peaks 
 
FOXA1 binding was restricted in the diversity of sites by 5 fold.  However, we 
observed that FOXA1 binding was lost at all sites regardless of subsequent ER 
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FOXA1 is not a pioneering factor (i.e. a factor that first binds leading to the 
enhancement of ER binding) but that all FOXA1 binding is reduced genome wide.  
 
 
Figure 49 Boxplot of Change in FOXA1 occupancy in sites co-occupy ER binding 
sites vs. those that are not used as ER binding sites from DM to E2 condition 
 
Figure 49 shows the boxplots of the differential enrichements of 222 and 1002 
binding sites. Our results show that there is global decline in all FOXA1 binding but 
the decline in FOXA1 binding used by ER is steeper than those sites without ER 
binding (t-test p-value = 9.415e-13). Therefore, FOXA1 binding site constriction is 
not the sole mechanism. Also, it is unlikely that the major role of FOXA1 is a 
pioneering factor for all ER binding sites but may still have a significant role in ER 
biology as a partner factor. The observation that ER recruitment is associated with 
falling off of FOXA1 at most of the sites is largely attributed to FOXA1 binding sites’ 
constriction and partially due to FOXA1 role as a pioneering factor for a few ER 
binding sites.  
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GATA3 on the other hand appears to behave with different kinetics.  While there 
is a considerable overlap between FOXA1 sites before and after E2 (with the only 
difference in the reduction in the number of other sites), GATA3 showed a modest but 
significant expansion of the number of binding sites (1370 to 2073) and a 
considerable shift in binding sites after E2 (Figure 50).  The overlap with ER binding 
sites also increased after E2.  This suggests that GATA3 functions as a co-occupying 
cofactor for ER.   
 
  
Figure 50 Overlap between GATA3 peaks and ER peaks 
A: Overlap between GATA3 DM peaks, ER E2 and DM peaks ; B: Overlap between 
GATA3 E2 peaks,ER E2 and DM peaks; C: Overlap between ER E2 peaks, GATA3 E2 
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Similarly, we investigated whether GATA3 can potentially function as a 
pioneering factor for ER. To examine this, we assessed the differential enrichment of 
of GATA3 binding sites common to both conditions that co-occupy ER binding sites 
vs. those do not i.e. 98 binding sites vs. 310 binding sites respectively as shown in 
Figure 50C. The boxplots of the differential enrichments of these two sets of binding 
sites is shown in Figure 51. There is no significant decline in GATA3 occupancy in 
the ER co-occupied sites and it is not different from the sites not used by ER. This 
indicates that GATA3 is not a pioneer factor for ER.  
 
Figure 51 Boxplot of Change in GATA3 occupancy in sites co-occupy ER binding 
sites vs. those that are not used as ER binding sites from DM to E2 condition 
 
In summary, FOXA1 does not play major role as a pioneering factor but the 
observation that ER recruitment associates with FOXA1 falling-off at most of the 
sites is largely attributed to FOXA1 binding sites’ constriction. On the other hand, 
GATA3 do not function as a pioneer factor but acts as a co-factor.  
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3.8 H3K4Me1 is the most predictive factor for identifying ER binding 
sites 
We would like to find rules that govern the binding sites occupancy by ER and 
make prediction on the binding sites utilization from the H3K4Me1 histone mark, 
FOXA1, GATA3 and FAIRE Signals. Using 6444 E2 binding sites and randomly 
selected 3333 non-binding sites, the corresponding signals at the binding sites location 
were extracted for the H3K4Me1 histone mark, FOXA1, GATA3 and FAIRE Signals. 
All binding sites that corresponded to known amplified regions were removed from 
the data analysis as amplified regions tend to exaggerate the binding sites enrichment 
which might not reflect true biological significance. Subsequently, the ‘rpart’ package 
in R, which is based on Classification and Regression Trees (CART) algorithms, was 
used for constructing the tree.  
 
Illustration 4 Decision Tree for rules governing ER binding 
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By using the ChIP-Seq counts of individual epigenetic marks or the sum of the 
ChIP-Seq counts of a group of epigenetic marks, the receiver operating characteristic 
(ROC) curve was constructed (Figure 52).  This is a graphical representation of 
sensitivity i.e. proportion of true positives versus (1 – specificity) i.e.  proportion of 
false positives. The ideal situation is to obtain significant true positive fraction and 
negligible false positive fraction, which leads to an ideal plot of an upper triangle. To 
facilitate the comparison between different models, the Area Under the ROC curve 
(AUC) was computed.  The higher the AUC values, the better the model in classifying 
the 2 classes of binding and non-binding sites.  
 
Figure 52 Plot of ROC curve for K4ME1 epigenetic mark 
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Table 17 Summary of AUC for all epigenetic marks alone and in 
combinations 
 
Based on Table 17, the optimal model for classifying ER binding sites and non-
binding sites is based on the combination consists of H3K4ME1 and FAIRE. 
H3K4ME1 alone was not far below. There was a slight improvement of 0.011 AUC 
over the prediction when combination of H3K4ME1 and FAIRE were used together 
compared to H3K4ME1 alone. Interestingly, FOXA1 and GATA3 marks alone were 
the worst predictors for the classification of putative ER binders. 
3.9 ER regulates distinctive promoters and enhancers in Ishikawa cell 
line from MCF-7 
ER is distributed with varying concentrations in different tissues. Possible 
explanations for the tissue-specific effects may be attributed to the differing levels of 
ER present and the differential transactivation properties of ER when binding to 
different enhancers. We hypothesized that the distinctive actions of ER in different 
cell lines is due to the distinctive and diverse binding sites profiles. Hence we 
obtained the binding site profile in uterus cell line (Ishikawa) and compared it to 
breast cell line (MCF-7). Table 18 shows the VFLM results on Ishikawa cell line. 
Index K4ME1 FAIRE FOXA1 GATA3 AUC
1 1 1 0 0 0.855
2 1 0 0 0 0.844
3 1 1 0 1 0.842
4 1 1 1 0 0.829
5 1 0 0 1 0.825
6 1 1 1 1 0.813
7 1 0 1 0 0.805
8 1 0 1 1 0.785
9 0 1 0 1 0.714
10 0 1 0 0 0.704
11 0 1 1 1 0.694
12 0 1 1 0 0.693
13 0 0 1 1 0.608
14 0 0 0 1 0.607
15 0 0 1 0 0.574
Lee Yew Kok  PhD Thesis 
  83 
Based on the same criteria used for MCF-7 cell line, i.e. p-value ≤0.05 and 1.5 fold 
change, 3661 E2-peaks, 4913 T-peaks and 5869 R-peaks were obtained. As seen in 
Figure 53, the overlap of MCF-7 and Ishikawa E2-peaks is only 12% of MCF-7 E2-
peaks or 22% of Ishikawa E2-peaks. This indicates almost completely different 
utilization of ER binding sites in MCF-7 and Ishikawa cell lines.  





(E2) E2 Peak DM Peak
Number of Binding 





(T) T Peak DM Peak
Number of Binding 





(R) R Peak DM Peak
Number of Binding 
Sites 8481 5869 710  
 
 
Figure 53 Overlap in binding sites between MCF-7 and Ishikawa with E2 
treatment 
When we compared the overlap between MCF-7 T-peaks and Ishikawa T-peaks 
as shown in Figure 54 and the overlap between MCF-7 R-peaks and Ishikawa R-
peaks as shown in Figure 55, there were overlaps of 6.4% and 8.1% of Ishikawa peaks 








88.1% 11.9% or 
21.6% 
78.4% 
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binding sites in MCF-7 and Ishikawa cell lines will be more distinctly different when 
SERMs were used instead of E2. Previously, the overlap was 22% when E2 was used 
instead of SERMs. This suggests that the mechanisms of SERMs actions are unique in 
different cell lines, thus changing the overlap from 22% to less than 10%.  
 
 




Figure 55 Overlap in binding sites between MCF-7 and Ishikawa with R treatment 
3.10 Concluding remarks 
In conclusion, we obtained genome-wide binding sites profiles with the 
customised ER chip for different drugs treatments (E2, T, R and I), different 
antibodies (ER, H3K4Me1, FOXA1 and GATA3), different experiments (ChIP and 
FAIRE) and different cell lines (MCF-7 and Ishikawa cell lines). A new algorithm 

















95.0% 5.0% or 
6.4% 
93.6% 
91% 9.0% or 
8.1%
91.9%
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E2 treatment. Genome-wide binding sites analysis showed high prevalence of pre-
occupied ER binding sites which also had a greater ER recruitment upon E2 treatment. 
Binding site profiles for SERMs showed similar location as E2 but the ER binding 
recruitments in SERMs were significantly much less than in E2. De novo motif 
analysis on the unqiue binding sites to different treatments showed that ER-SERMs 
might utilize tethering mechanism much more than ER-E2. ER-SERMs conformation 
was different in different SERMs with I seemed to have the greatest differential 
conformation change, followed by R and the least conformation change was T.  
Comparing E2 binding sites with and without basal occupancy, binding sites with 
basal occupancy showed more accessible chromatin configuration, had the greatest 
FAIRE signals and highest H3K4Me1 enhancer marks. H3K4Me1 was also found to 
be the most predictive factor for identifying ER binding sites through both decision 
tree and ROC curve. We also further confirmed the role of FOXA1 as pioneering 
factor while GATA3 functions as co-factor. Lastly, we showed that the ER binding 
were regulated differently in MCF-7 and Ishikawa cell line.   
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Chapter 4   Integrative Analysis of SERMs on ER Responses 
on a Genome Wide Scale 
4.1 Identification of regulated genes in SERMs and E2 treatments 
A comprehensive dataset of time-course microarray experiments was performed 
to investigate the effects of estrogen and SERMs treatment on gene expression 
profiles and to identify estrogen responsive genes. Estrogen treated (10 nM) or 
SERMs treated and DMSO-mock MCF-7 cells (negative control) for 0.5, 3, 6, 9, 12, 
24, and 48 hours were collected for RNA extraction and the labeled cDNA were 
hybridized to microarrays (HG-U133 Plus). 3 biological replicates were performed for 
each time point. The whole process of Affymetrix data analysis procedure is 
illustrated in Figure 56.  
 
Figure 56 Schematic of Affymetrix gene expression analysis 
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Normalisation was performed for all microarrays using Robust Multichip Average 
(RMA) Normalisation (Irizarry, Ooi et al. 2003) from the AFFY package with the 
software R (Ihaka R. & Gentleman R. 1996). Subsequently, the normalized data was 
analyzed using Pooled Variance Meta Analysis 1  and ranked by their scores. The 
expression values are given by the average of (E2/SERMs at time t – E2/SERMs at 0 hr) 
– (DMSO at time t – DMSO at 0 hr). Regulated genes are obtained based on Data-
driven Smoothness Enhanced Variance Ratio Test (dSEVRAT)2 cut-off≥200, minimum 
PVMA p-value ≥0.05 in any time points from 3 hrs to 48 hrs and fold change greater 
than 1.5 fold (≥0.585) or less than 1.5 fold (≤-0.585) in any time points from 3 hrs to 48 
hrs.  
Briefly, Pooled Variance Meta Analysis method defines a new T-statistics that 
incorporates a pooled variance from all the variances from different treatments. This 













1 Juntao li, Sneha Ravi, Jianhua Liu and R. Krishna Murthy Karuturi, Pooled Variance Meta-
analysis for Small-sample Multi-group Microarray Expression Data Analysis, in the poster proc of The 
18th Intl Conf on Genomic Informatics (GIW'07) , pp171-172, December, 2007, Singapore. 
2 Juntao Li, Jianhua Liu and R. Krishna Murthy Karuturi . Data-driven Smoothness Enhanced 
Variance Ratio Test to Unearth Responsive Genes in Unreplicated 0-time Normalized Time-course 
Microarray Studies, Springer Verlag Lecture Notes in Bioinformatics series for ISBRA'07 , USA, May 
2007.  
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unified or pooled variance will enable a better power to detect the responsive genes 
and comparison of the data across treatments and minimize the comparison errors 
arise from different variances of treatments due to differing variations of samples 
within the same treatment. Data-driven Smoothness Enhanced Variance Ratio Test 
(dSEVRAT) is able to assess the general smoothness of the expression of gene across 
time points. It is an accumulative measurement of the change in expressions between 
2 consecutive time points. In general, most gene expressions should follow a trend 
with only one or two turning points for the time course we have. Thus the dSEVRAT 
score is able to filter out genes with high noises or fluctuations that are probably not 
having any biological significance. 
Figure 57 below shows the number of probesets of genes filtered out by each 
criterion and their overlap for E2 treatment. Total number of probesets of genes 
selected was 12171, 16007 and 8009 for the criteria of p-value≤0.05, smoothness 
score≥200 and fold change≥1.5 respectively. When the criteria of both p-value and 
smoothness score were satisfied, the fold change criterion was also mostly fulfilled. 
Smoothness criterion alone also fulfilled either the criteria of P-value or fold change 
or both.  There were 8117 probesets of genes that satisfied both p-value and fold 
change criteria but out which 4172 might have irregular changes along the time points 
so they were not selected.  Lastly, we selected 3945 probesets of genes that fulfilled 
all 3 requirements: P-value≤0.05, smoothness score≥200 and fold change≥1.5. 
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Figure 57 Selection of probesets of genes based on 3 criterias 
Using the data analysis outlined above, 3945 probesets of genes or 3098 E2-
regulated genes were obtained. Regulated genes are classified as up-regulated or 
down-regulated genes as follows: With reference to Figure 58, an up-regulated gene 
has positive expression values at all time point (MYB gene). If expression values are 
inconsistent, i.e. a mixture of positive and negative expression values, gradient is 
computed by fitting a straight line on the expression values. If the gradient is positive 
(KLK11 gene), it is classified as up-regulated gene. For classification of down-
regulated genes, the vice-versa applies; CSTA gene had all negative expression values 
while REG4 gene had negative gradient with inconsistent expression across time-
course. 
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Figure 58 Examples for classification of genes 
For the 3098 E2-regulated genes, 1886 genes were up-regulated while 1212 genes 
were down-regulated. Figure 59 showed the heatmap on the E2-induced genes. For 
gene expression in E2, a large majority of genes had a general increasing or 
decreasing trend for up-regulated and down-regulated genes respectively.  
Up; All positive values 
Up; Positive gradient 
Down; Negative gradient 
Down; All negative values 
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Figure 59 Heatmap for E2-regulated genes in MCF-7 
In each treatment condition, the time points were arranged in order from 3, 6, 9, 12, 24 
and 48 hours. 
 
Validation on a panel of well-known E2 regulated genes across treatments 
and time 
We examined the expression measurements of well-known E2 regulated genes 
across treatments and time on our data (Figure 60). The housekeeping gene also 
shows low expression values throughout (Figure 61). In general, the expression of E2 
regulated genes increased with time in E2 treatment. SERMs also had differential 
antagonizing effects on the expressions of E2 genes.  
3 6 9 12 24 48  
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Figure 60 Heatmap for a panel of 15 well-known E2 responsive genes (true 
positives) 
 
Figure 61 Heatmap for false negative genes and GAPDHS house-keeping gene 
Subsequently, we examined – TFF1 (trefoil factor 1) gene for its response upon 
E2 treatment in greater detail. TFF1 has been established as the validation target for 
the E2 responsiveness in breast cancer cells (Brown, Jeltsch et al. 1984). As can be 
seen in Figure 62, the expression increases with time, the highest induction is 
registered at 48 hours. Also plotted along was the house-keeping gene (GAPDHS). 
Subsequently, it was of great interest to investigate the differential modulating effects 
of various SERMs, in combination with E2 or SERMs itself acting alone. Figure 63 
below showed that all SERMs reduced the fold change or expression of TFF1 gene. 
TE had the least reduction while all other SERMs reduced the expression greatly to 
similar level at 48 hours time point.  
In summary, through examination of a panel of E2-genes and the scrutinization of 
TFF1 gene across treatments and time, the expression changes were within the 
expectations on both E2’s induction and SERMs’ antagonizing properties. This shows 
that the array data is of good quality for subsequent exploration of gene expression 
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Figure 62 Fold Changes of Genes across time points for E2 
 
 
Figure 63 Fold Changes of TFF1 Gene across time points for E2 and SERMs 
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Gene ontology on all the E2-regulated genes revealed that the biological 
processes were largely related to cell proliferation such as cell cycle, metabolism, cell 
proliferation and differentiation (Table 19). 
Table 19 Gene ontology for E2-regulated genes 
Gene Ontology for regulated genes (E2)
Biological Process NCBI: H. sapiens genesREFLIST (25431)






Biological process unclassified 11321 907 1228.66 - 1.73E-34
Nucleoside, nucleotide and nucleic acid metabolism 3343 546 362.81 + 4.98E-21
Cell cycle 1009 203 109.51 + 5.40E-15
Intracellular signaling cascade 871 170 94.53 + 9.32E-11
Protein modification 1157 200 125.57 + 2.90E-08
mRNA transcription 1914 298 207.72 + 6.68E-08
Protein metabolism and modification 3040 432 329.93 + 1.53E-07
Other metabolism 559 110 60.67 + 1.62E-07
Cell cycle control 418 91 45.37 + 1.64E-07
Cell proliferation and differentiation 1028 175 111.57 + 2.51E-07
mRNA transcription regulation 1459 234 158.34 + 7.43E-07
Protein phosphorylation 660 124 71.63 + 1.52E-06
Olfaction 198 1 21.49 - 1.92E-06
Developmental processes 2152 314 233.55 + 2.65E-06
Cell structure and motility 1148 184 124.59 + 6.08E-06
DNA metabolism 360 77 39.07 + 6.10E-06
Chemosensory perception 207 2 22.47 - 6.49E-06
Signal transduction 3406 461 369.65 + 1.31E-05
Oncogenesis 472 88 51.23 + 4.63E-05
Intracellular protein traffic 1008 159 109.4 + 9.90E-05
DNA replication 155 40 16.82 + 1.45E-04
Proteolysis 960 155 104.19 + 1.77E-04
Other carbon metabolism 82 25 8.9 + 9.95E-04
Ectoderm development 692 114 75.1 + 1.94E-03
Immunity and defense 1318 189 143.04 + 2.82E-03
Endocytosis 277 55 30.06 + 3.70E-03
Neurogenesis 587 99 63.71 + 3.98E-03
Coenzyme and prosthetic group metabolism 174 37 18.88 + 4.27E-03
Apoptosis 531 87 57.63 + 4.91E-03
Other intracellular signaling cascade 225 47 24.42 + 5.78E-03
Transport 1306 185 141.74 + 6.11E-03
Sensory perception 506 31 54.92 - 8.93E-03
Phosphate metabolism 117 27 12.7 + 9.51E-03
General vesicle transport 251 49 27.24 + 1.47E-02
Other transport 61 18 6.62 + 2.67E-02
Carbohydrate metabolism 592 90 64.25 + 3.79E-02  
4.2 E2-regulated genes use more of Pol II preloading mechanism and 
mechanism of down-regulation involves Pol II pausing or stalling 
We compared the proximity of regulated genes to Pol II binding sites in both E2 
and DMSO conditions. Interestingly, the percentages of genes in each category of 
distances away from TSS of genes are similar for Pol II binding sites in E2 or DMSO 
conditions, i.e. between A and C; between B and D (Figure 64). This could indicate 
that E2 regulated genes may use more of Pol II preloading mechanism as opposed to 
the classical model of Pol II recruitment. 34.4% and 34.8% of E2 down-regulated 
genes were within 5-100kb of a Pol II binding site in E2 and DMSO conditions 
respectively compared to 20.3% and 22.2% of up-regulated genes respectively. This 
higher percentage of down-regulated genes within 5-100kb of a Pol II binding site 
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compared to up-regulated genes implies that more RNA Pol II binds along the gene 
body of down-regulated genes than up-regulated genes. These Pol IIs may possibly 
act as a hindrance to transcription process known as Pol II pausing or stalling, 
contributing to one of the mechanisms for down-regulation of genes.  
 
Figure 64 Percentage of E2 up-regulated genes in proximity to Pol II binding sites 
A) Percentage of E2 up-regulated genes in proximity to Pol II binding sites in E2;  B) 
Percentage of E2 down-regulated genes in proximity to Pol II binding sites in E2; C) 
Percentage of E2 up-regulated genes in proximity to Pol II binding sites in DMSO; D) 
Percentage of E2 down-regulated genes in proximity to Pol II binding sites in DMSO; 
A B 
C D 
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4.3 Strongly regulated genes in E2 treatment have ER binding sites in 
closer proximity than non-regulated genes 
We correlated 6482 estrogen receptor binding sites in E2 with the gene 
expression data upon E2 treatment for all time points. The correlation shows a bias for 
up-regulated genes at all time points while the bias for down-regulated genes only 
occurs much later at 24 and 48 hours (Figure 65). Up-regulated genes are strongly 
correlated to ER binding sites from early time point of 3 hours suggest that these 
genes are highly directly regulated by ER. In contrast, down-regulated genes only 
correlated to ER binding sites at a much later time of 24 hours onwards suggest that 
these genes are indirectly regulated by ER and may be regulated by a secondary 
transcription factor induced by E2 or through co-operating binding with other 
transcription factors. 
 
Figure 65 Correlation between gene expression and E2 binding sites 
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4.4 Strong E2-ER binding sites with basal occupancy associates with E2 
up-regulated genes 
The binding sites in Figure 27 were categorized in terms of differential 
enrichments (E2 – DMSO). Subsequently, numbers of E2 up-regulated or down-
regulated genes that have an ER binding site within 100kb from TSS of genes were 
computed. The categories of binding sites were then correlated to the ratio of number 
of E2 up-regulated over number of down-regulated genes as shown in Figure 66.  




























































Figure 66   Ratio of Up/Down E2 Genes across different fold change 
The blue line (E2_DM) refers to the 4205 binding sites (Overlap between binding 
sites in E2 and DMSO), i.e. basal occupied.  The pink line (E2Only) refers to the 2277 
binding sites appeared up on E2 treatment, i.e. without basal occupancy. Interestingly, 
the ratio of up-regulated genes over down-regulated genes increased for the E2_DM 
binding sites. Specifically, with fold change > 1.5, there were 20-50% more up-
regulated genes than down-regulated genes. With fold change < 1, there were more 
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down-regulated genes, 67% more down-regulated genes compared to up-regulated 
genes, whereas for the E2Only binding sites, there were equal numbers of up and 
down-regulated genes at differential enrichment of ≥ 1.5 fold. In summary, when 
there was basal occupancy, there were more up-regulated genes with higher 
differential enrichment. On the other hand, when there was no basal occupancy, there 
were similar numbers of up-regulated and down-regulated genes in higher fold change. 
By Wilcoxon signed rank tests for all the difference in ratios between E2_DM and 
E2Only binding sites, the p-value of difference between E2_DM and E2Only was 
0.03125, indicating that the difference was significant.  The above finding postulates 
that basal occupancy plays a role in the regulation of genes. 
4.5 Higher occurrence of ERE in E2-induced binding sites associated 
with higher regulated genes and higher binding sites fold change 
The above categories of binding sites were also correlated to the ERE consensus 
sequence with up to 2 mismatches and the average number of regulated genes. The 
results are shown in Figure 67 and Figure 68 below.  
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Average number of EREs per Binding 





































































Figure 67   Average number of ERE per Binding Sites across different fold 
changes 
Average number of Regulated Genes per 



























































































Figure 68 Average number of regulated genes per Binding Sites across different 
fold change 
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All binding sites with or without basal occupancy showed the same trend that 
with increasing fold change, both the average number of ERE per binding site (Figure 
67) and regulated genes (Figure 68) increased. The above observations lead to the 
hypothesis that more genes were up-regulated when there was higher ER occupancy, 
i.e. greater fold change.  Higher presence of EREs in turn associates with greater fold 
change. The finding above tallied with the report from the literature that the presence 
of ERE are commonly associated with up-regulated genes.  
4.6 Modulating effects of SERMs on gene expression 
Expression values indicated in this thesis are all with reference to DMSO unless 
it is stated otherwise (Illustration 5). Figure 69 showed the heatmap on the E2-induced 
genes with the corresponding gene expressions altered by SERMs. In order to show 
the relative effects of SERMs on E2, the changes from E2 to SERMs’ expression 
values are depicted in Figure 70 (This is the only time the reference is made to E2 
instead of DMSO). In general, SERMs had the effects on attenuating the intensity of 
either induced or repressed genes. For some down-regulated genes, effects of SERMs 
not just attenuated but reversed to up-regulation. The above observation similarly 
applied to some up-regulated genes, see illustration below. 
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Illustration 5 Expression values of E2/SERMs with reference to DM or E2 
 
Figure 69 Effects of SERMs on E2-regulated genes in MCF-7 
DM indicated the expression value in DMSO condition while E2 and SERMs indicated 
the change in expression with respect to DMSO. In each treatment condition, the time 
points were arranged in order from 3, 6, 9, 12, 24 and 48 hours. 
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Figure 70 Effects of SERMs on E2-regulated genes in MCF-7 with reference to 
E2 
In each treatment condition, the time points were arranged in order from 3, 6, 9, 12, 24 
and 48 hours. 
Global modulating effect of SERMs 
This section examined the modulating effects of SERMs on gene expression 
induced by E2 treatment. Using the data analysis outlined in section 4.1, regulated 
genes were similarly defined for SERMs treatment. Table 20 summarises the number 
of probesets and genes expressed in each treatment using DMSO as the control. The 
total number of regulated genes in E2 was 3098, of which 1886 genes were up-
regulated and 1212 genes were down-regulated. There were more up-regulated genes 
than down-regulated genes in E2 treatment. On the other hand, there were many more 
down-regulated genes than up-regulated genes in SERMs treatment which is expected 
due to SERMs’ antagonizing properties. Intriguingly, besides modulating E2-
regulated genes, SERMs also regulate their own unique set of genes. This may 
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partially explain why some SERMs treatments like TE, T, R and I treatments had 
larger total number of regulated genes than E2 treatments.  
Table 20 Probesets or genes enriched in each treatment w.r.t DMSO 
 
The barchart in Figure 71 shows that both E2 and TE have higher proportion of 
up-regulated genes which reflect the agonistic property of E2 while the remaining 
SERMs or combination of SERMs+E2 have a high proportion of down-regulated 
genes that reflect the antagonistic property of SERMs, see Figure 71. Figure 72 shows 
the suppression of E2 genes in different SERMs. 































Figure 71 E2/SERMs – DMSO (In MCF-7) 
Total Up Down Total Up Down
E 3945 2450 1495 3098 1886 1212
TE 5361 3338 2023 4028 2548 1480
T 4964 1225 3739 3810 961 2849
RE 2930 658 2272 2330 550 1780
R 4734 968 3766 3466 774 2692
IE 3181 765 2416 2504 664 1840
I 4021 1356 2665 3085 1146 1939
w.r.t DMSO (E2/SERMs - DMSO) in MCF-7
Treatment
Probesets Gene Symbol
Lee Yew Kok  PhD Thesis 
  104 
 
Figure 72 Suppression of E2-regulated Genes in Different Treatments 
In order to quantify the changes better in gene regulation in MCF-7, the actual 
numbers of up-regulated and down-regulated genes were computed across individual 
time points in different treatments (Figure 73). Genes responsive to E2 treatment 
accumulated in number with time and were strongest at 48 hours. There were 
fluctuations in number of down-regulated genes for Tamoxifen, Raloxifene and ICI, 
which might indicate a mixture of primary and secondary effect of targeted genes. On 
the other hand, the regulated genes in E2 treatment did not have any fluctuation which 
suggested mainly primary targeted genes were involved. Taken together, SERMs 
appear to induce an initial wave of gene down-regulation. 
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Figure 73 Summary of expression changes in terms of genes 
4.7 Differential trends of SERMs modulation on E2 up-regulated or 
down-regulated genes 
Both the binding sites and gene expressions profiles were further correlated to 
explore their relationship and roles in gene regulation with additional criteria of E2-
regulated genes within 5kb of estrogen receptor binding sites. There were 216 E2-
regulated genes fulfilled the above conditions and the corresponding heatmap had 
been constructed (Figure 74).  
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Figure 74 Gene expression profiles within 5kbs of E2 Binding Sites 
In general, SERMs attenuated or reversed the magnitude of response of genes; 
up-regulated genes in E2 were suppressed or down-regulated while the down-
regulated genes were also suppressed or up-regulated (Figure 74). For E2 up-
regulated genes, the degree of suppression was the greatest in R, I and IE treatment 
whereas the TE has the lowest degree of suppression (Figure 75A). In general, the E2 
up-regulated genes appear suppressed by SERMs for only 9-12 hours. Thereafter, . 
For E2 down-regulated genes, the degree of suppression was the greatest in I and IE 
treatment whereas T has the lowest degree of suppression (Figure 75B). In general, 
down-regulated genes exhibit a positive increasing trend for the change affected by 
SERMs. 
 
E2-DM  TE-DM  T-DM  RE-DM  R-DM IE-DM  I -DM
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Figure 75 Boxplot for gene expression profiles within 5kb of E2 binding sites 
A: Up-regulated genes in MCF-7 in E2 treatment and corresponding gene expressions 
affected by SERMs; B: Down-regulated genes in MCF-7 in E2 treatment and 
corresponding gene expressions affected by SERMs 
 
Box-plot for E2 Up-regulated Genes 
Box-plot for E2 Down-regulated Genes 
A 
B 
Lee Yew Kok  PhD Thesis 
  108 
With the above selection of genes, the modulating patterns of genes were 
classified into different groups. There were a number of distinct groups of E2 genes 
with different profile of SERMs’ expression levels. Four distinct groups of profile of 
SERMS were selected and their gene ontology was studied using Ingenuity Pathway 
Analysis Software (http://www.ingenuity.com/). The four groups were 1) E2-up; 
SERMs-down, 2) E2-down; SERMs-up, 3) E2-up; SERMs-up and 4) E2-down; 
SERMs-down. For the first two groups where SERMs acts as a strong antagonists, the 
molecular and cellular functions have shown cellular growth and proliferation and 
cellular development which are expected of SERMs’ action as being anti-proliferative 
as opposed to E2 ligand. Cellular proliferation will involve growth factors and cellular 
development involves cytokines as signaling proteins. Since the osteoclast and the 
osteoblast are targeted by estrogen putatively, this may confirm a unifying mechanism 
of estrogen actions in bone. For the last two groups where SERMs acts as weak 
antagonists or strong agonists like E2, the molecular and cellular functions are more 
on cancer and cellular movement. E2 and Tamoxifen have been shown inducing 
cytoskeletal remodeling and migration (Acconcia, Barnes et al. 2006). 
4.8 Discovery of unique novel genes to SERMs and E2, exclusive of one 
another 
Comparing the regulated genes between E2, T, R and ICI, unique genes were 
found pertaining to each treatment. For example, E2 unique genes are responsive only 
in E2 and not in any of T, R and I. The directionality of regulation was not considered 
in doing the intersection of regulated genes. There were 1450 unique E2 genes, 1368 
unique T genes, 824 unique R genes and 658 unique I genes.  
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Figure 76 Venn-diagram for intersections between E2, T, R and I 
The heatmap for the unique genes E2, T, R and I are shown in Figure 77, Figure 
78, Figure 79 and Figure 80 respectively.  
 
Figure 77 Heatmap for unique genes in E2 
 
Unique E2 
Unique T Unique R 
Unique I 
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Figure 78 Heatmap for unique genes in T 
 
 
Figure 79 Heatmap for unique genes in R 
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Figure 80 Heatmap for unique genes in I 
Using gene ontology software, the unique biology of for the above groups of the 
unique genes was deciphered. The molecular and cellular functions for unique E2 
genes were cell death, cell cycle, cellular development, cellular growth and 
proliferation, DNA replication, recombination and repair. The molecular and cellular 
functions for unique T were gene expression, lipid metabolism, small molecule 
biochemistry, cell cycle, vitamin and mineral metabolism. The molecular and cellular 
functions for unique R were gene expression, cell death, cellular function and 
maintenance, cellular assembly and organization, DNA replication, recombination 
and repair. The molecular and cellular functions for unique I were cell signalling, 
cellular development, cellular movement, post-translational  modification, DNA 
replication, recombination, and repair. Common molecular and cellular functions 
between E2 and T were cell cycle; E2 and R were cell death; E2 and I were cellular 
development, DNA replication, recombination and repair.  
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4.9 ER tends to remain occupied across SERMs conditions for up-
regulated genes 
The binding sites occupancy at those E2-binding sites within 5kb of E2-regulated 
genes were examined across SERMs and listed in Table 21 and Table 22 for down-
regulated and up-regulated genes respectively. From the 2 tables, ER was observed to 
remain present across different SERMs treatments for up-regulated genes.  
Subsequently, the 2 tables were converted into trend lines depicting the 
proportion of binding sites occupied for individual SERMs treatment. The binding 
sites had been ordered according to the distance of binding site to TSS of genes. 
Keeping the same order, the proportion of binding sites occupied was calculated up to 
the site taken into account. For E2 up-regulated genes within 5kb of an ER binding 
site, all treatments except IE and RE had high proportion of binding sites occupied (> 
60%) (Figure 81). IE and RE had low proportion of binding sites occupied (<35%). 
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Table 21 Binding sites detection across different treatments and down-
regulated E2 genes 
 




Position E D TE T RE R IE I Distance from TSS Gene Symbol Regulation
chr3_114737988_114738841 P P P P P P P P 4232 SIDT1 Down
chr1_112967955_112968614 P P   P   P 3621 PPM1J Down
chr12_54637517_54637731 P       P 3468 SILV Down
chr4_6815720_6816334 P P      P 2390 S100P Down
chr16_30023120_30023849 P  P      -148 GDPD3 Down
chr16_31049520_31050104 P       P -444 PRSS8 Down
chr7_72688028_72690097 P P P     P -781 CLDN4 Down
chr5_355807_356136 P       P -1319 AHRR Down
chr12_108939839_108940183 P  P     P -1691 FLJ40142 Down
chr17_35096087_35096301 P        -1724 ERBB2 Down
chr16_82766883_82767517 P P P  P P   -1761 TAF1C Down
chr16_83615353_83617845 P P P     P -2311 KIAA0513 Down
chr5_354616_355115 P       P -2425 AHRR Down
chr15_88126246_88126898 P P P   P   -2558 ANPEP Down
chr7_72686669_72687188 P        -2915 CLDN4 Down
chr6_3663379_3663736 P P P P  P  P -4295 C6orf145 Down
chr4_6808811_6809395 P        -4534 S100P Down
Position E D TE T RE R IE I Distance from TSS Gene Symbol Regulation
chr12_14930387_14931027 P P P P  P P P 4614 MGP Up
chr16_86425368_86426082 P        4595 SLC7A5 Up
chr21_42668809_42670053 P P P P  P  P 4363 TMPRSS3 Up
chr21_42659426_42660080 P P P P P P P P 4294 TFF1 Up
chr1_199035773_199036542 P P P P P P P P 3716 UBE2T Up
chr3_129285783_129286507 P P P P  P P P 3645 RUVBL1 Up
chr7_43574655_43574825 P        3229 BLVRA Up
chr6_1558462_1559162 P P P P P P  P 3133 FOXC1 Up
chr17_35590092_35590991 P P P P    P 2403 RAPGEFL1 Up
chr11_108043181_108043619 P P P P P P P P 2375 DDX10 Up
chr6_16238685_16239485 P P P P  P  P 1790 MYLIP Up
chr16_85998866_85999155 P  P      1647 ZCCHC14 Up
chr5_43639556_43639900 P     P  P 1147 NNT Up
chr19_40223787_40224080 P    P   P 684 HPN Up
chr3_133862288_133862724 P   P    P 663 UBE1DC1 Up
chr11_71176478_71176649 P        333 FLJ10661 Up
chr11_74811292_74811571 P P P   P P P 319 FLJ33790 Up
chr12_100593131_100595228 P P P P  P  P 295 CHPT1 Up
chr15_60726862_60727296 P P    P  P 278 TLN2 Up
chr6_152220412_152220996 P        -95 ESR1 Up
chr20_42776270_42777269 P P P P    P -529 WISP2 Up
chr1_143215501_143216460 P P P P  P  P -789 PDZK1 Up
chr21_45757581_45758092 P     P  P -1220 SLC19A1 Up
chr2_11620976_11626117 P P P P P P P P -1293 GREB1 Up
chr15_73448765_73449266 P P P P    P -1314 SIN3A Up
chr1_176929057_176929856 P P P P P P  P -1642 LHX4 Up
chr4_38867278_38867784 P P P P    P -1693 KLHL5 Up
chr16_15036997_15037339 P P P   P  P -2049 NTAN1 Up
chr20_52198661_52201967 P P P P   P P -3080 CYP24A1 Up
chr16_15035688_15036142 P        -3302 NTAN1 Up
chr14_74811741_74812183 P P P P  P P P -3321 FOS Up
chr3_151937598_151938629 P P P P P P P P -3495 SIAH2 Up
chr10_104460207_104461044 P P P P P P P P -3662 SFXN2 Up
chr22_27511319_27511562 P P P P     -3662 XBP1 Up
chr1_33143424_33143774 P  P   P P P -4076 AK2 Up
chr11_100409714_100410585 P P P P  P  P -4163 PGR Up
chr12_115429456_115429972 P P P P  P  P -4232 FLJ42957 Up
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Figure 81 E2 up-regulated genes within 5kb of ER binding sites 
For E2 down-regulated genes within 5kb of an ER binding site, all treatments 
except D, TE and I had low proportion of binding sites occupied (< 25%) (Figure 82). 
D and TE had only 50% proportion of binding sites occupied. E2 up-regulated genes 
would have higher proportion of binding sites that were still occupied by ER upon 
SERMs treatment than E2 down-regulated genes.  




































Figure 82 E2 down-regulated genes within 5kb of ER binding sites 
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Decision tree was used as the classifier for the 2 groups of regulated genes with 
the corresponding occupancy pattern in T, R and I (Figure 83). It was found that when 
T or R remains occupied, the probability that it is an up-regulated gene is very high 
(93% for T and 75% for R). From the decision tree, it can be observed that an up-
regulated gene is likely associated when ER remained occupied in (1) T or (2) R when 
ER not occupied in T or (3) Not occupied in either T, R and I. Writing the above 
relationship in Boolean Algebraic form: 
U = T + T’ R + T’ R’ I’ where U denotes up-regulated genes; T denotes ER 
remains occupied in T treatment; T’ denotes ER not occupied in T treatment; R 
denotes ER remains occupied in R treatment; R’ denotes ER not occupied in R 
treatment; I’ denotes ER not occupied in I treatment. For example, T’ is complement 
to T, i.e. if T = 1 , T’ = 0 and vice versa.  
Using the rules in Boolean Algebra, A + A’ B = A + B, 
U = T + T’R + T’ R’ I’  
Can be reduced to 
U = T + R + I’ 
The final equation above states that the likelihood of up-regulated genes is due to 
the continued occupancy of ER in T or R treatment but not in I treatment. With 
reference to section 3.4, unique I binding sites had a very different de novo motif 
prediction from consensus ERE whereas unique T and R binding sites had a similar 
motif to ERE. As such, unique I motif might provide an explanation for the 
association of ER remained occupied in I treatment to the down-regulated genes. 
T =?
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Figure 83 Decision tree for classifying up- and down-regulated genes 
In summary, pattern of binding sites occupancy in E2 and across SERMs 
condition can predict gene regulation. When the ER continues to bind across different 
SERMs treatment, the gene regulation is likely to be for up-regulated genes, 
especially for T or R treatment. 
4.10 SERMs alter ER’s spatial binding characteristics in promoter-
context and cell environment 
We introduced in the beginning of this thesis that when ER complexed with E2, 
the conformation was different from that of when complexed with SERMs, i.e. 
differential displacements of the carboxy-terminal helix (H12). Here we hypothesize 
that the different conformations of ER-SERMs change the binding characteristics of 
ER. It is also hypothesized that ER-SERMs complexes have a lower binding affinity 
than ER-E2 complex that they preferentially select those binding sites with chromatin 
configuration that are more opened and accessible. As such, we investigated the 
profiles of both FAIRE and H3K4Me1 signals for the common and unique binding 
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Since ICI works by degrading the estrogen receptor, similar analysis was not carried 
out on ICI treatment.   
The profiles of FAIRE signal for E2 and Tamoxifen, FAIRE signal for E2 and 
Raloxifene are shown in Figure 84 and Figure 85 respectively. Both FAIRE signals 
for unique Raloxifene and unique Tamoxifen binding sites showed that FAIRE 
signals were the strongest in DMSO condition while signals in E2 condition were the 
next highest. This implies that unique binding sites to either Tamoxifen or Raloxifene 
have the highest nucleosome free regions (Using t-test, p-value are 9.39e-6 and 2.42e-
6  for Tamoxifen and Raloxifene respectively). 
 
Figure 84 Profile of FAIRE signal for E2 and Tamoxifen 
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Figure 85 Profile of FAIRE signal for E2 and Raloxifene 
Similarly, the profiles of H3K4Me1 signal for E2 and Tamoxifen, H3K4Me1 
signal for E2 and Raloxifene are shown in Figure 86 and Figure 87 respectively. Both 
H3K4Me1 signals for unique Raloxifene and unique Tamoxifen binding sites showed 
that H3K4Me1 signals remained very high in both E2 and DMSO conditions (Using t-
test, p-value are 4.25e-25 and 5.0e-24  for Tamoxifen and Raloxifene respectively). 
This may imply that unique binding sites to either Tamoxifen or Raloxifene do not 
function as enhancers as there H3K4Me1 signals remain high in the center of ERE. 
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Figure 86 Profile of H3K4Me1 signal for E2 and Tamoxifen 
 
Figure 87 Profile of H3K4Me1 signal for E2 and Raloxifene 
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In summary, unique Tamoxifen or Raloxifene binding sites had distinctive 
FAIRE and H3K4ME1 profiles that suggest strongly SERMs alter ER’s spatial 
binding characteristics.  
4.11 Revealing Spatiotemporal Expression Profiles of ER-responsive 
Genes in Different Tissues Upon E2 And SERMs Treatments 
Many factors contribute to tissue-specific effects such as DNA methylation, 
histone modifications, differential co-regulator recruitments and the relative 
abundances of various transcription factors. Here we examined the global expression 
profiles of two different tissues – breast and uterine tissues by using MCF-7 and 
Ishikawa cell lines. Ishikawa cell line was treated with the same drugs and time 
course i.e. expressions were measured for the same treatments and time course as that 
of MCF-7. 
Using the data analysis outlined in section 4.1, the regulated genes in Ishikawa 
cell line under E2 and SERMs treatment were also obtained. Examing the number of 
regulated genes upon E2 and SERMs treatment across both MCF-7 and Ishikawa, 
there were much greater regulated genes in MCF-7 than Ishikawa cell line (Figure 88). 
For Ishikawa cell line, there were an exceptionally high number of genes induced in 
ICI treatment.  
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Figure 88 No. of regulated genes across treatments in MCF-7 and Ishikawa cell 
lines 
While there were higher proportions of down-regulation in SERMs treatment for 
MCF-7, there were more up-regulated genes in SERMs treatment in Ishikawa cell line 
(Figure 89).  
 
Figure 89 Up-regulation and down-regulation of genes across treatments in 
MCF-7 and Ishikawa cell lines 
Next, we examined in detail the expression of Ishikawa regulated genes in MCF-
7 cell line. The heatmap for the E2-regulated genes in Ishikawa (Figure 90) shows 
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that there are some oscillations in the expression for the up-regulated genes while the 
down-regulated genes are increasingly down-regulated with time. 
 
Figure 90 Heatmap for E2-regulated genes in Ishikawa 
To investigate the effects of SERMs on the E2-regulated genes, the heatmap on 
the E2-regulated genes and the corresponding expression levels in SERMs treatments 
were constructed (Figure 91). The heatmap shows that SERMs decrease the 
magnitude of E2-repressed genes but the intensities of E2-induced genes are hardly 
antagonized by SERMs. The phenomenon seen in Ishikawa cell line was in great 
contrast to that seen in MCF-7 depicted in Figure 69. For example, up-regulation in 
MCF-7 was attenuated or even reversed it to down-regulation by SERMs instead of 
unchanged in Ishikawa; down-regulation of genes was also greatly reduced in MCF-7 
than Ishikawa.  
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Figure 91 Effects of SERMs on E2-regulated genes in Ishikawa 
Here we examined the change of E2-regulated genes in Ishikawa cell line on 
MCF-7 instead. The expression of genes regulated in Ishikawa cell line remained high 
for most of the genes in another cell line - MCF-7 (Figure 92). Majority of the up-
regulated genes in Ishikawa continued to be up-regulated or have positive gene 
expression values in MCF-7 while about 50% of the down-regulated genes in 
Ishikawa were similarly down-regulated or had negative gene expression values in 
MCF-7. Figure 93A shows that up-regulation in MCF-7 also follows an increasing 
trend, albeit at a smaller magnitude unlike in Ishikawa cell line. 
     E2-DMSO  TE-DMSO T-DMSO  RE-DMSO  R-DMSO IE-DMSO  I -DMSO   
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Figure 92 Tissue-specific effects shown on MCF7 on E2-regulated genes in 
Ishikawa cell line 
 
A 
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Figure 93 Tissue-specific effects shown on MCF-7 on E2-regulated genes in 
Ishikawa cell line (Boxplot) 
A: Up-regulated genes in Ishikawa and corresponding gene expressions in MCF-7 cell 
line; B: Down-regulated genes in Ishikawa and corresponding gene expressions in 
MCF-7 cell line 
 
 The overlap in the E2-regulated genes in MCF-7 and Ishikawa cell lines was 
investigated. Only 10.9% of the genes responsive to E2 treatment in MCF-7 were also 
responsive in Ishikawa cell line for the same treatment (Figure 94). This small 
percentage of overlap in responsive genes in breast and uterine tissues was in 
accordance to the highly tissue-specific global gene expressions properties. 
B 
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Figure 94 Intersection between MCF-7 and Ishikawa cell lines in E2 regulated 
genes 
Similarly, we studied the ovelap in regulated genes responsive to different 
SERMs treatment between MCF-7 and Ishikawa cell lines. The overlap in terms of 
percentages of genes in MCF-7 was small for all SERMs (Figure 95) as in E2 
treatment (Figure 94).  The only exception was in I treatment that the overlap was 
33.4% in terms of regulated genes in MCF-7. This was because there were an 
exceptionally high number of I-regulated genes in Ishikawa, thus leading to the higher 
percentage of overlap.  
89.1% 10.9% or 
24.4% 
75.6% 
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Figure 95  Intersection between MCF-7 and Ishikawa cell lines in SERMs 
regulated genes 
Since we found that the overlap in the regulated genes between MCF-7 and 
Ishikawa cell line was low due to different tissues biology, we next examined in detail 
the corresponding changes in MCF-7 regulated genes in Ishikawa cell line. Figure 96 
shows the clustered gene expression profile of MCF-7 and Ishikawa genes together. It 
93.2% 6.8% or 
34.3% 
65.7% 88.2% 11.8% or 
35.7% 
64.3% 
93.2% 6.8% or 
23.2% 
76.8% 95.6% 4.4% or 
37.3% 
62.7% 
93.3% 6.7% or 
29.6% 
70.4% 66.6% 33.4% or 
29.5% 
70.5% 
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was interesting that the gene expression levels in Ishikawa cell line were generally 
much lower than that of MCF-7. Only about 50% of the up-regulated genes in MCF-7 
have positive gene expression values in Ishikawa cell line (Figure 96). Figure 97A 
confirms that up-regulation of Ishikawa cell line is stronger at 12 and 48 hours. 
Majority of the down-regulated genes in MCF-7 have negative gene expression values 
in Ishikawa. Figure 97B shows that the down-regulation in Ishikawa cell line also 
follow a decreasing trend, albeit at a smaller magnitude unlike in MCF-7.  
 
Figure 96 Tissue-specific effects shown on Ishikawa on E2-regulated genes in 
MCF-7 (Tree-view) 
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Figure 97 Tissue-specific effects shown on Ishikawa on E2-regulated genes in 
MCF-7 (Boxplot) 
A: Up-regulated genes in MCF-7 and corresponding gene expressions in Ishikawa cell 
line; B: Down-regulated genes in MCF-7 and corresponding gene expressions in 
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In summary, the small overlap in the number of regulated genes and different 
expression profiles in MCF-7 and Ishikawa cell lines show that ER is involved in 
completely different transcriptional programs in these cell lines.  
4.12 Concluding remarks 
In conclusion, we obtained genome-wide gene expression profiles with the 
Affymetrix array (HG-U133 Plus) for different drugs treatments (E2, T, R and I) at 
different time points (0, 3, 6, 9, 12, 24 and 48 hours). We combined published 
methods/approaches to gene expression analysis and obtained the regulated genes for 
each treatment. Using a panel of well-known genes, their gene expression patterns 
were examined in E2 and across SERMs conditions. The gene expression patterns 
were well within expectation which confirmed and validated the Affymetrix 
experiments and data. We correlated the E2-regulated genes to both ER and Pol II 
binding sites. There was a high prevalence of Pol II preloading mechanism for E2-
regulated genes as the distribution of genes away from TSS was similar for both E2 
and DMSO conditions. The high percentage of down-regulated genes in 5-100kb 
category away from TSS also suggests a potential mechanism for down-regulation 
which involves Pol II pausing or stalling. E2 genes that were strongly up- or down-
regulated have a higher propensity to have ER binding sites in proximity than non-
regulated genes. Strong E2-ER binding sites with basal occupancy associate with E2 
up-regulated genes whereas weak binding associates with tethered mechanism. ER 
binding sites with greater fold change associate more with higher presence of ERE 
and larger number of regulated genes. SERMs have the modulating effects on E2 gene 
expressions by attenuating or even changing the directionality of gene regulation. 
SERMs besides modulating E2 genes, they also regulate their own set of genes. Only 
E2 and TE had higher proportion of up-regulated genes from their own set of 
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regulated genes while the remaining treatments had higher proportion of down-
regulated genes. Unique genes to SERMs and E2 were found, exclusive of one 
another. The directionality of gene regulation, i.e. up-regulated or down-regulated, 
cannot be predicted based on ER occupancy in E2 and SERMs conditions. However, 
ER tends to remain occupied in E2 and across SERMs conditions for up-regulated 
genes. We explored the unique Tamoxifen or Raloxifene binding sites with reference 
to E2 binding sites by plotting the average FAIRE and H3K4Me1 profiles. The 
distinctive profiles and higher FAIRE and H3K4Me1 signals suggest strongly that 
SERMs alter ER’s spatial binding characteristics. ER-responsive genes in different 
tissues upon E2 and SERMs treatments revealed spatiotemporal expression profiles.  
There were much more number of regulated genes in MCF-7 than Ishikawa cell line. 
Interestingly, there was greater proportion of down-regulated genes in MCF-7 while 
Ishikawa cell line had greater proportion of up-regulated genes. This indicated that the 
antagonizing properties of SERMs were stronger in MCF-7 than Ishikawa cell line. 
The overlap in the regulated genes between MCF-7 and Ishikawa cell line was low 
which suggests that the two cell lines had different tissues biology even at the gene 
level. The corresponding Ishikawa gene expressions for the MCF-7 E2-regulated 
genes show a much lower signal.    
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Chapter 5 Functional Analysis of Transcription Factor 
Binding Site Variants in Human Population 
For polymorphism studies in ER binding sites, different breast cancer cell lines 
that have vast variations in the polymorphism pattern in binding sites are not readily 
available. As such, we chose a different cell line and transcription factor for studying 
and characterizing functional binding sites with polymorphism. Lymphoblastoid cell 
lines and p53 transcription factor were selected as the model system. 
5.1 Identification and Genotyping Analysis of SNP  
Identification of p53 Motif Polymorphisms  
542 high-quality p53 binding sites obtained from ChIP-PET platform on 
HTC116 cell line (Wei, Wu et al. 2006), were searched for SNPs using dbSNP 
databases. Out of which 235 sites were found containing an unequivocal p53 
consensus binding motif sequence (5’-RRRCWWGYYYRRRCWWGYYY-3’) and 
selected for SNP mining.   Using dbSNP database (version 115), 14 sites were found 
with SNPs identified within the binding motifs.  We have successfully genotyped 12 
SNPs in 76 anonymous germ-line DNA samples of Caucasian population. Lastly, 6 
SNPs were confirmed to be polymorphic with a minor allele frequency (MAF) above 
1%.   
Of the 6 confirmed SNPs in p53 binding motif, rs1860746 was found to be 
located within the p53 motif (Figure 98) in the third intron of the PRKAG2 gene 
which had high p53 transcription factor occupancy (Wei, Wu et al. 2006). rs1860746 
is a G/T substitution polymorphism located in the p53 consensus motif.   
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Figure 98 refSNP rs1860746 is located within the consensus p53 motif 
 The minor allele T causes a mismatch to the p53 consensus motif sequence: 
5’-RRRCWWGYYYRRRCWW[G/T]YYY-3’ while the major allele G has a perfect 
p53 consensus motif sequence. Therefore, sites containing p53 motif with major allele 
are expected to have high occupancy enrichments, whereas the sites carrying the 
minor allele T are associated with lower binding enrichment. Our genotyping analysis 
of the SNP in 76 CEPH germ-line DNA samples revealed its MAF to be 20%, which 
is consistent with the result from the HapMap project.  Interestingly, according to the 
results from the HapMap project, the MAF of this SNP in Asian populations (Chinese 
and Japanese) is only about 1%, as compared to the higher MAF of 20% observed in 
African and Caucasian populations. The genotype and allele frequency for this SNP 
can be found in Table 23.  
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PRKAG2 is a Homo sapiens protein kinase, AMP-activated, gamma 2 non-
catalytic subunit. Since AMPK protein complex is a central sensor of energy stress, 
this germ-line p53 binding motif SNP may act as a cis-regulatory variant linking p53 
and metabolic homeostasis.  Furthermore, AMPK and p53 are known to involve in 
cancer development besides having interesting frequency pattern in different 
population. With the above observations, we characterized the molecular and 
physiological function of this germ-line p53 binding motif polymorphism in cancer 
development.  
5.2 Molecular characterization of the p53 binding site within PRKAG2 
and its germ-line polymorphism (rs1860746) 












































Figure 99 Significant enrichment of p21 binding site sequence after 5-Fu 
treatment 
The results from the ChIP and real-time PCR analysis, showing the significant 
enrichment of the p53 binding motif sequence of the p21 promoter in the ChIP pull-
down DNA from lymphoblastoid cells without or with 5FU treatment for 6 or 10 hrs. 
 
We examined whether the putative binding site in Figure 98 is a true binding 
target of p53 transcription factor. We performed ChIP experiment validation using a 
well-characterized p53 target gene - CDKN1A(p21), which has a confirmed p53 
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binding site in its promoter region and encodes a cyclin-dependent kinase inhibitor 
(Kaeser and Iggo 2002). We also chose lymphoblastoid cell lines (LCLs) as in-vitro 
system because LCLs have a normal diploid genome and a large collection of cell 
lines where cells carrying different genotypes of germ-line SNPs are available for 
functional analysis.  As seen in Figure 99, there is already high baseline in the 
absence of 5-FU drug in the LCLs (about 200 fold enrichment). After the activation of 
the p53 protein by 5-fluorouracil (5FU) treatment for 6 hrs and 10 hrs, the fold 
enrichments increased to about 300 fold and 500 fold higher respectively, i.e. 1.5 and 
2.5 fold change. The cells were very responsive to 5-FU treatment and showed 
significant enrichment after drug treatment, which was probably due to the presence 
of p53 proteins. 5-FU is a well-established drug for increasing both the level of total 
and activated p53 proteins. LCL is therefore a good diploid cellular system for 
studying p53-mediated cellular response.      
CHIP analysis of rs1860746 in LCLs 
To investigate rs1860746’s impact on p53’s binding to its intronic binding site 
within PRKAG2, we performed the ChIP analysis on LCLs. We began with 
preliminary experiments on 2 cell lines and subsequently expanded to 8 cell lines.  
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Initial analysis of 2 cell lines 
Figure 100. Preliminary Study on the Influence of rs1860746 on p53 Binding 
Preliminary study in Figure 100 above showed that G allele increase binding of 
transcription factor. The study then moved on to three biological replicates and two 
technical replicates on 8 cell lines.  
Validation analysis of 8 cell lines  
The 8 cell lines consist of three homozygous for the mutant T allele; two 
homozygous for the wild-type G allele, and three heterozygous.  As shown in Figure 
101, A significant enrichment of the binding site sequence was observed at the 
baseline and further augmented after 5FU treatment (for 10hrs) in the five cell lines 
that carry either one or two copies of the wild-type G allele (12 fold enrichment in 
average), whereas the three cell lines carrying two copies of the mutant T allele 
showed little enrichment of binding sequence (2 fold enrichment in average). In 
summary, an allele-specific binding pattern was observed, i.e. genotypes associated 
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Figure 101 Effect of SNP on Enrichment of binding sites after ChIP Assay 
The differential enrichment of the binding site sequence at the baseline and after 5FU 
treatment in the cell lines carrying either only wild-type allele (G/G) (two cell lines), or 
mutant (T/T) allele (three cell lines), or both alleles (G/T) (three cell lines) 
 
In a separate study consisted of ChIP experiment pulled down with p53 
antibodies and followed by a special technique of cloning and sequencing in HCT119 
cell lines(Murphy, Weitsman et al. 2006), the above binding site had been identified 
as a high confidence p53 functional binding site with a cluster sizes of 8.  
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Confirmation analysis of allelic CHIP in 3 cell lines  
 
 
Figure 102 Validation of Taqman probes using Allelic Discrimination of Plot 
9 LCLs were used to validate the quality of Taqman probes. All the 3 different 
genotypes - AA, CC and AC had 3 different LCLs each. The non-template control 
(NTC) used wass water. The three different genotypes were distinguished very well 
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                                                                                                                       Figure 
103 Difference in Ct values across different DNA amount for Taqman Assay 
Since the difference in Ct values given by FAM and Vic was used to show the 
allele-specific enrichment after ChIP Assay, there was a concern that the difference 
between the Ct values was not constant across different DNA amount as the real time 
PCR template. As such, difference in Ct values for varying amount of DNA template 
amount was obtained. Figure 103 shows that the difference in Ct values is consistently 
constant for all DNA template amount.  
To further demonstrate the stronger binding of p53 to the wild-type binding motif 
(G allele) than the mutant binding one (T allele), we directly measured the relative 
abundances of the wild-type (G allele) and mutant (T allele) motif sequences in the 
ChIP pull-down DNAs from the three heterozygous cell lines after 5FU treatment by 
real-time PCR analysis. This takes away the bias and uncertainty on any other 
unknown confounding factors. There are also three biological replicates and two 
technical replicates.   After 5FU treatment for 6 or 32 hours, significantly more of the 
wild-type G allele sequences than the mutant T allele sequences were found in the 
ChIP pull-down DNAs (5 to 10 fold enrichment of wild-type over mutant alleles) 
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(Figure 104).   The enrichment of the wild-type G over mutant T allele could also be 
observed at the baseline, although the enrichment is less prominent.    
 
Figure 104 Taqman Assay result to show allele-specific enrichment of ChIP DNA 
with C Allele 
The enrichment of the wild-type G allele over the mutant T allele in the ChIP pull-down 
DNAs from the three heterozygous cell lines (G/T) after 5FU treatment for 8 and 32 
hours.  
 
Our series of the ChIP analyses clearly show that the p53 protein has a higher 
binding affinity to the wild-type G allele than to the mutant T allele, although the 
single base substitution does not totally abolish p53’s binding to this site.   
5.3 Binding affinity by reporter assay analysis  
To further investigate whether the suppressive transcriptional regulation was p53 
dependent, the transcription regulatory activities of the wild-type and mutant binding 
site sequences were directly measured through a reporter assay analysis. In the 
reporter assay analysis, both wild-type and mutant binding site sequences were cloned 
into a TATA-luciferase reporter vector and then transfected into HCT116 cells with 
either wild-type p53 protein or with the p53 disrupted by homologous recombination 
(p53 null). It was found that the presence of the wild-type binding site sequence could 
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strongly induce the expression of the reporter gene (20 fold induction) in the p53 
wild-type HCT116 cells, and this induction was augmented by the activation of p53 
by 5FU treatment (about 30 fold induction) (Figure 105). Comparatively, in the p53 
null HCT116 cells, this induction effect by the wild-type binding site sequence was 
largely abolished. In both p53 wild-type and null HCT116 cells, the mutant binding 
site sequence (T allele) showed a minimal induction of the report gene expression.  
This result gave direct evidence for this binding site sequence to be associated with a 

















Figure 105 Functional analysis of the binding site sequence (226 bp fragment) 
and its polymorphism (rs184672) by reporter gene assay in wild-type and p53-null 
HCT116 cells with or without 5FU treatment  
Control: TATA-luciferase pGL4 vector; G_TATA: TATA-luciferase pGL4 vector with a 
insert of the 226 bp binding site sequence of G allele;  T_TATA:  TATA-luciferase pGL4 
vector with a insert of the 226 bp binding site sequence of T allele. 
5.4 Transcription activity by real-time PCR analysis  
To investigate whether the observed differential binding activity will lead to the 
difference in the expression activity of its putative target gene PRKAG2, we first 
analyzed the transcription of PRKAG2 mRNA (with or without 5FU treatment) using 
real-time quantitative PCR (qPCR) in 2 cell lines. 
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Initial Analysis of 2 Cell Lines 
The presence of Rs1860746 further down-regulates target gene (PRKAG2)’s 
expression regulation (Figure 106). 
 
 
Figure 106. Preliminary Study on the Influence of rs1860746 on Gene Expression 
Validation Analysis of 13 Cell Lines 
We next analyzed the transcription of PRKAG2 mRNA (with or without 5FU 
treatment) using real-time quantitative PCR (qPCR) in 13 cell lines with different 
genotypes:  three cell lines homozygous for the mutant T allele, five cell lines 
homozygous for the wild-type G allele, and five heterozygous cell lines (G/T).  In 
most of the cell lines, there is a down-regulation of PRKAG2 expression after 5FU 
treatment (Figure 107).  Furthermore, the down-regulation of PRKAG2 expression in 
the five homozygous cell lines for the wild-type G allele is significantly stronger that 
the down-regulation in the three homozygous cell lines for the mutant T allele (p = 
0.025, t-test).   
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Figure 107.  Real-time PCR results for gene expression change of PRKAG2 
The results of the real-time gene expression analysis, showing the down-regulation of 
PRKAG2 expression after 5FU treatment in 13 cell lines carrying either only wild-type 
allele (G/G) (five cell lines), or mutant (T/T) allele (three cell lines), or both alleles (G/T) 
(five cell lines).   
5.5 Polymorphism’s impact on the protein levels by western blot analysis  
AMPK protein complex consists of one catalytic () and two non-catalytic 
regulatory (β and ) subunits, and the expression and activity of the AMPK protein 
complex depends on the co-regulation of its three subunits (Crute, Seefeld et al. 1998).  
We hypothesize that the interruption of p53’s down-regulation effect on the 
transcriptional expression of the AMPKγ subunit, this germ-line p53 binding motif 
variant can have an impact on the expression and activity of the AMPK protein 
complex.  As such , we investigated the polymorphism’s impact on the protein levels 
of both AMPK  and  subunits using western blot analysis.  The western blot 
analysis was performed in two cell lines (among the 13 cell lines subjected to real-
time PCR analysis) that show the most prominent difference in the p53-mediated 
down-regulation of PRKAG2 mRNA level (Refer to Figure 107).  Protein levels of 
p53, total and phosphorylated AMPK, AMPK and actin (endogenous control) were 
assessed in the two cell lines at baseline and after 5FU treatment for 8, 24 and 48 
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hours.   As shown in Figure 108, the expression of p53 protein was induced in a time-
dependent fashion by 5FU treatment in both cell lines.  In contrast the levels of the 
AMPK and total and phosphorylated- AMPKproteins after 5FU treatments differ 
significantly between the two cell lines.  In the cell line carrying mutant binding site 
(T/T), the levels of the AMPK and total and phosphorylated- AMPK proteins were 
largely unaffected by 5FU treatment, whereas in the cell line carrying wild-type 
binding site (G/G), a significantly decreased expression of the three proteins was seen 
after 5FU treatment, primarily of phosphorylated AMPK and AMPK especially at 
48 hours.  These results are consistent with the regulatory effect of AMPK on the 
activity of AMPK.  
 
Figure 108 Western blot analysis on AMPK sub-units, p53 and actin 
The results shows that the differential down-regulation effect of p53 activation by 5FU 
on AMPK protein complex (AMPK, total and phosphorylated- AMPKproteins) in 
cells carrying either wild-type (G/G) or mutant (T/T) binding motif.    
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5.6 Genetic association analysis of the p53 binding motif SNP (rs180746) 
with cancer susceptibility 
Given that both AMPK and p53 have been implicated in cancer development 
(Vousden and Lu 2002; Shaw 2006), it is postulated that this germ-line regulatory 
variant (rs180746) of the transcriptional link between p53 and AMPK may have an 
impact on cancer susceptibility. To test this hypothesis, the analysis of the SNP 
rs180746 in a large cancer sample from Sweden and Finland was carried out. The 
“worst case” assumption was that the effect of this SNP on cancer susceptibility 
would be low, as has been found for the recent identified breast cancer susceptibility 
loci (Easton, Pooley et al. 2007), and that only the homozygous TT genotype would 
show a phenotypic effect (as indicated by our in vitro functional analyses). The SNP 
in the cancer sample consisting of 1297 breast cancer patients, 579 endometrial cancer 
patients, 1637 healthy controls from Sweden, 2399 breast cancer patients and 1256 
healthy controls from Finland were genotyped. The MAF of rs1860746 was 18.2% in 
our samples, which was very similar to the one detected in the 76 CEPH DNA 
samples as well as the one reported in Caucasians by the HapMap project. The 
genotype frequencies at this locus were in Hardy-Weinberger equilibrium.  
Association analysis was performed using the χ2 test under a recessive model of 
inheritance, and the results are summarised in Table 24.  First, the association analysis 
was performed in the whole cancer sample of 4113 patients and 2983 controls. It was 
found that there was significant association of the homozygous mutant genotype (TT) 
with an increased risk for cancer development (OR = 1.36, p = 0.024).  Second, the 
association was investigated in the breast cancer sample including 3541 patients and 
2740 controls, and significant evidence was identified (OR = 1.34, p = 0.043) for the 
association with breast cancer susceptibility.  Finally, the association of this 
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regulatory polymorphism in different clinical subgroups of patients stratified based on 
the menopausal status, family history and ER status, was investigated. Interestingly, 
significant association was evident only in the premenopausal patients (OR = 1.66, p 
= 0.05) and the patients with family history (OR = 1.48, p = 0.04) but not in sporadic 
(OR = 1.25, p = 0.16), postmenopausal (OR = 1.38, p = 0.10) cases or the subgroup 
analysis based on ER status.  
Table 24 Analysis of the association of SNP with cancer susceptibility under a 
recessive model of inheritance 
Sample Set Sample Size  Genotype Freq (%)  
 
 
OR  (95% CI) 
 
P value
    GG or GT TT    




2.89    




Controls 2740  97.08 2.92    
 All Cases 3541  96.07 3.93  1.34 (1.01, 1.77) 0.04 
  ER+ Cases 2492  96.27 3.73  1.26 (0.92, 1.72) 0.15 





























 Sporadic cases 2359  96.31 3.69  1.25 (0.92, 1.70) 0.16 
 Familial cases 1098  95.72 4.28  1.48 (1.01, 2.17) 0.04 
         
 
5.7 Concluding remarks 
From the above functional analyses in LCL cells, we have proved that p53 is a 
suppressor on the γ2 subunit (PRKAG2 gene) of the AMPK protein complex. Upon 
exposure to a genotoxic agent – 5FU, the p53 proteins are both increased in levels and 
functionally activated, which subsequently down-regulates the expression of AMPKγ 
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(PRAKG2 gene). The germ-line variant (rs1860746) found within the p53 binding 
sites for PRAKG2 gene, reduced greatly the p53 binding, attenuating both the gene 
and protein expression.  
AMP-activated protein kinase (AMPK) is an important central censor of energy 
stress and stimulated AMPK are essential for maintaining normal metabolism through 
ATP-generating mechanism. AMPK activity is greatly controlled by the 
phosphorylation of Thr172 on AMPK. During conditions such as glucose deprivation 
and oxidative stress, the cells experience stresses that the AMP/ATP ratio is elevated, 
activating the AMPK. During AMPK protein activation, energy-consuming processes 
such as protein synthesis are inhibited while the energy-generating processes such as 
glucose uptake and fatty acid metabolism are promoted. In this way, the energy 
balance is restored in the cells and the stresses are gone. AMPK activates the p53 by 
phosphorylation on Ser-15 of p53, which in turns causes cell cycle arrest. (Jones, Plas 
et al. 2005) . Our findings lead to novel negative feed-back of p53 on AMPK that 
while p53 down-regulates AMPK, p53 itself is activated by AMPK. 
Our study provides the first genetic evidence, at the population level, that 
conditionally higher AMPK activity is associated with increased susceptibility to 
cancer development. By genotyping this p53 binding site polymorphism in a large 
cancer sample of 4113 patients and 2893 controls, significant evidence was found for 
association of the homozygous mutant genotype with high susceptibility to cancer 
development (OR = 1.36, p = 0.024). Because the mutant allele was shown to 
interrupt p53’s down-regulation of the PRKAG2/AMPK expression under conditions 
of genotoxic stress, our genetic analysis strongly suggests that AMPK more likely 
functions as a tumor promoter, at least at human population level.  Interestingly, our 
subgroup analysis in breast cancer suggests that this germ-line p53 binding site 
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polymorphism may play a more prominent role in pre-menopausal breast cancer 
patients with a positive family history. This finding is consistent with the observations 
that patients with germ-line p53 mutations in the families affected with Li-Fraumeni 
syndromes (LFS) are at risk for early-onset breast cancer(Olivier, Goldgar et al. 2003) 
and that germ-line p53 mutations can be found in the patients of hereditary breast 
cancer who are negative for BRAC1 and BRAC2 mutations(Walsh, Casadei et al. 
2006).  Given that there is good evidence for p53 and metabolic stress to function in 
the aging process (Bensaad and Vousden 2007), we speculate that the germ-line p53 
binding site polymorphism may also have an impact on some aspect of human 
longevity. 
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Chapter 6 Conclusion 
In conclusion, more than 40,000 mapped and putative ER binding sites have been 
incorporated into the customised array which was an isothermal array with ~380,000 
probes in which, each region was tiled with at least 6 probes. Mainly, the important 
design considerations of the ERα specific binding site array included the adoption of 
variable-length probes to ensure similar hybridisation specificity that 70% of all 
probes have similar melting temperature between 73 and 77 oC. It was also important 
to carry out various quality controls of the customised array such as assessments 
based on probe properties, technical and biological reproducibility and reuses of 
stripped arrays, so as to confirm that the array was capable of querying the biology 
questions in this thesis.  
With this customised ER chip, the different ChIP assays performed with virtually 
any antibodies (ER, H3K4Me1, FOXA1 and GATA3), cell lines (MCF-7 and 
Ishikawa cell lines), drug treatments (E2, T, R and I) and concentrations in time 
course experiments (ChIP and FAIRE), the profiles of the genome-wide binding sites 
were comprehensively surveyed.  
To detect enriched binding sites or peaks from the above profiles, a new 
algorithm called the VFLM was designed and implemented. It detected 6482 ER 
binding sites in E2 treatment. Genome-wide binding sites analysis showed a high 
prevalence of pre-occupied ER binding sites which also had a greater ER recruitment 
upon E2 treatment. ER binding profiles for SERMs showed a similar location as in E2 
but the ER binding recruitments in SERMs were significantly much less than in E2. 
Distribution of Full ERE, half ERE or no ERE on both the SERMs or unique binding 
sites to different treatments showed that ER-SERMs might utilise tethering 
mechanism much more than ER-E2. De novo motif analysis showed that ER-SERMs 
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conformation was dissimilar in different SERMs with I seemed to have the greatest 
differential conformation change, followed by R and the least conformation change 
was in T.  Comparing E2 binding sites with and without basal occupancy, the former 
showed a more accessible chromatin configuration, had the greatest FAIRE signals 
and the highest H3K4Me1 enhancer marks. H3K4Me1 was also found to be the most 
predictive factor for identifying ER binding sites through both decision tree and ROC 
curve. It was further confirmed that the role of FOXA1 was a pioneering factor while 
GATA3 served as a co-factor. Lastly, it was shown that ER binding were regulated 
differently in MCF-7 and Ishikawa cell line.   
Under different drugs treatments (E2, T, R and I) at different time points (0, 3, 6, 
9, 12, 24 and 48 hours), genome-wide gene expression profiles with the Affymetrix 
array (HG-U133 Plus) were obtained. With the combination of published methods, 
approaches and gene expression analysis, the regulated genes for each treatment were 
obtained. The regulation of genes (up-regulated or down-regulated) was classified 
using a novel approach whereby consistency in expression values and its gradient 
were used. The gene expression patterns of a panel of well-known genes were 
examined in E2 and across SERMs conditions for assessing the array data quality. 
The gene expression patterns were well within expectation which confirmed and 
validated the Affymetrix experiments and data. The E2-regulated genes were 
correlated to both ER and Pol II binding sites. There was also a high prevalence of Pol 
II preloading mechanism for E2-regulated genes as the distribution of genes away 
from TSS was similar for both E2 and DMSO conditions. The high percentage of 
down-regulated genes in 5-100kb category away from TSS also suggested a potential 
mechanism for down-regulation which involved Pol II pausing or stalling. E2 genes 
that were strongly up- or down-regulated had a higher propensity to have ER binding 
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sites in proximity than non-regulated genes. Strong E2-ER binding sites with basal 
occupancy associated with E2 up-regulated genes whereas weak binding ones 
associated with tethered mechanism. ER binding sites with greater fold change 
associated more with higher presence of ERE and a larger number of regulated genes. 
SERMs were found to have modulating effects on E2 gene expressions by attenuating 
or even changing the directionality of gene regulation. Besides modulating E2 genes, 
SERMs also regulated their own set of genes. From their own set of regulated genes, 
only E2 and TE had higher proportion of up-regulated genes while the remaining 
treatments resulted in a higher proportion of down-regulated genes. Unique genes to 
SERMs and E2 were found, exclusive of one another. The directionality of gene 
regulation, i.e. up-regulated or down-regulated, could not be predicted based on ER 
occupancy in E2 and SERMs conditions. However, ER remained occupied in E2 and 
across SERMs conditions for up-regulated genes. The unique Tamoxifen or 
Raloxifene binding sites with reference to E2 binding sites were also explored by 
plotting the average FAIRE and H3K4Me1 profiles. The results showed that the 
profiles were distinctive with unique SERMs binding sites showing higher FAIRE 
and H3K4Me1 signals, which strongly suggested that SERMs altered ER’s spatial 
binding characteristics. ER-responsive genes in different tissues upon E2 and SERMs 
treatments revealed spatiotemporal expression profiles.  There were a greater number 
of regulated genes in MCF-7 than Ishikawa cell line. Interestingly, there were a 
greater proportion of down-regulated genes in MCF-7 while Ishikawa cell line had a 
greater proportion of up-regulated genes. This indicated that the antagonising 
properties of SERMs were stronger in MCF-7 than Ishikawa cell line. The overlap in 
the regulated genes between MCF-7 and Ishikawa cell line was low which suggested 
that the two cell lines had different tissues properties even at the gene level. The 
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corresponding Ishikawa gene expressions for the MCF-7 E2-regulated genes showed 
a much lower signal. A key observation is that Ishikawa cell line is so different from 
MCF-7 cell line in their ER-dependent transcriptional programs.   
Our proposed model failed to explain all the relationships between ER binding, 
chromatin state, histone modifications and FoxA1. This could be due to a number of 
reasons. Since ERβ was not considered in the analysis, some of the results that 
deviated from the proposed model could be due to the involvement of ERβ. Macaluso 
and his colleagues reported the co-immunoprecipitation of both ERβ and pRb2/p300 
in MCF7 (Macaluso, Montanari et al. 2006). Instead of purely ERα homodimers, 
some ERα may dimerise with ERβ to form heterodimers. Together with ERβ 
homodimers, these different dimers shaped and defined the complex observations 
obtained from the various experimental approaches. ERβ has been shown to attenuate 
the transcriptional activities of ERα (Lindberg, Moverare et al. 2003) by binding to 
estrogen-responsive promoters and changing the association with c-Fos and c-Jun 
(Matthews, Wihlen et al. 2006). 
E2 was shown to modify the micro-ribonucleic acid (miRNA) expression profiles 
(Cohen, Shmoish et al. 2008). Since miRNA has the ability to repress translation, it 
can down-regulate mRNA by degradation or cleavage without the requirement of 
perfect complimentary targeted sequences (Lim, Lau et al. 2005). 
Even in DMSO only treated samples which served as a control, there was already 
high basal occupancy of 4729 binding sites albeit at low enrichments. These sites 
were probably occupied with estrogen receptor coupled with endogenous estrogen 
that was present despite the hormone starvation for 3 days. The presence of minute 
amount of endogenous estrogen may contribute to some of the binding sites profiles 
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which were observed in SERMs only treatments. Alternatively, a minority of ER 
could dimerise and bind to the DNA without forming ER-E2 complexes.   
A number of binding sites were found located within genes. A significant 
proportion of binding sites within the gene was even located within the first intron. 
Most of the time, it also coincided to the 5’ untranslated region (UTR). The 
observation that many binding sites were found inside genes often corresponded to 
down-regulated genes that led to the hypothesis that the binding sites may serve as a 
function to stop transcription. The TF may continue to recruit the associated factors 
and help to stop the transcription process.   
The data analysis on the nucleosomes array indicated that the majority of 
nucleosome positions remained relatively the same before and after E2 treatment. 
However, there was greater nucleosome depletion when the genes became actively 
transcribed upon drug treatment.   
The ideal study would be to determine the functional importance of ER binding 
to its cognate DNA sites in the whole tissue for active human populations. This 
however is not possible so we want to use alternative system – p53 binding in LCL 
cell lines. From the functional analyses in LCL cells, we have proven that p53 was a 
suppressor on the γ2 subunit (PRKAG2 gene) of the AMPK protein complex. Upon 
exposure to a genotoxic agent – 5FU, the p53 proteins were both increased in levels 
and functionally activated, which subsequently down-regulated the expression of 
AMPKγ (PRAKG2 gene). The germ-line variant (rs1860746) found within the p53 
binding sites for PRAKG2 gene, reduced the p53 binding greatly, attenuating both the 
gene and protein expression.  
AMP-activated protein kinase (AMPK) was an important central censor of energy 
stress and stimulated AMPK was essential for maintaining normal metabolism 
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through ATP-generating mechanism. AMPK activity was greatly controlled by the 
phosphorylation of Thr172 on AMPK. During conditions such as glucose deprivation 
and oxidative stress, the cells experience stress that the AMP/ATP ratio was elevated, 
activating the AMPK. During AMPK protein activation, energy-consuming processes 
such as protein synthesis were inhibited while the energy-generating processes such 
as glucose uptake and fatty acid metabolism were promoted. In this way, the energy 
balance was restored in the cells and the stresses were gone. AMPK activated the p53 
by phosphorylation on Ser-15 of p53, which in turned caused cell cycle arrest. (Jones, 
Plas et al. 2005) . Our findings led to novel negative feed-back of p53 on AMPK that 
while p53 down-regulated AMPK, p53 itself was activated by AMPK. More 
importantly, our study has further demonstrated that this modulation of p53-AMPK 
transcriptional link by the germ-line polymorphism will increase the risk for cancer 
development.  As an proof-in-principal study, our study has highlighted that 
combining the genome-wide discovery of transcription regulatory elements (such as 
transcription factor binding sites) with the forward genetic analysis in both model and 
human systems can greatly advance our understanding on the molecular and 
physiological functions of regulatory genetic variation.   We further posit that a 
‘marriage’ between the new genome-wide knowledge of various regulatory sequences 
and the rapidly accumulated disease association data on germ-line polymorphisms 
will bring a paradigm shift to regulatory variation research.    
Further studies could be carried out by obtaining the binding sites and gene 
expression profiles on the actual clinical breast cancer samples. Subsequently, a 
relational map of ER and gene expressions could be constructed that may help to 
predict pharmacologic effects. Since a pool of ER binding sites has been obtained, it 
would be of high interest to study what the consequences of human variation at the 
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validated ER binding sites are. Besides functional studies on the polymorphism on 
those binding sites, ER association study of the binding sites could be carried out. We 
should treat ChIP with different antibodies to co-factors such as N-Cor and SRC-1 
and examine the binding sites profiles in the same drug combination used in the 
studies. ERbeta binding sites could also be mapped to this customised array and 
assess the binding sites patterns under different conditions. In order to study the 
binding dynamics of ER, a time course ChIP could be performed. Lastly, all of the 
above could be performed and the studies could be carried out in this thesis using the 
latest technology – ChIPSeq to have an unbiased genome-wide study. 
In conclusion, the novel ER customised array platform and the comprehensive 
data on the ER-binding sites and the transcription activities affected by SERMs 
provided in this thesis would aid in the discovery of better SERMs and the improved 
understanding of their mechanism of actions. 
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Chapter 7 Materials and Methods  
7.1 Material and Methods for Binding Sites Array 
Cell Culture and Treatments 
MCF7 cells were in 20ml Dulbeco’s modified Eagle’s medium (DMEM/F-12 ) 
from Invitrogen/Gibco supplemented with 10% fetal bovine serum (FBS) from 
Hyclone at 37oC under 5% CO2. The cells were split to more plates before they 
reach > 90% confluence to prevent the cells from changing in characteristics when 
they reached full confluence.   
Chromatin Immunoprecipitation (CHIP) Assay 
 
Day 1: Starvation of cells 
MCF7 cells were grown to ~50% confluence. The cells were washed 3 times in 
each plate with 10ml of 1X PBS, and 20ml phenol-red free DMEM / F12 medium 
(Invitrogen/Gibco) supplemented with 5% charcoal-dextran stripped FBS(Hyclone) to 
starve them. The cells were then incubated for 3 days in preparation for 17E2-
estradiol (E2; Sigma) treatment.  
 
Day 2: (A) Estrodiol Treatment 
20µl of 10µM E2 (estrodiol in DMSO) was added into each plate to obtain a final 
concentration of 10nM, while 20µl of DMSO was added to other plates as negative 
control. All treated dishes were incubated for another 45 minutes before harvesting. 
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(B) Harvesting Cells 
MCF7 cells were harvested under the fume hood. 675µl of formaldehyde was 
added in each plate for cross-linking and rotated for 10 minutes on a rotator at room 
temperature (RT). 2ml of glycine was then added to stop the cross-linking followed 
by rotation for 5 minutes at RT. The medium was poured, washed 2 times with 10ml 
of cold 1 X PBS and finally the PBS was poured. Costar brand 3cm blade scraper was 
used to scrap the cells. The cells were then collected from one plate into 15ml tube 
individually.   
The cells in the 15ml tube were centrifuged at 3000 rpm for 15 minutes at 4°C 
using Sorvall Legend RT (Heraeus). After the supernatant was removed, the pellets 
were re-suspended and each was washed with 5ml 1 X PBS. Next, the pellet cells 
were centrifuged at 3000 rpm for 5 minutes at 4°C. Subsequently, the supernatant was 
removed. 
  
(C) Isolation of the Nuclei by Lysis of the Cell Membrane 
The pellets were re-suspended and washed individually with 5ml of TritonX-100 
lysis buffer. They were then incubated in cold room with 10 minutes gentle agitation 
and spun at 3000 rpm for 5 minutes at 4°C. This process of re-suspension, washing 
with the lysis buffer, incubation and centrifugation was repeated twice. The 
supernatant was removed. The pellet was re-suspended with 300l SDS lysis buffer 
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(D) Sonication of the Nucleus Lysate (Set up Branson digital sonifier in the cold 
room) 
2 sets of 15-second pulses is performed on the nucleus lysate using a sonicator, 
set to 20% of maximum power. Nucleus lysate was sonicated to shear genomic DNA 
to lengths between 500 and 1200 bps. The sample was chilled on ice for 15 seconds 
between sonications. The sample is kept on ice at all times to prevent DNA from 
denaturing by the heat generated by sonication.  
The pellet cell debris was centrifuged at 13 X 1000 rpm for 15 min at 4 °C and 
the supernatant was transferred into a 15ml tube. ~ 50µl of nuclear lysate was 
aliquoted for checking the sizes of the DNA fragments and stored at -80ºC. 
Day 3: Set Up of the CHIP Assay 
The bottle containing 50 % Protein A Sepharose (PAS or beads) slurry was 
shaken before use. 1.3ml of beads were placed into a 15ml tube and washed 2 times 
with 10ml of 1 X PBS with 0.1% TritonX-100 and 1 time with 10ml of TSE I buffer. 
They were spun down each time at 800rpm for 2 minutes at 4°C using Sorvall Legend 
RT (Heraeus) centrifuge. After the supernatant was removed, the beads were 
equilibrated in 1.3ml of TSE I buffer (to obtain 50% beads slurry). 
300µl of the 50% beads slurry were transferred into 1.5ml microfuge tube where 
the beads were treated by adding 100µl of BSA (20 mg/ml). The beads were mixed 
well and incubated in cold room with rotation for ~ 2 hours. 
Sonicated samples (from Day 2, section D) were thawed and each sample was 
diluted with 4ml dilution buffer. Samples were pre-cleared by adding ~ 250l of the 
50% beads slurry and incubated in the cold room with rotation for ~ 2 hours.  
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After 2 hours, pellet beads were spun down at 800rpm for 2 minutes at 4ºC and 
the supernatant was removed. The beads were then washed 3 times with 1ml of TSE I 
buffer. Finally the beads were equilibrated in 300µl of TSE I to obtain 50% beads. 
After pre-clearing on the sonicated samples, the pellet beads were spun down at 
800rpm for 2 minutes at 4ºC. The supernatant was collected, 0.5ml of it was taken out 
as total input, labeled and stored at -80ºC, and the rest of the supernatant was 
distributed evenly into a new 15ml tube. 
The immunoprecipitation (IP) was set up by using ~ 4.5ml of pre-cleared lysate, 
75µl of 50% beads and 5µl of polyclonal anti-ERα AB (HC-20) (200 µg/ml) or 
polyclonal anti-GST AB (Z-5) (200µg/ml) were added into each 15ml tubes. The 
tubes were then incubated in the cold room with gentle rotation overnight or for at 
least 12 hours. Parafilm was used to seal the cap properly. 
 
Day 4: Washing of the Bead and Eluting of the DNA 
The overnight IP was spun in a 15ml tube at 800rpm for 2 minutes at 4°C, in 
Sorvall Legend RT (Heraeus) centrifuge.  Next, the supernatant was removed with 
10ml serological pipette and P1000 without disrupting the beads.   
The beads were washed with 5ml of cold TSE I buffer by gentle rotation in cold 
room for 10 minutes. The pellet beads were spun at 800 rpm for 2 minutes at 4°C and 
the supernatant was removed. 
The beads were washed again with 5ml of cold TSE I buffer by gentle rotation in 
cold room for 10 minutes and the pellet beads were spun at 800 rpm for 2 minutes at 
4°C. Thereafter, the supernatant was removed. 
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Beads were washed with 5ml of cold buffer III by gentle rotation in cold room for 
10 minutes. Pellet beads were spun at 800rpm for 2 minutes at 4°C and the 
supernatant was removed. 
Finally, the beads were washed with 5ml of cold TE buffer by gentle rotation in 
cold room for 10 minutes. Pellet beads were spun at 800rpm for 2 minutes at 4°C and 
the supernatant was removed. 
150µl of room temperature elution buffer was added to the beads in the 15ml tube. 
About 2mm of the yellow pipette tip was cut and used to re-suspend the beads and for 
transferring to a new 2ml screw cap microfuge tube. Another 100µl of elution buffer 
was used to rinse the 15ml tube. The remaining beads were transferred to the 2ml 
screw cap microfuge. Incubation was done in the Thermomixer at 700rpm and at 65ºC 
for 30 minutes. The beads were spun down at 800rpm for 2 minutes.  The supernatant 
of each sample was transferred into new 2ml screw cap tube. ~ 250µl elute was 
recovered for all samples. 230µl of TE buffer (for dissolving DNA) was added into 
the beads. The beads were re-suspended and spun down. Another ~ 230µl elute was 
recovered and pooled together to yield ~ 480µl elute. 
20µl of pronase (20 mg/ml) was added to each sample to yield a total of 500µl. 
Incubation was done at 42°C water bath for 2 hours as protease treatment. The nuclear 
lysate and the supernatant for input DNA (in day 3 above) was thawed. The nuclear 
lysate was diluted to ~ 500µl by TE buffer (for dissolving DNA). The same protease 
treatment was done for all the samples. 
The CHIP samples, nuclear lysate and the total input samples were de-crosslinked 
together at 65°C overnight. (All the caps of the 2ml screw cap tubes were wrapped 
and sealed with parafilm before incubation to prevent evaporation of the volume.) 
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Day 5: DNA Extraction and Precipitation 
~ 500µl (1 vol) of phenol /chloroform /isoamyl alcohol (25: 24:1) was added to 
each sample, mixed well and spun at maximum speed for 10 minutes. The upper 
aqueous phase was saved into new tubes. ~500µl (1 vol) of chloroform was added to 
each sample, mixed well and spun at maximum speed for 10 minutes. The upper 
aqueous phase was saved into new tubes again. 1µl of glycogen (20µg/µl), 45µl (0.1 
vol) of 4M LiCl, and 500µl (1 vol) of 100% isopropanol or 1250µl (2 – 3 vol) of 
100% ethanol were added, mixed well and incubated at -80°C for 1.5 hours for 
precipitation of DNA. 
The DNA was spun at a maximum for 30 minutes at 4°C. The supernatant was 
discarded and the DNA pellet was rinsed with 1ml 95% ethanol, spun again at 
maximum speed for 15 minutes at 4°C. The supernatant was discarded again and the 
DNA pellet was air-dried. Next, 15µl of H2O was added into each of the CHIP 
samples to dissolve DNA and the CHIP DNA was stored at -20°C. 50µl of H2O was 
then added into each of the total input samples and nuclear lysate samples to dissolve 
DNA, followed by the addition of 1µl of RNase (10 mg/ml) into each input sample. 
Incubation was done at 37°C for 1 hour and the input DNA was stored at -20°C.  
WGA Amplification 
Library Preparation 
2μl of 1X Library Preparation Buffer was added to each sample, followed by 1μl 
of Library Stabilization Solution. The mixture was vortex thoroughly, consolidated by 
centrifugation and placed in thermal cycler at 95°C for 2 minutes. The sample was 
cooled on ice, consolidated by centrifugation and replaced on ice. Thereafter, 1μl of 
Library Preparation Enzyme was added to the sample and it was vortex thoroughly 
and before centrifugation was done briefly. Next, the sample was placed in a thermal 
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cycler and incubated as follows: 16°C for 20 minutes, 24°C for 20 minutes, 37°C for 
20 minutes, 75°C for 5 minutes and lastly, held at 4°C. The sample was then removed 
from the thermal cycler, centrifuged briefly and labeled as X. Samples may be 
amplified immediately or stored at –20 °C for three days. In the process of 
amplification, a master mix was prepared by adding the following reagents to the 15μl 
of X prepared earlier: 7.5μl of 10X Amplification Master Mix, 47.5 μl of Nuclease-
Free Water and 5μl (12.5 units) of Jumpstart Taq DNA Polymerase. The master mix 
was vortex thoroughly and centrifuged briefly before themocycling began. 
 
The following profile has been optimized for a PE 9700 or equivalent 
thermocycler: 
Initial Denaturation took place at 95°C for 3 minutes, 14 cycles were performed 
as follows: denaturation at 94°C for 15 seconds followed by extension at 65°C for 5 
minutes. After thermocycling was completed, the reactions were maintained at 4°C or 
stored at –20°C until they were ready for analysis or purification. The stability of 
WGA DNA was equivalent to genomic DNA stored under the same conditions. 
 
Nimblegen ChIP-on-chip protocols 
 
Sample Labeling 
Cy3 and Cy5 dye-labeled 9mers were diluted to 1 O.D./42l Random 9mer 
Buffer (8.6ml of VWR deionised water, 1.25ml of 1M Tris-HCl, 125l of 1M of 
MgCl2, 17.5l of β-Mercaptoethanol) . The random 9mer buffer was aliquot to 40l 
individual reaction volumes in 0.2ml thin-walled PCR tubes and stored at –20°C. 1g 
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of WGA amplified ChIP Sample (1g), 40l of Cy5-9mer Primers and VWR Water 
was added to make up a total volume of 80l of ChIP sample. 1µg of WGA input 
DNA (1g), 40l of Cy3-9mer Primers and VWR Water was added to make up a total 
volume of 80l of reference input DNA. Samples were denatured by heating in 
thermocycler at 98°C for 10 minutes and quick chilled in ice water bath. 10l of 50X 
dNTP mix, 8l of VWP deionised water and 2l of Klenow (50 U/ml) were added to 
both the denatured ChIP samples and input DNA samples. ChIP samples and input 
DNA samples were mixed well by pipetting 10 times. The contents were forced to the 
bottom of the tube by spinning down at low RPM. ChIP samples and input DNA 
samples were incubated at 37°C for 2 hours in a thermocycler protected from light. 
After 2 hours, 10l of Stop Solution (0.5M EDTA) was added to stop the solution. 
The samples were each transferred to a 1.5ml tube and precipitated by adding 11.5l 
of 5M NaCl and 110l of isopropanol to each tube, each with a cumulative total 
volume of 231.5l. The samples were vortex and incubated for 10 minutes at room 
temperature in the dark. Centrifugation was done for 10 minutes at maximum speed. 
The supernatants were then removed using a pipette. The pellets were rinsed with 
500l of 80% ice-cold ethanol and dislodged from the tube wall. Centrifugation was 
carried out again at maximum speed for 2 minutes and the supernatants were removed 
with a pipette. The supernatants were then speed-vac on low heat and protected from 
light for 5 minutes until they became dry. The labeled samples were stored at –20°C 
and protected from light. The dried pellets were then rehydrated in 25l VWR 
deionised water, vortex for 30 seconds and quick spun to collect contents at the 
bottom of each tube. The process of vortexing for 30 seconds and quick spinning to 
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collect contents at the bottom of each tube was done repeatedly until complete 
rehydration was achieved.  
The A260 in each sample was measured. It was important to consume as little 
sample as possible when performing this measurement. NimbleGen recommended the 
use of a NanoDrop spectrophotometer (www.nanodrop.com) that allows the 
measurement of a 1l sample without dilution and the typical yields range from 10g 
to 30g per reaction. 
 
Hybridization of Cy-labeled ChIP Samples 
The MAUI hybridization unit was set to 42°C and time was allowed for the 
temperature to stabilise. Based on the A260 measurement performed in the sample 
labeling step, 12g of each of the ChIP and input DNA samples were combined into a 
single 1.5ml microcentrifuge tube. The combined contents were dried in a Speed-Vac 
on low heat and then resuspended in 3.5l VWR water and vortex to completely 
dissolve the sample. The tube was spun down briefly to collect the contents in the 
bottom. Using the NimbleGen Array Reuse Kit, 3.5l of Cy labeled test & reference 
samples, 31.5μl of 2X Hybridization Buffer, 9l of Hybridization Component A, 
0.5l of 50nM Cy3 CPK6 50mer Oligo and 0.5l of 100nM Cy5 CPK6 50mer Oligo 
were added to the resuspended sample, making up a total volume of 45l. The tube 
was mixed briefly and spun down to collect the contents in the bottom and placed at 
95°C for 5 minutes. Thereafter, the tube was immediately transferred to the MAUI 
42°C sample block and was held at this temperature until sample loading is ready to 
be done. The MAUI Hybridization Chamber was placed on the array using the 
provided assembly/disassembly jig and the MAUI setup instructions were followed 
carefully. The sample was loaded using the pipet supplied with the MAUI Station. 
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During loading, a small amount (3-7μl) of the sample may flow out of the outlet port. 
It was important to ensure that there were no bubbles in the chamber by careful 
loading and remove any air in the pipet tip. If bubbles was present, very gently 
massaged the bubbles to either of the ends, away from the center of the array. Avoid 
applying too much pressure since this would force liquid out of the ports. The loaded 
array was placed into one of the four MAUI bays and allowed to equilibrate for 30 
seconds. Any sample leakage at the ports was wiped off with a Kim-Wipe, and MAUI 
stickers were adhered to both ports. The bay clamp was closed and mix mode B was 
selected. The mix button was held down to start mixing. The mixing was in progress 
before the cover was closed. The sample was left to be hybridised overnight (16-20 
hours). 
Washing of Arrays 
Before the array was removed from the MAUI Hybridization Station, the 
following solutions were prepared: two 250 ml dishes of Wash I (225ml of VWR 
water, 25ml of 10X Wash Buffer I and 25μl of 1M DDT), one 250ml of Wash II 
(225ml of VWR water, 25ml of 10X Wash Buffer II and 25μl of 1M DDT) and one 
250ml of Wash III (225ml of VWR water, 25μl of 10X Wash Buffer III and 25μl of 
1M DDT). One of the dishes of Wash I had to be shallow and wide enough to 
accommodate the array and mixer loaded in the MAUI assembly/disassembly jig. The 
other dish of Wash I, dish of Wash II and dish of Wash III solutions were placed in 
300ml wash tanks. The chip from MAUI Hybridization Station was removed, loaded 
back into the MAUI assembly/disassembly jig and immersed in the shallow dish of 
250ml Wash I. While the chip was submerged, the lid of the dish was carefully peeled 
off. The chip was then gently agitated in Wash 1 for 10-15 seconds. The slide was 
transferred into a slide rack in the second dish of Wash I and incubated for 2 minutes 
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with agitation. It was then transferred to the dish of Wash II and incubated for 1 
minute with agitation. The dish was rocked to move the wash over the tops of the 
arrays. Thereafter, it was transferred to the dish of Wash III and incubated for 15 
seconds with agitation. The array was removed and spun dry in an array-drying unit 
(e.g. the NimbleGen Array-Go-Round) for 1 minute. The dried array was then stored 
in a dark desiccator and the protocol for NimbleGen Two-Color Scanning of 
NimbleGen Arrays was followed immediately. 
Two-Colour Array Scanning 
The hybridized NimbleGen two-colour arrays were kept in a dark desiccator 
before they were scanned. The slide was placed in the slide carriage so that the array 
was faced down and the barcode end was closest to me. When the slide was lying flat 
on the right side of the carriage and held firmly, the scanning could then begin. While 
scanning, the zoom was set to view the whole image, the brightness and contrast of 
the displayed image was adjusted to eliminate visible saturation. The PMT setting was 
adjusted as appropriate so that the array features should be mostly yellow. It was then 
zoomed into a region as large as possible to get an accurate reading for the whole 
array. The histogram was calculated from all regions bounded by the current view, but 
ratios were selected for array areas only. The global intensity of the features was 
checked. It was made sure that the 532 and 635 wavelength boxes were checked so 
both wavelength histograms were displayed. Under Y-Axis, the Log Axis box was 
also checked. The red or green PMT setting was adjusted as appropriate so that the 
red and green curves were superimposed or as close as possible to each other. When 
the PMT setting was properly adjusted, the scan was restarted and allowed to run 
completely at the new settings. The scan was completed when the histogram was no 
longer changing. The images for the 532nm and 635nm wavelengths were saved as 
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single image .tif files as both images were needed to calculate test vs. reference ratios. 
After scanning, the slide was removed from the scanner and stored in a dark 
desiccator in the event that rescanning was necessary. 
 
Process NimbleChip Microarray Slides to Remove Sample (Strip array) 
All the steps to strip samples from the NimbleChip microarray slides were 
performed without interruption. 
The following is the preparation of processing stations. A water bath was filled 
and equilibrated to 45°C. One to four slide processing containers were filled with 
25ml of Array Reuse Solution. The slide processing containers were placed in a 
conical tube rack. The conical tube rack was submerged in the water bath and 
incubated for 30 minutes at 45°C to warm the Array Solution to 45°C. Each of the 
two processing tanks was filled with 200ml of purified water at room temperature and 
labeled as “processing tank 1” and “processing tank 2” respectively. 
Next, each slide was placed in the array processing rack. The array processing 
tank was submerged in processing tank 1 containing 200ml of purified water and 
incubated for 5 minutes at room temperature. The array processing rack was agitated 
vigorously for the first minute of incubation. The array processing rack was lifted 
from processing tank 1 and water was allowed to drain off the rack for 5 seconds. 
Each slide was transferred to a slide processing container in the conical tube rack 
submerged in the water bath. The conical tube rack was incubated for 2 hours at 45°C 
before it was agitated gently for the first minute of incubation. The array processing 
rack was placed in processing tank 2 containing 200ml of purified water. Immediately, 
the slides were transferred from the slide processing containers to the array processing 
rack in processing rack 2 and incubated for 5 minutes at room temperature. The array 
Lee Yew Kok  PhD Thesis 
  168 
processing rack was agitated vigorously for the first minute of incubation. During the 
5-minute incubation period, water from processing tank 1 was discarded and the tank 
was rinsed with clean purified water. The tank was then filled again with 200ml of 
clean purified water at room temperature. The array processing rack was transferred 
to processing tank 1 containing purified water and tank 1 was incubated for 5 minutes 
at room temperature. The array processing rack was agitated vigorously for the first 
minute of incubation. 
Thereafter, it was the drying of slides one at a time, step-by-step until all the 
slides were dried. To dry the slides, the slide was removed from the array processing 
rack and spun dry in the ArrayIt Microarray High-Speed Centrifuge for 1 minute. The 
slide was removed and the edges were blotted to remove any residual moisture. The 
slide was stored in the original case in a dark desiccator at room temperature until 
ready for use. 
Decision tree 
 Decision tree (Quinlan, J. R. 1993) is utilized to define conditions for the 
classification of transcription factor binding or non-binding events. Decision tree 
induction is one of the data mining methods to discover relationships from a set of 
data and present the data structure in the form of tree for easy visualization. (Quinlan, 
J. R. 1993) The constructed decision tree is subsequently used for predicting the 
outcome, which can be either categorical or numerical.  All nodes of the tree except 
leaf nodes have splits, evaluating the values on the data attributes. Each leaf node 
carries a class label. As such, Decision rules can be inferred from the tree by linking 
the conditions along the paths from the top node to each leaf node.  
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Motif Analysis 
Weeder program was used for the de novo prediction of the motif (Pavesi, 
Mereghetti et al. 2004). Subsequently, the obtained motif was drawn using Weblogo 
(http://weblogo.berkeley.edu/). 
 
7.2 Materials and Methods for Affymetrix Array 
RNA isolation 
Using the protocol – Column RNA isolation.pdf , RNA was extracted from MCF-
7 breast tumor cells subjected to different treatment conditions: Vehicle (DMSO), 
Estradiol (E2), SERM and  SERM + E2. Concentration of E2 is 10nM while that of 
SERMs was 1μM. MCF-7 breast tumor cells were serum starved for 3 days, followed 
by treatments for 0, 3, 6, 9, 12, 24 and 48 hours. SERMs used in the studies included 
tamoxifen, raloxifene and ICI 182,780. After extraction of RNA, the RNA was 
hybridized to Affymetrix U133 plus human array following the manufacturer’s 
protocol. (expression_analysis_technical_manual.pdf). The steps are summarized as 
below: 
Affymetrix protocols 
One-Cycle cDNA Synthesis 
First-strand cDNA Synthesis: 5g of RNA, 2l of the appropriately diluted poly-
A RNA controls, 2l of 50M T7-Oligo(dT) Primer were mixed in a 0.2ml PCR tube. 
RNase-free Water was added to a final volume of 12l. The tube was gently flicked a 
few times to mix and then centrifuged briefly (~ 5 seconds) to collect the reaction at 
the bottom of the tube. The reaction was incubated for 10 minutes at 70°C. The 
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sample was cooled at 4°C for at least 2 minutes. The tube was centrifuged briefly (~ 5 
seconds) to collect the sample at the bottom of the tube. In a separate tube, First-
Strand Master Mix for all the RNA samples was prepared. The First-Strand Master 
Mix (4l of 5X 1st Strand Reaction Mix, 2l of 0.1M DDT, 1l of 10mM dNTP) was 
mixed well by flicking the tube a few times. The tube was centrifuged briefly (~ 5 
seconds) to collect the master mix at the bottom of the tube. 7l of First-Strand 
Master Mix was transferred to each RNA/T7-Oligo(dT) Primer Mix for a final 
volume of 19l. It was mixed thoroughly by flicking the tube a few times. The tube 
was centrifuged briefly (~ 5 seconds) to collect the reaction at the bottom of the tube. 
The tubes were immediately placed at 42°C and incubated for 2 minutes at 42°C. 1l 
of SuperScript II was added to each RNA sample for a final volume of 20l. It was 
mixed thoroughly by flicking the tube a few times. The tube was centrifuged briefly 
(~ 5 seconds) to collect the reaction at the bottom of the tube. The tubes were 
immediately placed at 42°C and incubated for 1 hour at 42°C. The sample was then 
cooled for at least 2 minutes at 4°C. After incubation at 4°C, the tube was centrifuged 
briefly (~ 5 seconds) to collect the reaction at the bottom of the tube and the next step 
was performed immediately. 
Second-strand cDNA Synthesis: In a separate tube, Second-Strand Master Mix 
for all the samples was prepared. The Second-Strand Master Mix (91l of RNase-free 
Water, 30l of 5X 2nd Strand Reaction Mix, 3l of 10mM dNTP, 1l of E. coli DNA 
ligase, 4l of E. coli DNA polymerase I, 1l of RNase) was mixed well by flicking 
the tube a few times. The tube was centrifuged briefly (~ 5 seconds) to collect the 
solution at the bottom of the tube. 130l of Second-Strand Master Mix was added to 
each first-strand synthesis sample for a total volume of 150l. The tube was gently 
flicked a few times to mix and then centrifuged briefly (~ 5 seconds) to collect the 
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reaction at the bottom of the tube. It was then incubated for 2 hours at 16°C. 2l of T4 
DNA Polymerase was added to each sample and incubated for 5 minutes at 
16°C.After incubation with T4 DNA Polymerase, 10l of 0.5M EDTA was added and 
steps were carried out to clean up the double-stranded cDNA. 
Cleanup of Double-Stranded cDNA 
600l of cDNA Binding Buffer was added to the double-stranded cDNA 
synthesis preparation and mixed by vortexing for 3 seconds to obtain a yellow 
mixture. 500l of the sample was applied to the cDNA Cleanup Spin Column sitting 
in a 2ml Collection Tube and centrifuged for 1 minute at 10,000 rpm. Flow-
through was discarded. The spin column was reloaded with the remaining mixture and 
centrifuged as above. Flow-through and Collection Tube were discarded. The spin 
column was transferred into a new 2ml Collection Tube. 750l of the cDNA Wash 
Buffer was pipetted onto the spin column. It was centrifuged for 1 minute at ≥ 10,000 
rpm. Flow through was discarded. The cap of the spin column was opened and 
centrifugation was carried out for 5 minutes at maximum speed (≤ 25,000 x g). Flow-
through and Collection Tube were discarded. The spin column was transferred into a 
1.5ml Collection Tube. 14l of the cDNA Elution Buffer was pipetted directly onto 
the spin column membrane, incubated for 1 minute at room temperature and 
centrifuged for 1 minute at maximum speed (≤ 25,000 x g) to elute. Next, synthesis of 
Biotin-Labeled cRNA was carried out. 
Synthesis of Biotin-Labeled cRNA for One-Cycle Target Labeling Assays 
~ 12l of template cDNA was transferred to RNase-free microfuge tubes and 4l 
of 10X IVT Labeling Buffer, 12l of IVT Labeling NTP Mix, 4l of IVT Labeling 
Enzyme Mix were added. RNase-free Water was added to give a final volume of 40l. 
The reagents were mixed and the mixture was collected at the bottom of the tube by 
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brief (~ 5 seconds) microcentrifugation. The tube was incubated in oven incubator at 
37°C for 16 hours. The next step was the cleanup of biotin-labeled cRNA. 
Cleanup of Biotin-Labeled cRNA 
60l of RNase-free Water was added to the IVT reaction and mixed by vortexing 
for 3 seconds. 350l of IVT cRNA Binding Buffer was then added to the sample and 
mixed by vortexing for 3 seconds. 250l of ethanol (96-100%) was added to the 
mixture and mixed well by pipetting. 700l of sample was applied to the IVT cRNA 
Cleanup Spin Column sitting in a 2ml Collection Tube and it was centrifuged for 15 
seconds at ≥ 10,000 rpm. Flow-through and Collection Tube were discarded. The spin 
column was transferred into a new 2ml Collection Tube. 500l of IVT cRNA Wash 
Buffer was pipette onto the spin column and centrifuged for 15 seconds at ≥ 10,000 
rpm to wash. Flow-through was discarded. 500l of 80% (v/v) ethanol was then 
pipette onto the spin column and centrifuged for 15 seconds at ≥ 10,000 rpm and 
flow-through was discarded. The cap of the spin column was opened and centrifuged 
for 5 minutes at maximum speed of (≤ 25,000 x g). Flow-through and Collection Tube 
were discarded. Columns were placed into the centrifuge using every second bucket. 
Caps were positioned over the adjoining bucket so that they were oriented in the 
opposite direction to the rotation to avoid damage of the caps. The spin column was 
transferred into a new 1.5ml Collection Tube. 11l of RNase-free Water was pipetted 
onto the spin column membrane. It was ensured that water was dispensed directly 
onto the membrane. Centrifugation was done for 1 minute at maximum speed of (≤ 
25,000 x g) to elute the cRNA. 
Fragmenting the cRNA for Target Preparation 
The Fragmentation Buffer has been optimised to break down full-length cRNA to 
35 to 200 base fragments by metal-induced hydrolysis. 20g of cRNA, 8l of 5X 
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Fragmentation Buffer were mixed and RNase-free Water was added to give a total 
volume of 40l. The reaction mixture was incubated at 94°C for 35 minutes and then 
put on ice. An aliquot of it was used for analysis on the Bioanalyser. Undiluted, 
fragmented sample of cRNA was stored at -20°C until ready to perform the 
hybridization. 
Eukaryotic Target Hybridisation 
15g of Fragmented and Labeled cRNA, 5l of 3nM Control Oligonucleotide B2, 
15l of 20X Eukaryotic Hybridisation Controls (bioB, bioC, bioD, cre), 150l of 2X 
Hybridisation Mix, 30l of DMSO were mixed and Nuclease-free Water was added to 
give a final volume of 300l. Probe array was equilibrated to room temperature 
immediately before use. The hybridization cocktail was heated to 99°C for 5 minutes 
in a heat block. Meanwhile, the array was wet with 200l of Pre-Hybridisation Mix 
by filling it through one of the septa. The probe array was then incubated at 45°C for 
10 minutes with rotation. The hybridization cocktail that has been heated at 99°C, was 
transferred to a 45°C heat block for 5 minutes before spinning it at maximum speed in 
a microcentrifuge for 5 minutes to collect any insoluble material from the 
hybridization mixture. The array was removed from the hybridization oven and was 
vented with a clean pipette tip. The Pre-Hybridisation Mix was extracted from the 
array with a micropipettor. The array was refilled with 200l of the clarified 
hybridization cocktail, avoiding any insoluble matter at the bottom of the tube. The 
probe array was then placed into the hybridization oven set to 45°C. To avoid stress to 
the motor, probe arrays were loaded in a balanced configuration around the axis and 
rotated at 60 rpm. Hybridisation was carried out for 16 hours. 
Eukaryotic Arrays Washing, Staining and Scanning 
A. Preparing the stain reagents (the day before) 
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The bottles of reagents were mixed. 600µl Stain cocktail 1 was aliquot into 1.5ml 
tubes (x 2): POSITION 1 & 3. 600µl Stain cocktail 2 was aliquot into a 1.5ml tube: 
POSITION 2. 800µl Array holding buffer was aliquot into another 1.5ml tube. The 
tubes were spun to remove bubbles. The rack was wrapped in aluminum foil and kept 
at 4°C. Wash A and Wash B were filtered and kept at 4°C (1 set for every 4 chips). 
B. Probe array wash 
Hybridization cocktail was removed with a pipettor and stored in a tube at -80°C. 
The probe array was refilled with 300µl of Array holding buffer. 
C. Priming the fluidics station  
In the Fluidics window, the Fluidic station(s) to be used, were selected. The 
Fluidics station (left side of the machine) was turned on. The respective media bottles 
were filled with the correct solutions (MiliQ water, Wash A & Wash B) and it was 
ensured that there are fresh tubes in every station. The lever was pulled downwards 
towards the tubes. Protocol: “Prime 450” was selected for “all modules”.  
E1. Probe array stain  
After priming was completed, the tubes were removed. Stain cocktail 1 was 
loaded onto positions 1 & 3, Stain cocktail 2 onto position 2. In Fluidics window, 
“Experiment name”, “Probe array type” & Protocol = EukGE_WS2v5_450 for 
individual module were selected. The array probe was put into the respective cartridge 
holder with the label side facing out. “Run” was clicked for individual module to 
begin wash & stain. (~1.5hrs) 
E2. Probe array wash 
When the protocol was completed, the probe arrays were removed and any large 
bubbles or air pockets were checked. (If bubbles were present, the Array holding 
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buffer was removed using a pipettor and a fresh buffer was loaded). The tubes were 
removed and replaced with fresh tubes. The lever was pulled down to end the protocol. 
E3. Shutdown 
The new tubes were replaced again. Wash A & B were removed and the tubings 
were placed into the MiliQ bottle, before topping the bottle up with water. In Fluidics 
window, Protocol = Shutdown_450 for “all modules” was selected and run for 3 times 
before removing the waste solutions.  
F. Probe array scan 
The scanner was warmed up for 15 minutes. The 1st cartridge was inserted into 
the red slot of the scanner, the next 1 was in front of it (away from user). The Start 
Scan icon was selected. It took ~7 minutes per scan. 
G.  Analysis 
The image file was opened (D drive>program files>Affymetrix>genechip>affy 
data>data). Using the Grid, the runway lights was checked (=oligoB2 controls) in all 
4 corners and for any artifacts. Analysis was selected, followed by File Report to 
create a report file.  
 
7.3 Materials and Methods for Functional Studies 
 
The studies began with SNPs detection in p53 binding sites. Region of interests 
were found in 542 loci with high confidence of p53 interaction. Blasting against 
dbSNP databases, 482 binding sites were found to contain 1185 SNPS. Among these, 
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27 SNPs are within p53 motif. The polymorphism studies are performed in 
lymphoblastoid cell lines(LCLs) as they are more readily available and from greater 
sources compared to breast cancer cell lines. Initially, LCLs were tested for p53 
response. This was followed by ChIP analysis and transcriptional activity analysis. 
 
Samples  
The current study included the clinical samples from Sweden and Finland.  All 
the Swedish cases were randomly selected from a population-based Swedish cohort 
that included all Swedish-born breast and endometrial cancer patients between 50 and 
74 years of age and resident in Sweden between October 1993 and March 1995. A 
similar number of age-matched controls were randomly selected from the Swedish 
Registry of Total Population. Briefly, after informed consent, 1596 breast cancer 
patients, 719 endometrial cancer patients and 1730 healthy volunteers participated 
into this study by providing either whole blood or non-malignant paraffin-embedded 
tissues for DNA analysis. From whole blood samples, DNAs were extracted by using 
the QIAamp DNA Blood Maxi Kit (Qiagen) according to the manufacturer's 
instruction. From non-malignant paraffin-embedded tissues, DNA was extracted using 
a standard phenol/chloroform/isoamyl alcohol protocol.   
The Finnish breast cancer cases consist of two series of unselected breast cancer 
patients and additional familial cases ascertained at the Helsinki University Central 
Hospital. The first unselected series of 884 breast cancer patients studied were 
collected at the Department of Oncology, Helsinki University Central Hospital in 
1997-1998 and 2000 and cover 79% of all consecutive, newly diagnosed breast cancer 
cases during the collection periods. 876 patients (99%) from this series were 
successfully genotyped in this study. 
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The second unselected series, containing 986 consecutive newly diagnosed breast 
cancer patients, were collected at the Helsinki University Central Hospital 2001 – 
2004 and covered 87% of all such patients treated at the Department of Surgery 
during the collection period. Of this series, 979 patients (99%) were successfully 
genotyped. 
 The series of 538 additional familial breast cancer cases in this study have 
been collected at the Helsinki University Central Hospital as described(Eerola, 
Blomqvist et al. 2000). The genotyped series included 295 patients with strong family 
history, defined as three or more breast or ovarian cancer cases in the first or second 
degree family members including the index case. These families were screened 
negative for BRCA1/2 mutations as previously described in detail (Vehmanen, 
Friedman et al. 1997; Vahteristo, Eerola et al. 2001; Vahteristo, Bartkova et al. 2002). 
The remaining 243 genotyped familial cases had a single affected first degree family 
member; for 213 of these cases, the Finnish BRCA1/2 founder mutations have been 
excluded as described (Vahteristo, Eerola et al. 2001; Vahteristo, Bartkova et al. 
2002). All the cancer diagnoses have been verified through the Finnish Cancer 
Registry and hospital records. Allele and genotype frequencies in the normal 
population were determined in 1256 healthy female population controls collected 
from the same geographical region. 
 
This study was approved by the Institutional Review Boards in Sweden and 
Finland and the National University of Singapore. 
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SNP Genotyping  
Genotyping analysis of SNPs was performed by using the MALDI-TOF mass 
spectrometry-based MassARRAYTM system from the Sequenom (San Diego, CA, US) 
(Swedish samples) as well as the TaqMan assays from the AppliedBiosystesm (ABI) 
(Foster City, CA, US) (Finnish samples).  All genotyping plates included positive and 
negative controls, DNA samples were randomly assigned to the plates, and all 
genotyping results were generated and checked by laboratory staff unaware of case-
control status.    
Lymphoblatoid cell lines and culture 
All lymphoblastoid cell lines (LCLs) used in this study were obtained from the 
Coriell depository (http://www.coriell.org/). Cells were cultured in RPMI medium 
supplemented with 20% fetal bovine serum. For ChIP, real-time qPCR and western 
blot analyses, cells were treated with 5FU at the concentration of 375µM for various 
hours. All the drug treatments were done during the log phase of cell growth (about 1 
to 1.5 millions of cells per ml). Cells were harvested after culture with or without drug 
treatment(s) and stored at -80°C. 5FU was obtained from the Sigma.     
ChIP Analysis: ChIP assays were performed in LCLs using the protocol 
described previously (Weinmann and Farnham 2002; Wells and Farnham 2002). For 
all ChIP analyses, the DO1 monoclonal antibody for p53 (Santa Crux Biotechnology, 
Santa Cruz, CA) was used for immunoprecipitation, and real-time quantitative PCR 
analyses were performed using the PRISM 7900 Sequence Detection System and the 
SYBR protocol as described (Ng et al 2003). The real-time PCR analysis was 
performed using the following primers: CCATCCTGCCTGAGCATGTCTGAAC 
(forward) and CCGGCTTTGCCAGACAATTGG (reverse) (For PRKAG2); 
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CAGGCTGTGGCTCTGATTGGCTTTC (forward) and 
GCTGGCAGATCACATACCCTGTTCAGAGTA (reverse) (For p21); 
ACCCACACTGTGCCCATCTACGAG (forward) and 
TCTCCTTAATGTCACGCACGATTTCC (reverse) (For Actin). The primers were 
designed using Vector NTI. Relative occupancy was calculated by determining the 
immunoprecipitation efficiency (ratios of the amount of immunoprecipitated DNA 
over that of the input sample) and normalized to the level observed at a control region, 
which was defined as 1.0. The control region was a distal site around the binding site 
for Actin and not enriched by the immunoprecipitation. Each real-time quantitative 
PCR analysis was done in triplicate. 
 
Allele Enrichment Analysis of ChIP pull-down DNAs by real-time PCR 
The allele enrichment analysis of the ChIP input and pull-down DNAs from 
heterozygous cell lines was performed by real-time quantitative PCR using a made-to-
order TaqMan SNP assay for rs1804674 from the ABI.  The quality of the TaqMan 
SNP assay was first verified by genotyping 30 CEPH DNA samples, and all the 
genotype results are consistent with the ones from the HapMap project (data not 
shown).  For real-time PCR analysis, the Ct value difference (∆Ct) between G and T 
alleles of a ChIP pull-down DNA was normalized by the ∆Ct value of the 
corresponding input DNA (reflecting the equal numbers of G and T alleles in normal 
genomic DNAs from the heterozygous cell lines). The normalized ∆Ct value (∆∆Ct) 
was then used to calculate the enrichments (Fold Change using the formula of 2∆∆Ct) 
of the wild-type G allele over the mutant T allele in the ChIP pull-down DNA. All the 
real-time PCR analyses were done in triplicate. 
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Expression Analysis by Real-time PCR   
Total RNAs were extracted from cells (with or without 5FU treatment) using the 
RNeasy Kit from the Qiagen (with DNase digestion step). 200 ng RNA was then 
reverse transcribed into 20 µl cDNA using the SuperScript kit from the Invitrogen 
(CA, USA), and real-time PCR analysis was subsequently performed by using 2 µl 
cDNA as template.  All the real-time PCR analyses were done in the ABI Prism 7700 
sequence detection system by using the TaqMan assays from the ABI.  For PRKAG2, 
assay-by-demand assay was developed by using the Primer Express software from the 
ABI: GTTTCCCCTGGAATCCTATAAGC (Forward), 
CGAGGCATAGATGCGATTCTC (reverse) and CGAGCCTGAACGGT (probe).  For 
normalization, a ready-to-use TaqMan probe for the glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) gene was analyzed as endogenous control.  Each real-time 
PCR analysis was done in triplicate. 
All the Ct values from the real-time PCR analyses were analyzed by using the 
comparative Ct method provided by the manufacturer (ABI). Briefly, the Ct values 
from the PRKAG2 analysis were first normalized by the Ct values of the endogenous 
control, GHAP.  The normalized Ct (∆Ct) values were then used to calculate the Ct 
value difference (∆∆Ct) between 10h treatment and the baseline. Fold change in the 
expression of PRKAG2 between the baseline and the 10h treatment of 5FU was 
calculated by using the formula of 2∆∆Ct.     
 
Promoter Assay Analysis  
A 226 bp region encompassing the intronic p53 binding site within PRKAG2 was 
amplified using hotstart PCR with forward primer 5’-
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TAGGAGACCTGGGGGACTTT-3’ and reverse primer 5’-
CAGGCATCTCGAAGAGATCA -3’ and 50 ng of genomic DNAs isolated from the 
individuals carrying either the wild-type (WT) G or mutant (MUT) A allele. The PCR 
conditions were; 94oC for 15 mins, followed by 35 cycles of denaturation at 94oC for 
45s, annealing 55oC for 45s, and extension at 72oC for 45s. The resultant PCR 
products of 226 bp were purified from agarose gels and cloned using TOPO-TA 
cloning system (Invitrogen, Calsbad, CA).  The genotypes of the cloned DNA 
fragments were confirmed by DNA sequencing. Subsequently, the DNA fragments 
were subcloned into the upstream of TATA-luciferase (fire-fly) containing pGL4 
vector (Promega) using Kpn I and Xho I restriction enzymes (New England Biolabs). 
Reporter assay analysis was performed by using both HCT116 wild type and 
null for p53 cells (provided by Dr Bert Vogelstein’s lab at the Johns Hopkins School 
of Medicine) that were maintained in DMEM containing 10% fetal bovine serum.   
5X104 cells were plated in triplicate in 24–well plates and transfected next day with 
250 ng of either parent TATA-luc, WT-TATA-luc or  MUT-TATA-luc plasmid 
DNAs under serum free conditions using 1 µg per well of Lipofectamine 2000 
(Invitrogen, Calsbad, CA).   2.5 ng of pRL-CMV vector containing renilla luciferase 
was co-transfected in each well to normalize transfection efficiency across wells.  
After 8 hours the cells were recovered for 3 hours in serum containing medium, 
following which the cells were treated for 12 hours with 375 µM 5-Fluorouracil or 
DMSO. The cells were lysed in passive lysis buffer and promoter assays were carried 
out as per manufacturer’s instructions using Promega Dual-luciferase assay system. 
The values obtained for each construct were normalized as fold change to that of the 
activity of parental TATA-luc vector in HCT116 WT cells (designated as 1).  
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Extraction of proteins using modified radioimmunoprecipitation (RIPA) lysis 
buffer 
100ml of modified RIPA buffer was prepared as follows. 790mg of Tris base was 
added to 75ml of distilled H2O. 90mg of NaCl was added and the solution was stirred 
until all solids were dissolved. The pH was adjusted to 7.4 by adding HCl. 10ml of 
10% NP-40 (stored at room temperature) was added to the solution. 2.5ml of 10% Na-
deoxycholate (stored at room temperature) was added and the solution was stirred 
until it was clear. 1ml of 100mM EDTA was then added to the solution and the 
volume of the solution was adjusted to100ml using a graduated cylinder. *RIPA 
buffer stock was prepared and stored in the fridge at 4°C. The remaining protease and 
phosphatase inhibitors were added to the solution on the same day the assay was run. 
Protocol for Protein Extraction with 1x Modified RIPA Buffer 
After cells were harvested by trypsinisation or scraping, the cells were washed 
twice with ice-cold 1x PBS. Pellet cells were spun at 1200 rpm at 4°C for 4 minutes. 
The cell pellet was resuspended in 5 volume of 1x Modified RIPA Buffer. Cells were 
lysed on ice for 30 to 60 minutes where vortex was done for 15 seconds in every 10 
minutes. Samples were centrifuged at 16000xg at 4°C for 15 minutes. The supernatant 
containing soluble proteins, was transferred to new tubes. 
Preparation of stock solutions 
10% NP-40: 100% NP-40 stock (stored at room temperature) was melted by 
heating. 10ml of 100% NP-40 solution was dissolved in 100ml of distilled H2O, 
mixed well and stored at room temperature. 
10% Na-deoxycholate: 10g of Na-deoxycholate salt was dissolved in 100ml of 
distilled H2O, mixed by stirring and stored at room temperature, protected from light. 
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200mM PMSF: 3.48g of Phenylmethylsulfonyl fluoride (PMSF) salt was 
dissolved in 100ml of isopropanol, mixed with stirring and heating and stored at room 
temperature. 
200mM NaF: 0.4g of sodium fluoride (NaF) was dissolved in 50ml of distilled 
H2O, mixed well and stored at room temperature. 
Activation of Sodium Orthovanadate 
Sodium orthovanadate was activated for maximal inhibition of protein 
phosphotyrosyl-phosphatases. A 200mM solution of sodium orthovanadate (Na3VO4) 
was prepared by dissolving 1.8g of Na3VO4 salt in 50ml of distilled water. The pH 
was adjusted to 10.0 by using either 1M NaOH or 1M HCl. The yellow solution was 
boiled until it turned colourless. It was then cooled to room temperature. The pH was 
re-adjusted to 10.0 and the boiling and cooling of the solution to room temperature 
was repeated until the solution remained colourless and the pH stabilized at 10.0. The 
activated sodium orthovanadate was stored as aliquots at -20°C. 
Protein Quantitation 
1x Bradford’s reagent was prepared from 5x stock solution. 1mg/ml Bovine 
Serum Albumin(BSA) was also prepared. Each well was loaded with 200µl of 1x 
Bradford’s reagent. For standard curve, the lanes for the amount of protein in µg were 
Blank, 0.5, 1, 2, 4, 6, 8 and 10. (i.e, 0.5µl was loaded for 0.5µg or 8µl was loaded for 
8µg, etc.) Next, the protein samples were loaded and the machine was used to 
quantitate the proteins. Finally, the standard curve was plotted and the equation 
obtained was used to calculate the unknown protein concentration. 
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SDS-PAGE 
Assembly: Plates/ spacers were washed with 70% ethanol. The plates were slided 
into casting frame, keeping the short plate facing the front of the frame. Pressure cams 
were engaged to secure glass plates. The casting frame and plates were secured in the 
casting stand. 
Pouring Resolving Gel: APS and TEMED were added just before casting. The 
resolving gel was poured between plates to a level ~1cm below the bottom of wells. 
The top level was made flat with water-saturated butanol and the gel was allowed to 
set for ~1 hour before the water-saturated butanol was rinsed off with milliQ water.  
Pouring Stacking Gel: APS and TEMED were added just before casting and it 
was poured between plates until they were full. The plates were then inserted in a 
comb carefully, ensuring that no air bubbles were trapped. ~1 hour was allowed for 
gel to polymerize. 
Loading Samples and Gel Eletrophoresis: Casting plates were unclipped from 
stand and clipped to the U-shaped gaskets, making sure that the short plate faced 
inward toward the notches of the U-shaped gaskets. The whole thing was lowered into 
the tank and the inner chamber was filled until full with running buffer. The samples 
were heated at 95°C for 5 minutes in 1x sample loading buffer. Samples (usually 
10μg) were loaded into wells. 5μl of protein molecular weight marker was also loaded 
into 1 lane. The rest of buffer was poured into the lower buffer chamber, making sure 
the buffer was 1cm above bottom of plates. For 1 run, 500ml 1x running buffer was 
prepared and the power was connected to run gel at constant voltage of 100V for 1.5 
hours. 
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Western Blot Analysis   
Total protein was extracted from cells using the Modified RIPA buffer. The 
Micro BCA Protein Assay Reagent Kit (Pierce, Rockford, IL, U.S.A) was used to 
quantify protein concentration. Western blot was performed using 40µg of protein 
using the established protocol and the following antibodies: 1) antibody for actin 
(control, 1:5000 dilution), 2) p53(DO-1) sc-126 (Santa Crux Biotechnology, 1:1000 
dilution);  3) AMPKα,  Phospho-AMPKα (Thr172) antibodies for both the total- and 
phosphor-AMPK proteins (Cell Signaling technology, 1:1000 dilution), and 4) 
AMPKγ2 antibody (Cell Signaling technology, 1:1000 dilution) .   
Preparation for blotting: The gels after electrophoresis were equilibrated in 
transfer buffer for 15 minutes at room temperature. The membranes were cut to 
8.8mm by 6.2mm and wet in 100% methanol for 15 seconds, followed by ultrapure 
water for 2 minutes and lastly soaked in transfer water for 15-30 minutes. Two thick 
and two thin filter papers were also cut to 8.8mm by 6.2mm and were soaked in 
transfer buffer. 
Assemble the transfer stack: The safety cover and the stainless steel cathode 
assembly were removed. 1 thick and 1 thin pre-soaked filter papers were placed onto 
the platinum anode and a 50ml tube was rolled over the surface of the papers to 
exclude all air bubbles. Pre-wetted Immobilon-P membrane (transfer membrane) was 
placed on top of the filter papers followed by equilibrated gel on top of the transfer 
membrane. 1 thick and 1 thin filer papers were then placed on top of the equilibrated 
gel. Finally, the cathode assembly and the safety cover were placed back. The power 
was turned on and the gel was transferred at 15V for 1 hour. After transferring, the 
blotted membrane was dried by soaking it in 100% methanol for 10 seconds, followed 
by drying on top of a piece of filter paper. 
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Immunodetection: (1) Blocking- Non-specific binding sites were blocked by 
immersing the membrane in 5% non-fat dried milk, 0.1%(v/v) Tween 20 in PBS for 1 
hour at room temperature on an orbital shaker. (2) Washing – The membrane was 
rinsed with washing buffer (PBS-T) for 2 minutes and repeated once. (3) Binding of 
Primary Antibody (Ab)- The primary antibody (anti-goat antibody) was diluted in 
blocking solution, i.e. 2.5μl Ab in 2ml blocking solution. The membrane was 
incubated in diluted primary antibody on an orbital shaker at room temperature for 1 
hour.  (4) Washing – The membrane was briefly rinsed with 2 changes of washing 
buffer. It was then soaked in washing buffer in a rotary shaker for 15 minutes. The 
membrane was then rinsed with wash buffer in rotary shaker for 5 minutes and was 
repeated twice. (5) Binding of Secondary Antibody- The secondary antibody (anti-
goat antibody) was diluted in blocking solution, i.e. 1.5μl Ab in 2ml blocking solution. 
The membrane was incubated in diluted secondary antibody on an orbital shaker at 
room temperature for 1 hour. (6) Washing – The membrane was briefly rinsed with 2 
changes of washing buffer. It was then soaked in washing buffer in a rotary shaker for 
15 minutes. The membrane was then rinsed with wash buffer in rotary shaker for 5 
minutes and was repeated twice. (7) Detection – 2ml of solution 1 and 50μl of 
solution 2 were mixed to get the detection reagent ready. Excess wash buffer was 
drained from the washed membrane and the membrane with the protein side faced up 
was placed on a large glass panel. The protein side of the membrane was covered with 
the detection reagent and incubated for exactly 1 minute. Excess detection reagent 
was drained off by holding the membrane vertically and letting its edge to touch a 
tissue paper. The membrane with protein side faced down was then gently placed onto 
a transparency and covered by another transparency. Any air pocket was gently 
smoothened out. The blots with protein side up was placed in the film cassette. Lights 
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were switched off and a sheet of auto radiography film such as Hyperfilm ECL was 
carefully placed on top of the membranes. The cassette was closed and exposed for 8 
seconds with the exposure duration adjusted accordingly. The film was removed and 
developed using the machine.     
Statistical Analysis   
Hardy-Weinberg Equilibrium (HWE) test was performed in the Finnish and 
Swedish control samples separately, and no evidence for deviation from HWE was 
found.  Association analysis was performed using the χ2 test under a recessive model 
of inheritance.   For the joint association analyses of the combined Swedish-Finnish 
breast cancer sample and the combined breast-endometrial cancer sample, the Mantel-
Haenszel method for meta-analysis was used by assuming fixed effect.  For the joint 
analysis of the breast-endometrial sample, the Swedish cases were defined as having 
either breast or endometrial cancer.  All statistical analyses were performed by using 
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Appendix of Technology platforms 
ChIP-PET platform: ChIP-PET data were generated in the steps below. Chromatin 
Immunoprecipitation (ChIP) assay with E2 treatment was performed first. Cloning was 
performed through a DNA tag sequencing and mapping strategy called gene identification 
signature (GIS) analysis, in which 5’ and 3’ signatures of the ChIP DNA fragments were 
extracted into paired-end ditags (PETs), which are subsequently concatenated for efficient 
sequencing and mapping to human genome (Buckland, Hoogendoorn et al. 2005). 
 
This is an example of a cluster whose PET is 11 but moPET is 6.  
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